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Introduction and outline 
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Chapter 1 
Rheumatoid arthritis  
Rheumatoid arthritis (RA) is a common autoimmune disease characterized by synovial 
inflammation, autoantibody production and destruction of cartilage and bone (1). 
Classically, the disease affects the small joints of the hands and feet in a symmetrical 
pattern. As RA is a systemic disease, extra-articular manifestations can be present in almost 
any system of the body e.g. the skin, heart, lungs and blood vessels (1). The diagnosis of RA 
is predominantly a clinical one, as a history of progressive joint swelling, stiffness and 
increased pain after a period of inactivity is indicative of an inflammatory  joint disease. 
Early diagnosis and timely initiation of disease-modifying antirheumatic drugs, has been 
shown to have a favourable effect on the course of disease (2-4). However, timely diagnosis 
remains a challenge as classical signs of structural changes may be missing in early disease 
and subtle synovitis may escape notice during clinical examination.    
Over the past few years, research in the field of RA has focused on the earliest stages of 
disease, leading to the discovery that circulating autoantibodies, such as rheumatoid factor 
(RF) and anti-citrullinated protein antibodies (ACPA) which precede the clinical onset of 
disease (5-7).  ACPA are highly specific for RA (8) and the presence of the self-reactive 
antibodies reflects the complexity of disease. As RA seems to be a highly heterogenous 
disease, classification criteria have been developed with the aim to identify more 
homogenous patient groups to facilitate comparison with international studies. Using a 
quantitative scoring system patients can be classified based on scores obtained from; joint 
involvement, serologic markers, inflammatory markers and duration of symptoms. 
Although RA is a clinical diagnosis and diagnostic criteria for RA do not exist, classification 
criteria have been developed to arrive at homogeneous inclusion in clinical trials. The 1987 
American College of Rheumatology (ACR) classification criteria for RA were not very well 
suited for the inclusion of recent onset RA as they rely on the expression of clinical 
symptoms, a feature of established RA (9). These findings led to the inclusion of an 
additional early serological marker, ACPA, to the current 2010 American College of 
Rheumatology/European League Against Rheumatism (2010 ACR/EULAR criteria) 
classification criteria for rheumatoid arthritis (10), (Table 1).     
Although biomarkers provide valuable information to identify patients at an early disease 
phase, interpretation within the clinical context remains vital. For example, if the prior 
probability of RA is relatively low, such as in patients in primary care who have only knee 
pain or those who meet no other ACR criteria, measuring antibodies reactive to cyclic 
citrullinated peptide (CCP) alone seems to be a reasonable strategy that avoids too many 
false-positive results. If however, the prior probability of RA is relatively high, such as in 
patients  seen in rheumatology clinics, measuring both autoantibodies seems to be a 




Table 1. ACR/EULAR 2010 classification criteria for rheumatoid arthritis.  
Joint involvement  
1 large joint 
2-10 large joints 
1-3 small joints (large joints not counted) 
4-10 small joints  








Negative RF and negative ACPA status 
Low-positive RF or low-positive ACPA 






Normal CRP and normal ESR 




Duration of symptoms 
<6 weeks  




A score ≥ 6 is the cut point for rheumatoid arthritis. Patients can also be classified as having 
rheumatoid arthritis in the presence of 1) erosive disease, 2) long-standing disease according to 
the previous classification criteria. Target population: patients who have at least one joint with 
definite clinical synovitis, not better explained by another disease. Joint involvement: any swollen 
or tender joint on examination. Large joint: shoulders, elbows, hips, knees and ankles. Small joint: 
joints in the hands, writs and feet. Negative serology: below or equal to upper limited of normal 
(ULN). Low-positive serology: higher than ULN, less then 3 times ULN. High-positive serology: 
more than 3 times ULN. Acute phase reactants: according to local standards. Duration of 
symptoms: reported by the patient or symptoms of synovitis at the time of assessment.              
RF= rheumatoid factor, ACPA=anti-citrullinated protein antibodies, CRP= C-reactive protein, ESR= 
erythrocyte sedimentation rate (10). 
 
 
Autoantibodies in RA 
The first RA associated autoantibody was RF which was identified in 1940 (11). RFs are 
antibodies that bind immunoglobulin (Ig)G and recognizes epitopes in the fragment 
crystallizable (Fc) region, which is responsible for effector functions like complement 
binding (12). Although usually measured as IgM-RF, RF activity can also be found in other 
subclasses of Ig (13). RF can be detected in 50-90% of RA patients, but are also found in the 
sera of patients with other connective tissue diseases, patients with infectious diseases and 
elderly healthy individuals (14). RF was the most valuable diagnostic marker for RA before 
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the discovery of ACPA and is still part of the 2010 ACR/EURLAR classification criteria. The 
presence of RF and ACPA represents an important early biomarker as these autoantibodies 
can be detected early in the disease course and can precede the clinical onset of disease (5-
7). RF an ACPA can be found in sera of patients a median of 5 years before onset of clinical 
symptoms (6). Subjects with arthralgia which are seropositive for these autoantibodies have 
an approximately 30% chance of developing RA within one year (15). These findings 
highlight an important role for autoantibodies in the preclinical phase of RA which precedes 
the onset clinical signs and symptoms. Most research on the role of autoantibodies in RA 
has focused on ACPA, which are directed against citrullinated proteins. In the past several 
years it has become clear that the autoantibody response in RA extends to several other 
modified proteins, such as proteins modified by carbamylation and acetylation. As all these 
auto-antibodies recognize post-translationally modified proteins, these antibodies are 
collectively called anti-modified protein antibodies (AMPA). A variety of AMPAs against 
different protein modifications (anti-citrullinated (16), -carbamylated (17) and -acetylated 
protein antibodies (18)) have now been described in RA suggesting a shared common 
‘developmental’ basis.  
 
Post-translational protein modifications 
Post-translational protein modification refers to the covalent and generally enzymatic 
modification of proteins following biosynthesis. Protein modifications can exist in different 
forms e.g. addition of small chemical groups, fatty acids or sugar chains, and can occur on 
the amino acids side chains or at the protein’s C- or N- termini (19). Most post-translational 
modifications can modulate the protein conformation, function, activity, stability and/or 
location of a protein. For example, phosphorylation is a very general post-translational 
protein modification involved in the regulation of enzyme activity.  
AMPA responses directed against post-translational modified proteins are highly specific for 
RA as they are, by and large, not found in other auto-immune or inflammatory diseases (20). 
As many proteins in the joint are long-lived especially extra-cellular matrix proteins 
expressed in the cartilage, it is not surprising that modified proteins can be found at higher 
levels in the joint compartment (21). Interestingly, the increased expression of modified 
proteins in the joints and cartilage might contribute to the production of AMPAs and 
possibly explain why AMPAs are associated with rheumatic diseases especially RA. As these 
post-translational modified proteins are prolongedly  expressed and possibly more exposed 
by extracellular expression in the synovial compartment and cartilage, AMPA responses can 
contribute to increased susceptibility and risk of chronic inflammatory responses of the 
joints (20). For example, plasma proteins which carry post-translational modifications are 
readily recognised by AMPAs which can result in immune complex formation, complement 
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activation and subsequent clearance of the circulation. By contrast, modified matrix 
molecules recognised by AMPAs also induce immune complex formation and complement 
formation, however as these proteins are expressed in the synovial compartment they are 
immobile and these immune responses do not result in clearance of the modified proteins 
(22). This enables a prolonged process of complement activation, attraction of immune cells 
and release of mediators like myeloperoxidase (MPO) which stimulates local inflammation 
and protein modification contributing to chronic inflammatory responses.  
 
Anti-citrullinated protein antibodies 
Citrullination is a post-translational modification of proteins, in which a positively charged 
peptidylarginine residue is converted into a neutral peptidylcitrulline (Figure 1) (8). The 
conversion is catalysed by the calcium dependent peptidylarginine deiminases (PAD) 
enzyme. This modification takes place during a variety of biological processes including 
inflammation. ACPA are a hallmark of RA as these autoantibodies can be present many years 
prior to disease onset, and their presence is associated with an increased risk of developing 
RA (6, 15, 23). In the pre-RA phase the ACPA response matures which is characterised by an 
increase in isotype diversity, the range of epitopes recognized and the levels of antibodies 
(24). Both the presence of ACPA as well as the extent of the ACPA response are associated 
with clinical outcomes (25). ACPA positive patients respond different to therapy compared 
to ACPA negative patients (23, 24), have an more destructive disease course (26) and have 
an increased risk of relapse after tapering of disease-modifying antirheumatic drug 
(DMARD) therapy (27). The presence of ACPA can be detected by several commercially 
available laboratory tests. The first assay was based om the artificial CCP. Antibodies 
reactive to this assay are referred to as anti-CCP antibodies. While ACPA and RF are highly 
prevalent in RA they can also be identified in a small percentage of healthy individuals. The 
anti-CCP assay has a moderate sensitivity for RA (67%), comparable to IgM-RF (69%), and a 
very high  specificity (95%) at the optimal cut-off value, whereas the sensitivity of IgM-RF is 





Figure 1. Chemical structures of post-translational protein modifications. Conversion of arginine into 
citrulline by PAD enzymes. Chemical modification of lysine into homocitrulline through cyanate. 
Enzymatic modification of lysine to acetyl-lysine by Acetyl-CoA.   
 
Anti-carbamylated protein antibodies 
When compared to ACPA, anti-carbamylated protein antibodies (anti-CarP antibodies) were 
discovered more recently (17). Anti-CarP antibodies target proteins that contain 
homocitrullines, also referred to as carbamylated proteins. Carbamylation is a chemical 
modification which occurs in the presence of cyanate. The formation of cyanate may result 
in a reaction with any accessible primary amine, including that of the lysine side chain and 
the amine at the N-terminus of polypeptides (29). The product formed by carbamylation, 
peptidyl-homocitrulline, highly resembles peptidyl-citrulline but contains one additional 
CH2 group (Figure 1). Conversion of lysine into homocitrulline, similar to the conversion of 
arginine into citrulline, results in the loss of a positive charge which influences protein 
structure and function. Cyanate can be increased upon chronic inflammation (30) due to 
the conversion of thiocyanate into cyanate by myeloperoxidase, atherosclerosis (31) and 
smoking (32). Cyanate, a dissociation product of urea, is also increased in patients with renal 
failure as urea accumulates with decline of renal function (33).    
The observation that the chemical structure of homocitrulline strongly resembles citrulline 
inspired experiments to analyse whether autoantibodies exist that target carbamylated 
proteins as well. In the first experiments to identify anti-CarP antibodies, carbamylated fetal 
calf serum (FCS) was used as a model antigen (17). Subsequent studies revealed that anti-
CarP antibodies recognize carbamylated self-antigens like human fibrinogen(34), 
demonstrating that anti-CarP antibodies are autoantibodies, able to recognize modified 
self-protein. Using molecularly-defined peptides (containing carbamylated epitopes) anti-
CarP antibodies were found to be reactive to peptides from α-enolase (35), collagen (36), 
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fillagrin (37) and vimentin (18). These studies revealed that protein modification is crucial 
for antibody recognition. Although several human proteins are currently used in the 
laboratory for the detection of anti-CarP antibody response, there is little information 
available on the specific nature and location of carbamylated proteins present in the 
(inflamed) joint.   
Recent clinical studies revealed that anti-CarP antibodies are specific for RA and can be 
found  in 45% of patients with early RA (17, 34, 36, 38, 39). Similar to ACPA, anti-CarP 
antibodies and can be identified in sera of patients years before onset of clinical symptoms 
(39-41). In addition, anti-CarP antibodies are associated with bone erosions, disability and 
mortality, independent of anti-CCP antibodies (17, 38, 39, 41). As anti-CarP antibodies occur 
in 10-20% of RA patients seronegative for ACPA (17, 38, 40), anti-CarP antibodies are 
thought to represent an additional serological marker distinct from ACPA. The sensitivity of 
the anti-CarP assay is reported to be moderate (44%) and with a high sensitivity (89%) (42). 
With the arrival of anti-CarP antibodies as a serological marker, it is intriguing whether these 
autoantibodies could contribute to the early identification and classification of patients with 
RA. Although anti-CarP antibodies are distinct from ACPAs, it has been described that some 
ACPA can bind peptides or proteins containing homocitrulline (18, 34, 35). However, the 
degree of cross-reactivity of ACPA for homocitrullinated proteins varies between studies. 
These discrepancies may be a result of proteins that contain different numbers and 
locations of homocitrulline and citrulline. Current studies using the same peptide backbone 
are inconclusive as the affinity of antibodies to citrulline and homocitrullinated peptides 
was not investigated (18, 35, 36, 43). However, the relative cross-reactivity between ACPA 
and anti-CarP antibodies suggests that these autoantibodies may originate from the same 
B-cell population.  
Interestingly, anti-CarP antibodies can be detected in sera of mice with collagen-induced 
arthritis, even in the absence of ACPAs (44). Studies revealed that anti-CarP antibodies can 
be generated by immunization of rodents and rabbits with carbamylated proteins (37, 45). 
In rabbits, the induced response was partially cross-reactive. Comparison of different 
mouse and rat models of arthritis revealed that anti-CarP antibodies are only present in 
models that require active immunisation (46). Time course experiments in collagen-induced 
arthritis models indicate that the presence of anti-CarP antibodies precedes the onset of 
clinical symptoms (44), an observation similar to findings in patients with RA. These data 







Anti-acetylated protein antibodies 
The most recent identified AMPA responses in RA are the anti-acetylated protein 
antibodies, directed against the post-translationally modification lysine by acetylation. Anti-
acetylated protein antibodies have been described in approximately 40% of RA patients, 
mainly in the ACPA positive group (18). The identification of another AMPA response in RA 
provides interesting new insights in the pathophysiology of RA.  
Lysine acetylation is a common post-translational modification and is involved in various 
biological processes such as chromatin remodelling, activation of transcription factors and 
regulation of metabolic enzymes. Protein lysine acetylation refers to the post-translational 
addition of an acetyl group to the ε-amino group of the side chain of a lysine residue (47). 
Acetylated lysine resembles homocitrulline except for the side-chain terminal amine, which 
is replaced by a methyl group (Figure 1). Multiple acetyltransferases are responsible for 
lysine acetylation and the first lysine acetylation was discovered on histones (48). Imbalance 
in histone acetylation has been found to change the chromatin structure and is associated 
with dysregulation of genes involved in cell-proliferation, differentiation and apoptosis (49-
51). Protein acetylation has historically been considered a predominant eukaryotic 
phenomenon. Recent evidence, however, shows that also many bacterial species are able 
to acetylate proteins (52), including bacteria postulated as link between periodontal 
infection and RA (53, 54). These bacteria include Porphyromonas Gingivalis as well as 
Aggregatibacter Actinomycetemcomitans. It has been hypothesised that bacterial 
acetylation could play a role in the development of AMPA responses. Epidemiological data 
suggest that periodontal disease is more common in RA (35%) compared to controls (37%) 
(55). Interestingly, citrullinated, carbamylated and malondialdehyde-acetyladehyde (MAA) 
adduct modified proteins have been found in inflamed periodontal tissues (56). It has been 
shown that MAA adduct formation, as a result of oxidative stress, are increased in RA 
patients (57). Current studies reveal that the AMPA response is diverse and heterogenous 
between patients, but also point at the possibility of a shared developmental basis and role 










Outline of this thesis 
The general aim of this thesis was to elucidate the immune regulation and breach of 
tolerance towards modified proteins in RA. AMPA responses are a hallmark of disease and 
are implicated in the pathogenesis of RA. Recent studies have shown that these 
autoantibodies can serve as diagnostic and prognostic biomarkers.  
The studies described in chapter 2 describe the current evidence supporting the notion that 
autoimmunity against citrullinated proteins is already present at a preclinical phase of RA 
and how the ACPA response matures over time. Recent clinical studies have demonstrated 
that effective treatment of arthritis can lead to reduced levels of ACPA or a change in 
composition of ACPA. Many autoimmune diseases including RA, are characterized by the 
production of antibodies that can bind self-antigens. Animal studies have shown that the 
immunogenicity of proteins is enhanced upon protein modification (58-60). However, how 
these self-reactive B cells escape negative selection in the thymus is not known. To 
understand how autoreactive B cell responses are generated to post-translational modified 
proteins we hypothesised that exposure to carbamylated self-antigens is sufficient for a 
breach of immunological tolerance. The studies described in chapter 3  show that exposure 
of mice to carbamylated self-antigens can lead to the formation of anti-CarP antibodies. Our 
observations reveal that not only carbamylation of self- but also foreign proteins is sufficient 
to induce self-reactive AMPA responses. In line with these findings, it was recently shown 
that homocitrulline containing peptides are also immunogenic in SE-expressing DR4tg mice 
and lead to T and B cell responses directed to carbamylated antigens (61).  
Activation of naïve B cells by T cell dependent signals is characterised by the formation of 
germinal centers. Activated T-cells provide a stimulatory signal to B cells via CD40L-CD40 
interaction (62) which subsequently leads to B cell proliferation and differentiation. In 
chapter 4 we analysed whether carbamylation of an antigen can result in the generation of 
neo-epitopes and the subsequent induction of a breach tolerance at T cell level towards 
self-antigens. Our results indicate that carbamylated self-proteins are sufficient for a breach 
of immunological tolerance and are able to trigger primary immune responses, including 
autoantibody formation, T cell activation and cytokine production. In our studies we 
describe the concept that post-translational modification of self-proteins can create “new” 
antigens for which immune tolerance does not yet exist. To better understand the origin of 
AMPA responses and development of AMPA-producing B cells we immunized mice with 
different post-translational modified proteins and studied the induced humoral responses. 
These studies are described in chapter 5 and indicate that exposure to a particular class of 
modified proteins (carbamylated or acetylated) can induce an immune response against 
another class of modified proteins as well. Likewise, AMPA from RA-patients purified 
against one PTM can recognize different classes of PTMs. These findings are important as 
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they indicate that the different AMPA-responses observed in RA-patients can be derived 
from the same inciting antigen(s) carrying only one particular modification. 
Since the discovery of autoantibodies in RA it has been hypothesized that patients may 
benefit from treatment tailored to “autoantibody status”. As methotrexate is the most 
widely used anti-rheumatic drug in clinical practice, it would be important to know whether 
the presence of autoantibodies is associated with better treatment response. In chapter 6 
we show that autoantibody status is not associated with early remission in newly diagnosed 
RA-patients receiving methotrexate. The results from our study in 1826 RA-patients from 
the METEOR database (an international rheumatoid arthritis registry) indicate that 
methotrexate is effective as initial treatment strategy regardless of autoantibody status. 
The studies described in chapter 7 focus on the preclinical disease phase of RA as it has 
been thought that treatment initiation in pre-arthritis stages might result in an improved 
treatment efficacy and possibly the prevention of a full-blown disease. In animal studies 
with the collagen-induced arthritis and adjuvant-induced arthritis model we aimed to study 
whether treatment initiation in a prophylactic or pre-arthritis setting could reveal 
differences in treatment efficacy between antirheumatic drugs. In this systematic literature 
study we describe the evidence that both prophylactic and pre-arthritis treatment 
strategies can lead to a significant reduction of arthritis severity scores, which hints at a 
possibility for preventive treatment strategies in RA.     
Several studies have shown a clinical and epidemiological association between periodontitis 
and RA (63). Periodontal disease is characterized by gingivitis and a chronic inflammatory 
process of the bone. Aggregatibacter actinomycetemcomitans (Aa), a specific periodontitis-
associated bacterium and its lytic toxin (Leukotoxin A or LtxA) were hypothesized to be 
involved in the initiation of ACPA responses in genetically predisposed individuals (54). In 
chapter 8 we studied whether RA patients of Leiden Early Arthritis Clinic had an increased 
prevalence of Aa, measured by the presence of anti-LtxA antibodies. Furthermore, we 
aimed to replicate the finding that the association between human leukocyte antigens 
shared epitope (HLA SE) alleles and ACPA-positive RA is limited to the anti-LtxA-positive 
subset of patients. Using sera of arthritis patients we found that the presence of anti-LtxA 
antibodies was not specifically associated with RA. In addition, no association with the 
presence of ACPA or HLA SE alleles among RA patients was found. Finally, chapter 9 
discusses and summarizes the results of the studies described in this manuscript and 
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The identification of anti-citrullinated protein antibodies (ACPA) has had a major impact on 
the understanding of rheumatoid arthritis (RA). In the late 1990’s it was described for the 
first time that RA patients produce autoantibodies which target peptides and proteins 
containing citrulline, a modified form of the amino acid arginine (1) (2). Citrullination is a 
posttranslational modification of protein-bound arginine into citrulline residues which is 
mediated by peptidyl arginine deiminase (PAD) enzymes and is essential for the generation 
of antigens recognized by ACPA (3). Although the physiological role of citrullination is not 
precisely known, it is clear that this protein modification can occur during a variety of 
biological processes, including inflammation. Following the identification of citrullinated 
proteins, several diagnostic tests were developed based on cyclic citrullinated peptides 
(CCP) as a test substrate for detecting ACPA. Using the CCP-assay, a highly reliable diagnostic 
tool became available for routine testing of antibodies directed against citrullinated 
epitopes in early RA patients.  
The presence of ACPA in the sera of patients represents an important early biomarker and 
has been added to the 2010 American College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) classification criteria for RA (4). The selected parameters in the 
2010 classification criteria were designed to include early markers of disease rather than 
established clinical features as was the case in the 1987 ACR guidelines. The ACPA serology 
enables the clinician to identify recent-onset RA patients earlier, which is crucial for 
achieving timely control of disease progression. Using the ACPA test it is possible to 
distinguish two subclasses RA patients: ACPA-positive and ACPA-negative. When comparing 
these two subclasses of RA, major differences have been observed regarding genetic- and 
environmental risk factors, progression, remission, and response to treatment. In this 
review, we will provide an update on the latest findings concerning the ACPA maturation 
profile, the association between RA and the HLA DR-locus, and the hypotheses about 
disease pathogenesis that contribute to a greater understanding of the role of ACPA in early 
RA.  
 
Auto-immunity related to RA is present long before onset of clinical symptoms 
Autoantibodies are an important hallmark of RA and several classes of autoantibodies have 
been described that precede the development of RA, including ACPA, rheumatoid factor 
(RF) and the recently identified anti-carbamylated protein antibodies (5-8). Especially ACPA 
are of particular interest as these autoantibodies are highly specific for RA and can be found 
in about 50% of early RA patients. The fact that ACPA are quite rare in healthy individuals, 
suggests that auto-antibody positive healthy individuals are at an increased risk of 
developing RA (9). These findings suggest that ACPA and/or the underlying B-/T-cell 
responses play a prominent role in disease pathogenesis. Shortly before clinical onset of 
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disease, there appears to be maturation of the ACPA response which is characterized by an 
increase in ACPA titre, isotype switching, an increased antigen-recognition profile, and a 
change in Fc glycosylation pattern (10-15). Different observations strongly suggest that the 
development of ACPA-positive RA is based on a two-hit model. Environmental triggers and 
epigenetic stochastic events are thought to play a role in the initial break of tolerance 
leading to the formation of ACPA. A ‘second hit’, such as an infection or other factors, 
triggers the expansion of the ACPA response, which occurs relatively short before disease 
manifestation (16). Epidemiological studies have indicated that the HLA molecules do not 
play a considerable role during the first hit, but mainly contribute to the second hit that 
enables the expansion of the ACPA response.     
ACPA can recognize a variety of citrullinated antigens, including type II collagen, fibrinogen, 
vimentin and many other citrullinated proteins. An increase or shift of the antigen 
recognition profile, epitope spreading, can be a sign of maturation of the antibody response 
and disease progression. Epitope spreading is a hallmark of maturation of the ACPA 
response and is predictive for disease progression to early RA. After disease onset, the 
increased citrullinated epitope-recognition profile stabilizes and does not change anymore 
(10). A recent 2-year follow up study enrolling 316 early RA patients in a Swedish 
pharmacotherapy trial  suggested that disappearance of particular ACPA reactivities may be 
associated with a good treatment response in early RA (17). These results differ from 
previous reports in which the ACPA fine specificity did not seem to correlate with disease 
activity, progression, or response to therapy (18-20). In the case of the response against 
recall antigens, antibodies undergo class switching, somatic hypermutation and affinity 
maturation to improve the immune reaction against the antigen. 
The variable region of ACPA has undergone extensive somatic hypermutation, indicative of 
a T-cell-dependent B-cell response (21). The avidity maturation of ACPA however, appears 
to be different from recall antigens. As compared with antibodies against recall antigens, 
ACPA display a considerably lower avidity and the ACPA response shows only limited avidity 
maturation over time (22, 23). The presence of these low-avidity ACPA in RA patients is 
associated with a higher rate of joint destruction. ACPA can activate the complement 
system and can therefore play a role in the complement-mediated recruitment of 
inflammatory cells (24), which suggests that ACPA could be directly involved in the disease 
process. Moreover, ACPA-immune complexes combined with IgM or IgA RF can directly 
trigger Fcγ receptors on macrophages and mast cells leading to the production of 
proinflammatory cytokines which contribute to RA synovitis (25, 26).  
Maturation of antibody responses leads to a shift in isotype which enables the activation of 
other immune effector mechanisms. ACPA can use multiple isotypes, and these ACPA 
isotypes are already present before onset of RA (27). In addition, the number of different 
ACPA isotypes is predictive for the development of radiological damage (28). Similar to the 
epitope-recognition profile, the ACPA isotype profile appears not to expand anymore during 
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disease progression, indicating that maturation of the ACPA response takes place before 
onset of arthritis. As mentioned above, the fragment crystallisable (Fc) region of an antibody 
interacts with Fc receptors of immune effector cells and the complement system, and thus 
determines which immune effector mechanisms can be recruited by the antibody. The 
glycosylation of the IgG-Fc region of ACPA has been reported to be different from non-ACPA 
IgG. The Fc region of ACPA-IgG1 contains reduced numbers of sialic acid and galactose 
residues (29), a feature which is generally considered to render IgG antibodies 
proinflammatory (30). The changes in ACPA Fc glycosylation pattern become more 
prominent around 3 months before onset of RA (15). Differences in glycosylation pattern 
between Ig isotypes might influence their affinity for Fc receptors. A recent study showed 
that ACPA-IgG1 has a different Fc glycan profile compared to non-CCP2 reactive IgG1 (30), a 
particularity which can influence the affinity of ACPA IgG to Fc receptors and complement 
and may modulate ACPA effector- and immune-regulatory functions (31). In conclusion, all 
these different autoantibody characteristics evolve and mature before disease onset, and 
once patients present with arthritis, the ACPA response is generally increased in titre, uses 
more isotypes, displays a different glycosylation pattern, and are cross-reactive towards 










Figure 1. Maturation of the ACPA-response. Antibodies reactive towards citrullinated proteins are 
already present in the preclinical phase of RA. Environmental triggers and epigenetic stochastic events 
are thought to play a role in the ‘first hit’, leading to the formation of ACPA. A ‘second hit’, such as an 
infection, triggers further expansion and maturation of the ACPA response. Once the disease 
manifests itself, the ACPA response is generally increased in titre, uses more isotypes, has a different 
glycosylation pattern, and an increased antigen recognition profile towards various citrullinated 
proteins. Abbreviations: MHC, major histocompatibility complex; TH, T-helper cell; Fab, fragment 
antigen-binding; Fc, fragment crystallisable.  
 
HLA class II associations in rheumatoid arthritis 
The most important genetic risk factor for ACPA positive RA is the HLA class II region. RA, 
like many other autoimmune diseases, is characterized by a strong association with variants 
in the human leucocyte antigen (HLA) class II region. These HLA-associations differ in ACPA-
positive and ACPA-negative disease (32-35), highlighting the complexity of pathogenic 
mechanisms underlying HLA associations in RA. The HLA class II region encodes for HLA-DR, 
HLA-DQ and HLA-DP proteins and is involved in antigen presentation to HLA-class II 
restricted CD4+ T-helper cells. In 1976, analysis of mixed lymphocyte cultures from RA 
patients revealed that these individuals had certain HLA-DR4 molecules in common (36). 
The HLA haplotypes that encode for the HLA-DR4 molecules were found to be characterized 
by the so-called ‘HLA-shared epitope (SE)’, a common amino acid sequence in the HLA-DRB1 
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chain  (37). Recent genome wide analysis revealed specific amino acids at positions 11, 13, 
71 and 74 of the HLA-DRB1 chain as well was single-amino-acid polymorphisms at position 
nine of HLA-B and HLA-DPB1 are associated with the greatest risk for RA (38). Amino acid 
positions 11 and 13 of HLA-DRB1 are among the most polymorphic and are highly relevant 
for the shaping of peptide binding pockets located in peptide-binding groove of the HLA 
molecule. It is therefore not surprisingly that the statistically significant amino acid positions 
are those involved in peptide presentation.  
The HLA SE alleles, are now known to be specifically associated with ACPA-positive RA (38) 
(32). Conversely, HLA-DRB1*13 alleles haplotypes have been found to protect against the 
development of ACPA-positive RA (33, 34). A possible explanation for the association of the 
‘HLA-shared epitope’ with ACPA-positive RA might be that peptide presentation by the 
‘HLA-shared epitope’ HLA molecules can facilitate the activation of CD4+ T-cells which 
provide help to ACPA-producing B-cells. In ACPA positive RA, ACPA are cross-reactive and 
bind to a wide variety of citrullinated self-proteins which indicates to a loss of B-cell 
tolerance. However, it is unclear to what extent T-cell tolerance is lost. Identification of 
citrullinated epitopes recognized by autoreactive T-cells in patients with RA has proven 
difficult. Analysis using peptide-HLA tetramers and in vitro T-cell responses to candidate 
epitopes revealed T-cell recognition of several citrullinated epitopes in humans (39-42).  
The HLA-DRB1*13 alleles which are protective for RA, carry a five amino-acid sequence 
called: DERAA. The DERAA sequence is also expressed by many microbes and in a self-
protein vinculin. Citrullinated vinculin is expressed in the inflamed synovial membrane and 
was recently identified as a novel autoantigen for ACPA antibodies (43). It is proposed that 
molecular mimicry of self-proteins with pathogenic microbial proteins might lead to a break 
of T-cell tolerance. Indeed, it was recently shown, that T-cells present in HLA-DRB1*13-
negative donors were able to specifically recognize a DERAA-containing vinculin epitope 
that cross-react with DERAA sequences derived from pathogens (44). However, many T-cell 
responses are absent in HLA-DR13+ donors, indicating the induction of DERAA-specific T-
cell tolerance in these donors. Together, these studies suggests that the HLA class II locus 
can directly influence the maturation of the ACPA response via antigen-specific T-cells, 
providing help to ACPA-producing B-cells and enabling the maturation of the citrullinated 








Pathogenic role of the immune response against citrullinated proteins 
Besides the diagnostic application of ACPA as a biomarker, several clinical observations 
suggest that ACPA could play a direct role in disease pathology. First, ACPA may be found 
early in the course of disease, up to 7 years before RA manifests (5, 6). Second, various 
follow-up studies revealed that ACPA-positive patients with recent-onset RA develop more 
bone erosions compared to ACPA-negative RA patients (45-48). Third, bone loss and 
reduced bone mineral density can be found in healthy ACPA-positive individuals, even 
before clinical onset of arthritis (49).  Selective B-cell depletion using rituximab has been 
found to be effective in the treatment of RA (50-52), providing evidence for the involvement 
of B-cells in the pathogenesis of RA. ACPA-producing B-cells are found to be enriched in 
synovial fluid (21, 53), which suggests that ACPA can be produced locally and directly 
contribute to synovial inflammation. Moreover, the numbers of ACPA-producing B-cells in 
the blood of RA patients correlate with ACPA serum levels (54). 
Functional studies showed that immune complexes formed with ACPA mediate effector 
functions via Fc-γ receptors (55), and can induce complement activation (24) and enhanced 
neutrophil extracellular trap formation (56). In addition, there are reports that purified 
ACPA can induce osteoclastogenesis and bone resorption in mice (57), suggesting a direct 
link between ACPA and more severe joint destruction. So far, only two experimental studies 
succeeded in showing in vivo that ACPA may facilitate the transition from autoimmunity to 
inflammation. Transfer of antibodies specific to citrullinated fibrinogen (58) and transfer of 
antibodies targeting citrullinated-collagen (59) to mice with mild experimental arthritis led 
to disease exacerbation. It is interesting that no other positive data have been reported 
allowing that these two positive papers are similar as the many non-replicated preclinical 
papers in other fields such as oncology (60).  
RA patients receiving Abatacept show reduced levels of ACPA and RF in response to 
treatment (61). Moreover, a Swedish pharmacotherapy trial reported a decline of all ACPA 
levels independent of the clinical response on disease activity during the first three months 
of methotrexate treatment (17). However, effective treatment of established arthritis does 
not necessarily lead to reduced ACPA levels or a change in ACPA composition. For example, 
a Canadian cohort in early arthritis patients found that anti-CCP antibody fluctuations did 
not relate to clinical scores such as disease activity scores and the presence of erosions (62). 
These findings suggest that autoantibody producing B-cells rather than the autoantibodies 
produced may be responsible for disease pathogenesis. Activated B-cells secrete pro-
inflammatory cytokines, such as IL-6 and TNF, and ACPA-producing B-cells are found to be 
increased in the inflamed synovial membrane (16).   
Besides ACPA, other autoantibodies and/or auto-antibody-producing B-cells may also be 
involved in RA pathogenesis. Similar to ACPA, both rheumatoid factor and anti-CarP 
antibodies are associated with disease severity and persistence (8, 63, 64). Anti-CarP 
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autoantibodies recognize carbamylated proteins containing a homocitrulline, a post-
translational modification of lysine driven by cyanate, and can be found in patients with 
ACPA-negative RA. More recently, antibodies targeting another post-translational 
modification, malondialdehyde/acetaldehyde (MAA) adducts, are found to be increased in 
RA patients and this antibody response is associated with the presence of ACPA (65). Similar 
to carbamylation, MAA adducts are capable of the modification of a lysine. These findings 
raise the question why RA patients produce auto-antibodies towards post-translational 
modified proteins and whether these autoantibodies are implicated in disease 
pathogenesis. Further research is needed to confirm the current observations of anti-CarP 
antibodies in ACPA-negative and positive RA patients, and to determine whether these 































ACPA have proven to be a very useful biomarker for diagnosing RA and for predicting a 
severe disease course. Future investigations on the role of ACPA, other autoantibodies, and 
ACPA-producing B-cells in RA may provide further insight in and understanding of the 
underlying disease pathogenesis. Follow-up studies of RA patients may provide useful 
information on the fluctuation of ACPA levels and changes in ACPA composition during 
disease progression and treatment. Together, these observations may allow for new 
approaches to treat RA at an early, preclinical, stage of disease, and thus enable prevention 
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Over 50% of rheumatoid arthritis (RA) patients harbor a variety of Anti-Modified Protein 
Antibodies (AMPA) against different post-translationally modified (PTM) proteins, including 
anti-carbamylated protein (anti-CarP) antibodies.  At present it is unknown how AMPA are 
generated and how autoreactive B cell responses against PTM proteins are induced. Here 




 Serum reactivity towards five carbamylated proteins was determined for 160 RA-patients 
and 40 healthy individuals. Antibody cross-reactivity was studied by inhibition experiments. 
Mass spectrometry was performed to identify carbamylated self-proteins in human 
rheumatic joint tissue. Mice were immunized with carbamylated- or non-modified 
(auto)antigens and analyzed for autoantibody responses.  
 
Results 
We show that anti-CarP antibodies in RA are highly cross-reactive towards multiple 
carbamylated proteins, including modified self- as well as modified non-self proteins. 
Studies in mice show that anti-CarP antibody responses recognizing carbamylated self-
proteins are not only induced by immunization with carbamylated self-proteins but also by 
immunization with carbamylated proteins of non-self origin. Similar to the data observed 
with sera from RA patients, the murine anti-CarP antibody response was, both at the 
monoclonal- and polyclonal level, highly cross-reactive towards multiple carbamylated 
proteins, including carbamylated self-proteins.  
 
Conclusions 
Self-reactive AMPA-responses can be induced by exposure to foreign proteins containing 
PTM. These data show how autoreactive B cell responses against PTM self-proteins can be 
induced by exposure to PTM foreign proteins and provide new insights on the breach of 








Autoimmunity in rheumatoid arthritis (RA) patients is characterized by a spectrum of anti-
modified protein antibodies (AMPA) directed against post-translationally modified (PTM) 
proteins. The best-known AMPA in RA are autoantibodies directed against citrullinated 
proteins. Anti-citrullinated protein antibodies (ACPA) target proteins that have undergone 
a post-translational modification of arginine into citrulline by an enzymatic process 
mediated by peptidylarginine deiminases (PAD) (1, 2). The identification of ACPA as specific 
serological marker have had a major impact on the understanding of RA and disease 
prognosis as their presence predicts a more destructive disease process (3-7). Much less is 
known about the occurrence and aetiology of other AMPA responses in RA such as 
autoantibodies directed to malondialdehyde-acetaldehyde (MAA) adducts, acetylated 
antigens, and carbamylated proteins (8-11). Anti-carbamylated protein (anti-CarP) 
autoantibodies recognize carbamylated proteins containing a homocitrulline, a PTM 
structurally similar to citrulline (8, 12). Like ACPA and rheumatoid factor, also anti-CarP 
antibodies can be detected in serum many years before RA manifestation (13-18) and 
similar to these autoantibodies, the presence of anti-CarP antibodies is predictive of 
increased radiological damage (13). In contrast to deimination (citrullination), 
carbamylation occurs through an enzyme-independent reaction in which a lysine is 
converted into a homocitrulline through a reaction with cyanate (19), (Figure 1A).  
With the presence of various AMPA responses in RA, PTM proteins have been implicated in 
the breach of autoreactive B cell tolerance leading to the formation of these autoantibodies 
(20, 21). As AMPA have undergone isotype switching and somatic hypermutation, it is often 
speculated that AMPA-producing B cells have received T cell help from autoreactive T cells 
recognizing the same PTM self-proteins. So far, attempts to provide more insight into how 
autoreactive B cell responses against citrullinated proteins are induced have been 
hampered by the fact that ACPA do not occur in murine models of arthritis (22).   
Interestingly, anti-CarP antibodies, do occur in mice with collagen-induced arthritis (CIA) 
(23). The kinetics of anti-CarP antibodies in CIA mice display similarity to RA as these 
antibodies can be detected before disease onset. In addition, humoral responses to 
carbamylated proteins are only present in arthritis models that require active involvement 
of the adaptive immune system (24). Given the observation that anti-CarP antibodies, in 
contrast to ACPA, do occur in both humans and mice, we here investigated for the first time 
how PTM (foreign) proteins could contribute to a breach of B cell tolerance.   
Our findings show that autoreactive B cell responses against PTM proteins can be induced 
by exposure to PTM foreign proteins and provide new insights on the breach of autoreactive 





Human serum samples  
Serum samples from 160 RA patients of the Leiden Early Arthritis Cohort (EAC) (25) and 40 
healthy controls were used to study anti-CarP antibody cross-reactivity. RA patients fulfilled 
the 1987 RA classification criteria. All subjects provided informed consent prior to inclusion 
and ethical permission was provided by the institutional review board.  
 
Carbamylation and citrullination 
Fetal calf serum (FCS, Bodinco), myelin basic protein (MBP, Sigma), human serum albumin 
(HSA, Sigma), H1 Histone (H1 Merck Millipore), Prothrombin (ProT, provided by Prof. Blom 
Malmö, Sweden), ovalbumin (OVA, Sigma-Aldrich) and mouse albumin (mAlb, EMD 
Millipore) were incubated with 1M potassium cyanate (Sigma-Aldrich) during 12 hours at 
37°C, followed by dialysis. Fibrinogen, mouse (Cell Sciences) and human (Sigma-Aldrich), 
was incubated with 0.5M potassium cyanate during 7 days. For citrullination; 10mg FCS or 
2mg fibrinogen in 1ml containing 0.1M Tris-HCl pH 7.6 and 0.15M CaCl2 was incubated with 
40U PAD4 (Sigma-Aldrich) for 3 hours at 37°C. Protein carbamylation and citrullination was 
determined afterwards by in-house developed and standardized ELISAs confirmed by mass 
spectrometry. 
 
Detection of human anti-CarP antibodies  
Carbamylated and non-modified proteins were coated at 10ug/ml (diluted in 0.1M 
carbonate-bicarbonate buffer with a pH of 9.6) and incubated overnight on Nunc Maxisorp 
plates (Thermo Scientific) (8, 23). Plates were blocked for at least 6 hours with PBS/1% BSA 
(Sigma). Sera were diluted 50x in PBS/1%BSA/0.05%Tween (PBT) and incubated overnight. 
As standard, serial dilutions of a pool of positive sera was used. Binding of human IgG was 
detected using in PBT-diluted rabbit anti-human IgG conjugated to HRP (horseradish 
perixodase, DAKO, P0214), which was visualized with ABTS (2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid)). Washing with PBS/0.05% Tween was carried out 
between steps. All incubations, but the ABTS detection took place at 4 °C. The reactivity to 
the non-modified protein was subtracted from the reactivity to the corresponding 
carbamylated protein. The cut-off for positivity was set as mean plus two times the standard 
deviation of healthy individuals. For inhibition assays, sera were pre-incubated for one hour 
with 0 or 0.2mg/ml carbamylated or non-modified versions of one from five antigens before 
addition of serum samples to the ELISA plate. 
 
Detection of mouse anti-CarP antibodies  
Non-modified or modified proteins were coated overnight at a concentration of 10 µg/ml 
(diluted in pH 9.6 0.1 M carbonate-bicarbonate buffer) on Nunc Maxisorp plates (Thermo 
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Scientific). The plates were washed with PBS/0.05% Tween (Sigma) and subsequently 
blocked for 6 hours at 4°C with 100 µl of PBS/1% BSA (Sigma). After washing, the wells were 
incubated with 50 µl serum 1/50 diluted in PBS/1% BSA/0.05% Tween. The ELISA plates 
were incubated overnight at 4 °C. Total Ig, IgG1, and IgG2a were detected using HRP-
conjugated rabbit anti-mouse Ig antibody (Dako), HRP-conjugated goat anti-mouse IgG2a, 
HRP-conjugated goat anti-mouse IgG1 (all from Southern Biotec). HRP enzyme activity was 
visualized using ABTS. As a standard, serial dilutions of a pooled serum sample from mice 
with CIA were used. 
 
Sample preparation for mass spectrometric analysis 
RA joint tissue samples were obtained from knee-replacement surgery leftover material 
(Department of Orthopedic surgery, LUMC). This procedure was approved by the local 
ethical committee. Synovial tissue samples (20 mg) from RA and OA patients obtained from 
joint replacement surgery were washed with PBS to remove adherent body fluids such as 
synovial fluid and blood. Samples were incubated in ST lysis buffer (4% SDS in 0.1 M Tris-Cl 
pH 7.6) for 15 min at 70°C. Initially, SDS lysates were subjected to FASP II as described above, 
but yielding low numbers of carbamylated peptide hits. In contrast, subsequent treatment 
of the samples with trypsin yielded many more hits. Therefore, the synovial tissue samples 
(after their extraction with hot SDS to remove adherent and easily soluble protein) were 
digested with trypsin using the following procedure; samples were incubated in 100 μl 100 
mM DTT in 25 mM NH4HCO3 for 20 minutes at 54°C. After centrifugation, the supernatant 
was saved and the pellet incubated in 150 μl 15 mM iodoacetamide in 25 mM NH4HCO3 for 
30 minutes at room temperature. After centrifugation, the supernatant was saved and the 
pellet incubated in 200 μl 25 mM NH4HCO3 containing 10 μg trypsin for 4 hours at 37°C. The 
combined supernatants from DTT and iodoacetamide incubation were concentrated on a 
30 kDa filter (Microcon, Millipore), washed 3 times with 100 μl 25 mM NH4HCO3 and also 
incubated with 1 μg trypsin for 4 hours at 37°C. Next, the supernatant containing digested 
protein from the pellet was added to the digest on the filter. The filter was washed once 
with 100 μl 0.5 M NaCl. Peptides were recovered from the filtrate and subjected to solid 
phase extraction on C18 cartridges (Oasis HLB Waters).  
 
Proteome analysis and mass spectrometric identification of carbamylation  
Peptides were analyzed via on-line C18-nano-HPLC-MS with a system consisting of an Easy 
nLC 1000 gradient HPLC system (Thermo Scientific), and a Q-Exactive mass spectrometer 
(Thermo Scientific). Fractions were injected onto a homemade precolumn (100 μm × 15 
mm; Reprosil-Pur C18-AQ 3 μm, Dr. Maisch) and eluted via a homemade analytical nano-
HPLC column (15 cm × 50 μm; Reprosil-Pur C18-AQ 3 um). The gradient was run from 0% to 
50% solvent B (100/0.1 water/formic acid (FA) v/v) in 120 minutes. The nano-HPLC column 
was drawn to a tip of 5 μm and acted as the electrospray needle of the MS source. The Q-
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Exactive mass spectrometer was operated in top10-mode. Parameters were resolution 
70,000 at an AGC target value of 3 million maximum fill time of 100 ms (full scan), and 
resolution 17,500 at an AGC target value of 100,000/maximum fill time of 60 ms for MS/MS 
at an intensity threshold of 17,000. Apex trigger was set to 1 to 5 seconds, and allowed 
charges were 2-5. For peptide identification, MS/MS spectra were submitted to the uniprot 
Homo Sapiens database (UP000005640; Jan 2015; 67911 entries) using Mascot Version 
2.2.04 (Matrix Science) with the following settings: 10 ppm and 20 millimass units deviation 
for precursor and fragment masses, respectively; trypsin was set as enzyme.The fixed 
modification was carbamidomethyl on Cys. Variable modifications were carbamylation on 
K and protein N-terminus, oxidation on M and acetylation on the protein N-terminus.  
 
Peptide synthesis and confirmation of identity 
Peptides for the confirmation of the sequences identified with mass spectrometry were 
synthesized according to standard fluorenylmethoxycarbonyl (Fmoc) chemistry using a 
SyroII peptide synthesizer (MultiSynTech). The integrity of the peptides was confirmed using 
reverse-phase HPLC and MS. Synthetic peptides were submitted to MS2 on the same 
instrument and compared with MS2 spectrum from biological samples to confirm the initial 
identification. 
 
Mice and immunizations 
Animal experiments were performed conform national guidelines following approval by the 
local Ethical Committee for Animal Experimentation. DBA/1 mice were obtained from our 
breeding colony (originally Harlan) and C57BL/6 mice were purchased from Charles River 
(8-10 weeks old). For alum immunizations mice received two i.p. injections containing a 1:1 
mixture of antigen (100μg) and alhydrogel (Invivogen). Complete Freund’s adjuvant (CFA) 
immunizations were given at the tail base, 100μg antigen in CFA (Difco). Three weeks later 
a subcutaneous boost was given, 100μg antigen in incomplete Freund’s adjuvant (IFA; 
Sigma-Aldrich). For immunizations in the absence of adjuvant, mice received two injections 
with 100µg antigen diluted in PBS. 
 
Generation of the anti-CarP monoclonal antibody 
Spleen cells of Ca-OVA immunized mice were fused with SP2/0 myeloma cells [1] using 
PEG1500 (Roche). Hybridoma cells were seeded in ten 96-wells plates and supernatant was 
tested for anti-CarP positivity by ELISA. SP2/0 cell line was tested for mycoplasma 
contamination.  
 
Antibody variable region cloning 
Antibody variable region genes were amplified from hybridoma cells by RT-PCR, using heavy 
and light chain variable region specific primers. A pool of degenerate ‘forward’ primers that 
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anneal to sequences encoding mouse immunoglobulin leader peptides were used with a 
pool of ‘reverse’ primers that anneal to sequences spanning the framework 4–constant 
region junctions of the heavy and light chains. Alternatively, a pool of degenerate ‘forward’ 
primers that anneal to sequences encoding the start of mature mouse heavy and light chain 
variable regions were used. Restriction sites incorporated in the PCR primers allowed 
cloning of the amplified variable region genes into mouse IgG2a or mouse kappa 
mammalian expression vectors. 
 
Cultivating CHOSXE cells 
Large scale transient transfections were carried out using UCB’s proprietary CHOSXE cell 
line and electroporation expression platform. Cells were maintained in logarithmic growth 
phase in CDCHO media (LifeTech) supplemented with 2mM Glutamax and agitated at 
140rpm in a shaker incubator (Kuhner  AG) supplemented with 8% CO
2 
at  37ºC  
 
Electroporation Transfection 
Prior to transfection, the CHOSXE cell numbers and viability were determined using CEDEX 
cell counter (Innovatis AG) and the required amount of cells (2x10
8
 cells/ml) were 
centrifuged at 1400 rpm for 10 minutes. The pelleted cells were  washed in  Hyclone R 
MaxCyte R buffer (Thermo Scientific) and re-suspended for a further 10 minutes and the  
pellets were re-suspended at  2x10
8
 cells/ml in fresh buffer. Plasmid DNA, purified using 
QIAGEN Plasmid Plus Giga Kit® was then added at 400ug/ml. Following electroporation 
using  a MaxCyte STX®  flow electroporation  instrument,  the cells were transferred into  
ProCHO medium (Lonza) containing 2mM Glutamax and antibiotic antimitotic solution  and  
cultured in a wave bag  (Cell Bag TM  GE Healthcare)   placed  on Bioreactor platform set at 
370C and 5% CO2 with wave motion induced by 25rpm rocking. 24hr post transfection, a 
bolus feed was added and the temperature was reduced to 320C and maintain for the 
duration of the culture period (12-14days). At day four, 3mM Sodium butyrate was added 
to the culture.  At day14,  the cultures were centrifugation for 30 minutes at 4000rpm and 
the retained supernatants were filtered  through 0.22um SARTO BRAN- P (Millipore) 




The murine IgG2A antibodies were purified as follows. Following expression a Protein A 
affinity capture step was performed followed by a preparative size exclusion ‘polishing’ 
step. Clarified cell culture supernatants were first 0.22µm sterile filtered and loaded at 
4ml/min onto 2x 5ml stacked MabSelect SuRe HiTrap columns (GE Healthcare) equilibrated 
in PBS pH7.4 (Sigma Aldrich Chemicals).    
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After loading the columns were washed with PBS pH7.4 and then eluted with 0.1M Sodium 
Citrate pH3.4. The elution was followed by absorbance at 280nm, the elution peak 
collected, then neutralised with 1/5th volume of 2M Tris/HCl pH8.5. The neutralized 
samples were concentrated using Amicon Ultra-15 concentrators with a 30kDa molecular 
weight cut off membrane and centrifugation at 4000xg in a swing out rotor. Concentrated 
samples were applied to an XK26/60 Superdex200 column (GE Healthcare) equilibrated in 
PBS, pH7.4. The column was developed with an isocratic gradient of PBS, pH7.4 at 
2.6ml/min respectively. Fractions were collected and analyzed by size exclusion 
chromatography on a TSK gel G3000SWXL; 5µm, 7.8 X 300mm column developed with an 
isocratic gradient of 0.2M phosphate, pH7.0 at 1ml/min, with detection by absorbance at 
280nm.  Selected monomer fractions were pooled. Final samples were assayed; for 
concentration by A280 Scanning UV-visible spectrophotometer (Cary 50Bio); for % 
monomer by size exclusion chromatography on a TSK gel G3000SWXL; 5µm, 7.8 X 300mm 
column developed with an isocratic gradient of 0.2M phosphate, pH7.0 at 1ml/min, with 
detection by absorbance at 280nm; by reducing and non-reducing SDS-PAGE run on 4-20% 
Tris-Glycine 1.5mm gels (Novex) at 50mA (per gel) for 53minutes; and for endotoxin by 




Prism7 (GraphPad) or IBM SPSS Statistics23 was used for statistical testing. Statistical 
differences in inhibition experiments were determined by the Wilcoxon signed-rank test. 
Differences in antibody levels between subjects and controls were determined by the 
Mann-Whitney U test. Differences in antibody positivity were determined by Pearson’s chi-













Anti-CarP antibodies of RA patients recognize multiple carbamylated antigens.  
To characterize the antigen recognition profile of human anti-CarP antibodies, we studied 
antibody reactivity against a set of five different carbamylated proteins; fetal calf serum 
(FCS), human serum albumin (HSA), human prothrombin (ProT), bovine histone H1 (H1) and 
bovine myelin basic protein (MBP). As depicted in Figure 1B and Figure 2A, serum samples 
from 160 RA patients showed increased recognition of multiple carbamylated antigens as 
compared to serum from healthy individuals (n=40) (Mann-Whitney U test, p<0.001 for 
each test). Although the overall number of RA patients displaying antibody reactivity 
towards these five different antigens is similar (ranging from 39% till 58%) (Figure 1C), the 
antigen recognition profile among individuals differs. In sera of healthy individuals, anti-
CarP antibody reactivity, when present, is limited to only one or two carbamylated antigens, 
while up to 5 out of 5 carbamylated protein antigens are recognized by 24% of RA patients 
(Figure 1D). Furthermore, antibody levels correlate with the total number of proteins 
recognized (Figure 1E and Figure 2B). A strong correlation is observed between the mutual 
recognition of several carbamylated antigens (Figure 1F). Together, these data show that 
anti-CarP antibodies have a broad antigen recognition profile that correlates with antibody 
levels. Within this broad antibody response, both self- and foreign carbamylated antigens 









Figure 1. Characterization of anti-CarP antibody reactivities in RA patients. (A) During carbamylation 
a lysine residue is converted into a homocitrulline residue trough a chemical reaction with cyanate. 
Levels of cyanate are in equilibrium with urea and can be increased, for example, during kidney 
disease. Cyanate levels can also be elevated during inflammation by the action of myeloperoxidase. 
(B) Anti-CarP antibody reactivities against five carbamylated and non-modified counterparts were 
measured by ELISA in 160 RA patients and 40 healthy controls. A standard serum pool was used to 
calculate the arbitrary units. The represented value was calculated by subtracting the non-modified 
antigen reactivity from the carbamylated antigen reactivity. The dotted line represents the cut-off 
while the continuous line represents the median. Statistical differences were determined by the 
Mann-Whitney U test (***: p < 0.001). (C) Percentages of anti-CarP antibody positivity for all five 
antigens in RA patients. (D) Fractions of patients that display antibody reactivity towards multiple 
carbamylated antigens are shown for RA patients and controls. (E) Correlation between the amount 
of antigens recognized by individual serum samples and the anti-Ca-FCS antibody levels. The small 
continuous line represents the median. Reactivity towards Ca-FCS is shown as an example, Spearman 
rank test, P<0.001 for all carbamylated antigens. (F) The correlation between two anti-CarP antibody 
reactivities is shown for different carbamylated antigens. The spearman rank test was carried out to 
determine the degree of statistical correlation. Anti-CarP; anti-carbamylated protein, AU/ml; arbitrary 
units per milliliter, RA; rheumatoid arthritis, Ca-; carbamylated, FCS; Fetal Calf Serum, HSA; human 
















Figure 2. Anti-CarP antibodies of RA patients recognize multiple carbamylated antigens. (A) Anti-
CarP antibody reactivities against five carbamylated and non modified counterparts were measured 
by ELISA. Differential binding of RA sera to the carbamylated proteins compared to the unmodified 
proteins is shown for 160 RA patients.  AU/ml; arbitrary units per milliliter, Ca-; carbamylated, FCS; 
Fetel Calf Serum, Fib; fibrinogen, HSA; human serum albumin, ProT; prothrombin, H1; H1 Histones, 
MBP; myelin basic protein. (B) Anti-CarP antibody positivity sorted by anti-Ca-FCS antibody levels. An 
overview of anti-CarP antibody binding towards five different carbamylated antigens is shown for 160 
RA patients. The list was sorted on anti-Ca-FCS antibody levels, showing the highest anti-Ca-FCS 
antibody levels on top and the lowest levels at the bottom. The dark boxes indicate positivity for that 
particular antigen, while a white box indicates that a sample was negative. Ca-; carbamylated, FCS; 


















Human anti-CarP antibodies are highly cross-reactive.  
Since anti-CarP antibodies recognize a variety of carbamylated antigens and a high 
correlation was observed between reactivities, we next investigated whether antibody 
cross-reactivity could explain these features. Cross-reactivity was determined by inhibition 
assays using carbamylated proteins or their unmodified counterparts. Titrations and control 
experiments were performed to ensure non-saturating conditions for sera and inhibitors 
(Figure 3A-B). Inhibition assays employing the same protein used as antigen and inhibitor 
acted as positive control. Successful signal inhibition is observed for each of the five 
antigens (FCS, HSA, ProT, H1 and MBP) using carbamylated inhibitors, while no inhibition is 
observed for their non-carbamylated counterparts (Figure 3C). Next ten serum samples 
both reactive to Ca-MBP and Ca-ProT were selected for subsequent inhibition experiments.  
Binding of anti-Ca-MBP antibodies could be inhibited by incubation with Ca-ProT (Figure 4A 
and Figure 3D), unlike incubation with unmodified ProT. To characterize the anti-CarP 
antibody cross-reactivity profile in more detail, two representative serum samples 
containing antibodies reactive towards all five antigens were studied. In both samples, each 
carbamylated and non-carbamylated antigen was used to inhibit all five carbamylated 
antigens (Figure 4B). Most of the carbamylated inhibitors can interfere with antibody 
binding, although differences between samples and inhibitors exist. Non-carbamylated 
counterparts do not display an extensive inhibition profile although some inhibition was 
observed for H1, possibly due to the presence of other PTM on histones (26). Altogether, 
we observed that carbamylated proteins are able to interfere with antibody binding to other 
unrelated carbamylated proteins, indicating that anti-CarP antibody cross-reactivity is 





Figure 3. Titration and control experiments for the inhibition studies. (A) Representative figure of an 
inhibition assay in which the plate was coated with Ca-FCS and Ca-FCS (left) or FCS (right) was used as 
an inhibitor in different concentrations. (B) Titration assay of two RA serum samples containing 
antibodies reactive to all five carbamylated antigens. (C) Representative results of inhibition assays 
employing the same proteins as both antigen and inhibitor, accompanied by the non-modified protein 
inhibitor as well. The dotted line indicates the anti-CarP antibody reactivity without inhibition. (D) 
Three examples of anti-Ca-MBP antibody binding when inhibited with no antigen, Ca-ProT or ProT. 
Anti-CarP; anti-carbamylated protein, AU/ml; arbitrary units per milliliter, RA; rheumatoid arthritis, 
Ca-; carbamylated, FCS; Fetel Calf Serum, Fib; fibrinogen, HSA; human serum albumin, ProT; 





Figure 4. Anti-CarP antibodies are highly cross-reactive. (A) Ten serum samples containing both anti-
Ca-MBP and anti-Ca-ProT antibodies were used for inhibition experiments. Anti-Ca-MBP antibody 
binding was measured with or without the presence of Ca-ProT (0.2mg/ml) or ProT (0.2mg/ml) as 
inhibitor. Statistical differences were determined by a Wilcoxon signed-rank test (**: P<0.01). (B) An 
overview of the cross-reactivity of anti-CarP antibodies is depicted. Inhibition assays by ELISA were 
carried out to determine the degree of cross-reactivity, using two representative serum samples 
containing antibodies against five carbamylated antigens. Plates were coated with one protein 
(indicated vertically) and binding of the antibodies towards this coating was inhibited with another, 
or the same protein (indicated horizontally). Inhibition was calculated as a percentage of the antibody 
binding without inhibition. The blank was subtracted before calculating. The darkest color indicates 
an inhibition of more than 75%, followed by an inhibition of more than 50% and the light color 
indicates an inhibition of more than 25%. The white blocks indicate that the inhibition is less than 25%. 
Ca-; carbamylated, FCS; Fetal Calf Serum,  HSA; human serum albumin, ProT; prothrombin, H1; H1 




Carbamylated self-proteins are present in RA synovial tissue.  
The cross-reactive nature of anti-CarP antibodies suggests that these antibodies might react 
to a variety of carbamylated proteins present in target tissue. However, little is known about 
the presence of carbamylated proteins within affected tissue of RA patients. Therefore, we 
aimed to identify carbamylated self-proteins in synovial tissue of two RA patients by mass 
spectrometry. From a list of potential hits, four peptides from carbamylated human albumin 
were selected for further analysis: VFDEFkPLVEEPQNLIK, kLVAASQAALGL, 
kVPQVSTPTLVEVSR, and ADDKETcFAEEGkK. The bold, underlined non-capital k, indicates 
the homocitrulline residue. Three of these four carbamylation sites could be identified in 
both patients. A representative MS-spectrum of carbamylated albumin-derived peptide 
VFDEFkPLVEEPQNLIK is depicted in Figure 5. Importantly, synthetic peptides with the same 
sequence displayed highly similar MS-spectra confirming the correct identification of these 
peptides. MS-spectra of the other albumin-derived peptides are depicted in Figure 6A-C. 
Other verified proteins in which carbamylation was detected in RA patients include several 
collagens, fibronectin, fibromodulin, albumin and Sushi-repeat containing protein SRPX2. 
Similar carbamylated proteins could be detected in the osteoarthritic joint (data not 
shown). Although, the extent of carbamylation was not quantified, these results indicate 







Figure 5. Identification of carbamylated albumin in RA synovial tissue. Tandem mass spectrometry 
(MS2) spectrum from eluted VFDEFkPLVEEPQNLIK peptide (upper panel) derived from carbamylated 
albumin identified in RA synovial tissue. The synthetic VFDEFkPLVEEPQNLIK peptide (lower panel) was 
submitted to MS2 on the same instrument. The bold, non-captical k, indicates the position of 








Figure 6. Additional carbamylated albumin peptides identified in the synovial compartment of RA 
patients. Additional peptides identified in the synovial compartment in RA. MS/MS spectra of 
peptides derived from carbamylated albumin identified in the RA synovial compartment (upper 
panel). The synthetic (lower panel) peptide was submitted to MS/MS on the same instrument. The 
non-captical k, indicates the position of the identified homocitrulline residue. (A) Peptide 









Immunization with carbamylated foreign proteins induces anti-CarP antibodies 
recognizing carbamylated foreign and self-antigens. 
As anti-CarP antibodies from RA patients can recognize both carbamylated self- and non-
self proteins, we next investigated whether a carbamylated foreign antigen can facilitate a 
breach of B cell tolerance towards carbamylated self. Therefore, we immunized mice with 
Ca-OVA or native OVA in aluminum hydroxide (alum) as a protein free adjuvant. As depicted 
in Figure 7A and Figure 8A, immunization with both OVA and Ca-OVA results in the induction 
of a strong antibody response recognizing both modified and non-modified OVA. We 
subsequently analyzed whether murine anti-CarP-antibodies were cross-reactive by 
determining antibody reactivity to another carbamylated foreign protein, Ca-FCS (Figure 
7B). In this setting, antibody reactivity to the OVA backbone will not be detected. Sera from 
OVA-immunized mice do not react to Ca-FCS, whereas sera from Ca-OVA immunized mice 
do contain antibodies reactive to Ca-FCS.  
To determine whether AMPAs induced by PTM foreign proteins can cross-react with self-
proteins, we examined whether sera from Ca-OVA immunized mice contained antibodies 
recognizing carbamylated mouse Albumin (mAlb) and fibrinogen (mFib). As depicted in 
Figure 4C, both Ca-mAlb and Ca-mFib are recognized by sera from Ca-OVA-immunized mice 
but not by sera from OVA-immunized control animals. Importantly, unmodified mAlb or 
mFib are not recognized by sera from Ca-OVA-immunized mice. These data show that auto-
reactive AMPA-responses can be induced by exposure to carbamylated foreign proteins. 
These findings were not confined to foreign antigens, as also immunization with 
carbamylated self–proteins (mAlb and mFib) induced, a cross-reactive anti-CarP antibody 
response (Figure 7D-E and supplementary Figure 8B-D). Nonetheless, these data are 
important as they show that even in the context of a highly immunogenic ‘foreign’ antigen 
the immune response also specifically recognizes small PTMs as evidenced by the presence 
of anti-CarP antibody responses. 
Because of the high structural homology between citrulline and homocitrulline we next 
determined whether murine anti-CarP antibodies could recognize citrullinated antigens as 
well. However, despite minor difference in chemical structure, no binding to Cit-Fib or Cit-
FCS was detectable using anti-CarP antibody containing sera from Ca-OVA immunized mice 
(Figure 7F). In contrast, ACPA-containing sera from RA patients do recognize these 
citrullinated antigens. To examine the potential immunogenicity of carbamylated foreign 
proteins in absence of adjuvants, we next immunized mice with Ca-OVA in PBS. 
Interestingly, significant antibody responses against carbamylated self-proteins were 
induced (Figure 7G), showing that immunization with carbamylated foreign proteins in 
absence of adjuvant also results in a cross-reactive B cell response against modified self-
proteins. These findings further support the notion that AMPA responses can be generated 






Figure 7. Carbamylated foreign proteins can induce cross-reactive anti-CarP antibodies. (A) Mice 
were immunized with foreign antigens ovalbumin (OVA) or Ca-OVA. Sera from immunized mice, OVA 
(circles) and Ca-OVA (squares), was analyzed for binding towards OVA (left panel) and anti-Ca-OVA 
(right panel) by ELISA (n=10). (B) Antibody reactivity towards Ca-FCS from mice immunized with OVA 
(circles) and Ca-OVA (squares) was determined by ELISA. Representative data from 3 experiments are 
shown. Each dot represents data from one mouse (n= 10, *** p<0.001 and ** p<0.01, Mann-Whitney 
U test). (C) Antibody reactivity towards Ca-mFib (left panel), Ca-mAlb (middle panel) and native mAlb 
(right panel) from immunized mice, OVA (circles) and Ca-OVA (squares). Representative data from 3 
experiments are shown (n= 10, Mann-Whitney U test, *** p<0.001). (D) Mice were immunized with a 
carbamylated self-antigen, mouse albumin (Ca-mAlb), or native albumin (mAlb) in aluminum 
hydroxide. Sera from immunized mice (Ca-mAlb (depicted as squares), mAlb (depicted as circles) and 
non-immunized mice (depicted as triangles) was analyzed for reactivity towards Ca-mAlb. 
Representative data from 3 experiments are shown. Each dot represents data from one mouse. 
Statistical difference was determined by the Mann-Whitney U test (n= 10, *** p<0.001). (E) Sera of 
(Ca-)mAlb immunized mice was analyzed for reactivity towards Ca-FCS (left panel), Ca-human 
fibrinogen (Ca-hFib) (middle panel) and Ca-mouse fibrinogen (Ca-mFib) (right panel). Sera from Ca-
mAlb (depicted as squares), mAlb (depicted as circles) and non- immunized mice (depicted as 
triangles) were analyzed by ELISA. Representative data from 3 experiments are shown. Each dot 
represents data from one mouse. (n= 10, *** p<0.001, Mann-Whitney U test).  (F) Correlation 
between antibody reactivity of Ca-OVA immunized mice towards carbamylated human fibrinogen (Ca-
Fib) and citrullinated human fibrinogen (Cit-Fib) (left panel) and correlation between antibody 
reactivity towards Ca-FCS versus citrullinated FCS (Cit-FCS) (right panel) (n=10, Spearman rank test). 
(G) Mice were immunized with foreign antigens ovalbumin (OVA) or Ca-OVA in the absence of 
adjuvant. Sera from immunized mice OVA (circles), Ca-OVA (squares) and non-immunized mice 
(triangles) was analyzed for binding towards carbamylated self-proteins, Ca-mAlb (left panel) and Ca-





Figure 8. Immunization with carbamylated proteins induces anti-CarP antibodies. (A) Sera from mice 
immunized with carbamylated ovalbumin (Ca-OVA) (squares, n=8) or non-modified OVA (triangles, 
n=8) and sera from non-immunized mice were tested for antibody reactivity towards OVA (left panel), 
Ca-OVA (middle panel) and citrullinated ovalbumin (Cit-OVA) (right panel). (B) Mice were immunized 
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with a carbamylated self-antigen, mouse albumin (Ca-mAlb) in alum. Correlations between antibody 
reactivity towards Ca-mFib (mouse fibrinogen) versus Ca-hFib (human fibrogen) (left panel) and Ca-
mAlb versus Ca-mFib (right panel) of Ca-mAlb immunized mice are shown. Statistical correlation was 
determined by the Spearman’s rank test (n=10, p<0.001). (C) Sera from Ca-mAlb immunized mice were 
pre-incubated with either Ca-OVA (squares) or OVA (circles) and subsequently analysed for residual 
binding using a Ca-hFib ELISA (n=10). (D) Mice were immunized with carbamylated self-antigen Ca-
mFib or non-modified mFib emulsified in Freund’s adjuvant. Sera from mice immunized with mFib 
(circles) and Ca-mFib (squares) were harvested and analysed for binding towards Ca-mFib by ELISA 
(n= 4, Mann-Whitney U test, * p<0.05) 
 
 
Monoclonal anti-CarP antibodies show a similar pattern of cross-reactivity towards 
carbamylated foreign and self-proteins.  
To confirm the cross-reactive nature of anti-CarP antibody responses, we generated a 
murine anti-CarP monoclonal from a mouse immunized with Ca-OVA. As depicted in Figure 
9A, this monoclonal antibody binds both carbamylated foreign- and self-proteins. We 
observe a significant correlation between the monoclonal antibody binding to Ca-FCS, Ca-
OVA and Ca-Fib (Figure 9B) confirming its cross-reactive nature. Thus, as observed for 
polyclonal anti-CarP antibodies from mice immunized with a foreign antigen, strong cross-
reactivity is observed towards different carbamylated foreign and self-proteins at the 
monoclonal antibody level, confirming that self-reactive AMPAs can be induced by exposure 





Figure 9. Monoclonal antibodies are highly specific and cross-reactive towards carbamylated foreign 
and self-antigens. (A) Binding of a murine anti-CarP monoclonal antibody towards carbamylated 
foreign proteins; Ca-FCS, Ca-Ovalbumin (Ca-OVA), Ca-human Fibrinogen (Ca-Fib) and non-modified 
counterparts was tested using ELISA (left panel). Reactivity of the anti-CarP monoclonal antibody 
towards carbamylated self-proteins; Ca-mouse fibrinogen (mFib) and Ca-mouse Albumin (mAlb) and 
non-modified counterparts was measured by ELISA (right panel). (B) The correlation between anti-
CarP antibody reactivity towards Ca-Fib and Ca-FCS is shown in the left panel (rho=0.999) and for Ca-
Fib compared to Ca-OVA is depicted in the middle panel (rho=0.936). Correlation between anti-CarP 
antibody reactivity towards Ca-OVA and Ca-FCS is depicted in the right panel (rho=0.936). The 










A key characteristic of RA is the occurrence of autoantibodies against PTM proteins (2, 8-
10). Here, we report that post-translational modification of foreign proteins, in particular 
carbamylation, represents one way in which immune tolerance at the B cell level towards 
self can be broken. In RA patients we found that anti-CarP antibodies present within one 
serum sample are cross-reactive towards different carbamylated proteins, including foreign 
and self-proteins. To study how autoreactive B cell responses against PTM self-proteins can 
be induced, we used carbamylated model antigens (OVA and mAlb) in mice. Our 
observations reveal that not only carbamylation of self- but also of foreign proteins is 
sufficient for a breach of immunological tolerance and the formation of autoreactive anti-
CarP antibodies. Previous animal studies showed that immunogenicity of proteins is 
enhanced upon citrullination (27-29). Likewise, although cross-reactive AMPA responses 
have been described (9, 10, 30), it has not been demonstrated that AMPA-producing B cells 
recognizing a particular modified self-protein can be induced by other -unrelated- modified 
proteins or that immunization with a modified (structurally unrelated) foreign protein leads 
to the induction of a cross-reactive AMPA-response against self. Clearly, human studies 
demonstrating this principle are challenging as the autoantibody-inciting events are 
unknown and difficult to control (31).   
Recently, we showed that mice are able to mount an antibody response against 
carbamylated proteins (23). Therefore, we could now address the question whether 
exposure of a host to a carbamylated foreign protein can lead to the formation of an 
autoreactive B cells response. Our data show that anti-CarP autoantibodies can, indeed, be 
induced by carbamylated foreign antigens. These autoantibodies react, both at the 
polyclonal- as well as the monoclonal level, to different carbamylated proteins, confirming 
that anti-CarP antibodies are cross-reactive. This high-level cross-reactivity is likely 
explaining why carbamylated foreign proteins can induce an autoreactive B cell response, 
and indicate that the epitope recognized by responding B cells can be present on a variety 
of proteins, either of self- or non-self origin. In RA, we have shown that anti-CarP antibodies 
are able to recognize different carbamylated (auto)antigens. Similar findings have been 
reported for other AMPA responses(9, 10, 30). For example, previous human studies have 
shown that also ACPA exhibit cross-reactive properties towards different citrullinated self- 
and foreign antigens (30, 32-36).  Interestingly, although citrulline greatly resembles 
homocitrulline in structure, we were unable to detect an antibody response against 
citrullinated proteins in mice. Also vaccination with citrullinated proteins did not induce an 
ACPA response (data not shown). Therefore, we were not able to analyze whether 
autoreactive ACPA could also be induced by (citrullinated) foreign proteins. Nonetheless, 
given the cross-reactive properties of ACPA (37-40), it is highly conceivable that similar 
principles as identified for anti-CarP-antibody responses apply to other classes of AMPA as 
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well. Although it is unknown how autoantibodies against PTM proteins are generated in 
humans, it is often speculated that an autoreactive T cell response recognizing such self-
proteins is crucial for their appearance.  
Clearly, our results are not incompatible with this notion and do not indicate that such T cell 
help would not contribute the induction of B cell mediated autoimmunity against PTM 
proteins. However, our results provide first evidence that also T cells recognizing 
“conventional” foreign antigens could be involved in the induction of AMPA-producing B 
cell responses that recognize modified self-proteins. So far it is unclear to what extent T cell 
tolerance is lost in RA as identification of PTM epitopes recognized by autoreactive T cells 
has been proven difficult. Although T cell responses against PTM self-proteins have been 
described (41-43), frequencies of citrulline specific T cells are estimated to be 10 times 
lower as compared to T cell frequencies to recall antigen as approximately 1 in 100,000 CD4 
cells have been reported to react with tetramers containing citrullinated peptides 
compared to 1:10,000 CD4 cells for tetanus toxoid specific T cells (43, 44). Nonetheless, 
animal studies show that PTM proteins can generate antigen-specific T cell responses (19, 
27-29, 45).  However, at present it is still unclear to what extent these T cells provide help 
to autoreactive B cells in human RA. Our data indicate that T cell help required for the 
generation of isotype-switched AMPA-responses can be provided by T cells directed against 




Figure 10. Interferon-y production by bulk T-cell cultures after stimulation with ovalbumin as 
foreign antigen. Mice were immunized with carbamylated ovalbumin (Ca-OVA, n=9) (black bars) or 
non-modified ovalbumin (OVA, n=9) (white bars) in CFA and boosted with the same antigen in IFA. 
Spleens cells of Ca-OVA, OVA and naïve  mice (striped bars, n=2) were in vitro stimulated with D1 cells 
pulsed with different concentrations of Ca-OVA (A) and OVA (B), or medium. Interferon-γ ELISA was 
performed as readout for T-cell activation after in vitro stimulation of spleen cells. The samples are 




We consider it likely that the initiating event leading to the formation of autoantibodies 
against carbamylated proteins is not found in the induction of a (T cell) response against 
carbamylated self-proteins but rather in the induction of immune responses against 
modified foreign antigens. The only requirement would be that the foreign antigen 
recognized by the T cells contains PTMs seen by B cells. Such requirement could be met 
during infection as the conditions to post-translationally modify microbe-derived proteins 
readily occur during infection. This could, for example, be mediated through release of PAD 
by neutrophils during netosis (citrullination) (46, 47), the release of myeloid peroxidase 
leading to enhanced carbamylation or the presence of bacterial-derived acetylated proteins 
(1, 12, 48). In all these cases, microbe-derived proteins express or can acquire a PTM that 
can be targeted by responding B cells. These B cells are likely to obtain help from microbe-
directed T cells required for further somatic hypermutation. Since self-proteins can also 
undergo similar PTM, some B cells will conceivably be selected on modified self-proteins 
leading to the development of a self-reactive B cell response. In this scenario, autoimmunity 
can emerge without the presence of autoreactive T cells.   
These considerations are important for the development of tolerizing protocols aiming to 
dampen or inactivate putative autoreactive T cells in an antigen-specific fashion. Likewise, 
they are also of relevance to define the autoimmune inciting antigen as the recognition of 
a particular antigen by autoreactive B cells or antibodies might not relate to the antigen that 
was required to induce the B cell response.  
In conclusion, our results clearly indicate that carbamylated foreign proteins are able to 
induce a breach of tolerance at the B cell level leading to the formation of cross-reactive 
anti-CarP antibodies recognizing modified self-proteins. We consider it likely that anti-CarP 
B cell responses can result from inflammatory conditions induced for example by infection, 
as it is conceivable that in such conditions carbamylated foreign proteins are recognized by 
the responding immune system. The evoking anti-CarP immune response might 
subsequently cross-react to carbamylated self-proteins that are also expressed in the joints 
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Posttranslational modifications (PTM) are thought to play a role in the breach of tolerance 
and onset of autoimmunity. In Rheumatoid arthritis (RA) autoantibodies directed against 
PTM proteins are implicated in disease pathogenesis, however why anti-modified protein 
responses are initiated in RA is still unknown. Here, we investigated whether 
posttranslational modification e.g. carbamylation of an antigen can result in the generation 
of neo-epitopes and subsequently induce a breach of tolerance towards self-antigens at a T 
cell level.  
 
Methods 
Mice were immunised with carbamylated or non-modified mouse Albumin (mAlb). Using 
pulsed DCs, T cell responses were studied by proliferation assays, IL-5 and IFN-γ ELISA. 




Studies in mice show that antigen specific T cell responses recognising carbamylated mAlb 
are induced by immunisation with carbamylated mAlb. Using mass spectrometry five 
carbamylated mouse albumin peptides were identified in digested carbamylated mouse 
albumin. Stimulation of spleen cells with carbamylated mouse albumin peptides induced a 
PTM specific T-cell response indicated by IFN-γ production.  
 
Conclusions 
These results indicate that carbamylation of self-proteins is sufficient for a breach of 
immunological tolerance at a T cell level. These results contribute to the concept that 
formation of anti-CarP antibodies occurs in a ‘hapten’-like manner, suggesting that the help 
provided to anti-CarP antibody producing B cells can come from T cells directed against 










During normal physiological conditions, posttranslational protein modifications are 
important for biological function and critically influence protein structure and function. In 
Rheumatoid arthritis (RA) posttranslationally modified proteins (PTM) have been implicated 
in disease pathogenesis as different anti-modified protein antibody (AMPA) responses can 
be identified sera of RA patients (1-5). Why these autoimmune responses against PTM 
antigens are initiated in RA is currently unknown. It has been postulated that 
posttranslational modifications can play a role in the breach of tolerance towards self-
antigens. A possible mechanism by which posttranslational modifications could break 
immune tolerance is that the modified self-antigen is not presented in the thymus, and 
therefore reactive T cells escape tolerance induction and migrate into the periphery. A 
second mechanism may be that antigen processing of proteins and peptides containing 
posttranslational modifications is different compared to the unmodified native 
counterparts allowing the presentation of otherwise ‘cryptic’ self-epitopes. Likewise, 
posttranslational modifications might affect the binding of the epitope to the major 
histocompatibility complex (MHC) class II molecules.  
Besides citrullinated proteins, several other post-translational modifications can be 
targeted by antibodies in sera of RA patients. Anti-CarP antibodies are present in 
approximately 45% of RA patients and target proteins that are modified through an 
enzymatic modification named carbamylation. Carbamylation changes the charge of an 
amino acid (lysine has a positive charge, whereas homocitrulline has a neutral charge) and 
it can change the structure of a protein. This new feature could have implications for the 
binding of antibodies, recognition by T cell receptors and/or binding to MHC molecules. 
Given the observation that anti-CarP antibodies, in contrast to ACPA, do occur in both 
humans and mice, these autoantibodies enable us to study the etiology of AMPA responses 
in more detail. 
We have previously shown that a breach in B cell tolerance could be readily induced upon 
immunization with carbamylated self- or foreign proteins leading to the formation of cross-
reactive anti-CarP autoantibodies (6). The presence of different anti-CarP isotypes and 
subclasses upon immunization with carbamylated antigens and in sera of mice with collagen 
induced arthritis (7) is indicative of antigen-driven selection and T cell dependent antibody 
production against carbamylated autoantigens. It can be hypothesized that upon exposure 
to PTM self-proteins autoreactive T cell responses can be generated; however it is also 
conceivable that a T cell reaction against PTM foreign antigens provides help to self-reactive 
AMPA producing B cells. In this study we aimed to investigate whether posttranslational 
modification e.g. carbamylation of an antigen can result in the generation of neo-epitopes 





Carbamylation of mouse Albumin 
For generating carbamylated mouse albumin (Ca-mAlb; EMD Millipore), proteins were 
diluted in PBS to a protein concentration of 10 mg/ml. The diluted protein was incubated 
for 12 hours at 37 °C with 1 M potassium cyanate (Sigma-Aldrich). After incubation the 
samples were extensively dialyzed against PBS.  
 
Mice and immunizations 
All animal experiments were approved by local regulatory authorities and conform national 
guidelines. C57BL/6 mice were purchased from Charles River. Mice were immunised when 
they were 8-10 week old mice. For aluminum hydroxide immunizations the mice received 2 
intraperitoneal injections with a 1:1 mixture of antigen or peptide and alhydrogel 
(invivogen) containing 100 μg of antigen per immunization. Complete Freunds adjuvant 
(CFA) immunizations were done via injection at the tail base with 100 μg of antigen 
emulsified in complete Freunds adjuvant (CFA; Difco). Three weeks later mice received a 
subcutaneous boost with 100 μg of the same antigen in incomplete Freunds adjuvant (IFA; 
Sigma-Aldrich). 
 
T cell assays 
Spleen cells were harvested and cultured in RPMI supplemented with 8%FCS, penicillin, 
streptomycin, L-glutamin and 50 μM 2-mercaptoethanol. Cells were stimulated with 20 
µg/ml antigen and cultured for 4 days. After 4 days cytokine levels in the supernatant were 
determined by ELISA. For experiments with peptides, D1 dendritic cells (8) were pulsed for 
24 hours with 20 µg/ml peptide, whole protein or protein digest in combination with 
0.1µg/ml LPS. After D1 cell maturation cells were washed, irradiated with 3000 RAD and 
plated out with spleen cells in a 1:2 ratio. Cells were cultured four 4 days and after this cells 
were pulsed with 3[H]-thymidine and incubated overnight at 37C and 5% CO2. Cytokine 
levels in the supernatant were determined by IL-5 or IFN-γ cytokine ELISA.  
Ca-mAlb was reduced with DTT and digested 2h at 37°C with either trypsin (enzyme protein 
ratio 1:20; pH 8.3), chymotrypsin (ratio 1:20; pH 8.3) or proteinase K (ratio 1:100; pH 11).  
 
Protein digestion and mass spectrometry 
Ca-mAlb was reduced with DTT and digested 2h at 37°C with either trypsin (enzyme protein 
ratio 1:20; pH 8.3), chymotrypsin (ratio 1:20; pH 8.3) or proteinase K (ratio 1:100; pH 11).  
Chymotryptic peptides (from 500 μg Ca-mAlb) were separated on a 4.6 mm C18 reverse 
phase column equilibrated with 0.1% formic acid. Peptides were analyzed via on-line C18-
nano-HPLC-MS with a system consisting of an Easy nLC 1000 gradient HPLC system (Thermo, 
Bremen, Germany), and a Q-Exactive mass spectrometer (Thermo). Fractions were injected 
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onto a homemade precolumn (100 μm × 15 mm; Reprosil-Pur C18-AQ 3 μm, Dr. Maisch, 
Ammerbuch, Germany) and eluted via a homemade analytical nano-HPLC column (15 cm × 
50 μm; Reprosil-Pur C18-AQ 3 um). The gradient was run from 0% to 30% solvent B 
(10/90/0.1 water/ACN/FA v/v/v) in 120 min. The nano-HPLC column was drawn to a tip of 
~5 μm and acted as the electrospray needle of the MS source. The Q-Exactive mass 
spectrometer was operated in top10-mode. Parameters were set at resolution 70,000 at an 
AGC target value of 3,000,000, maximum fill time of 20 ms (full scan), and resolution 17,500 
at an AGC target value of 100,000/maximum fill time of 60 ms for MS/MS at an intensity 
threshold of 17,400. Apex trigger was set to 1 to 5 seconds, and allowed charges were 1-6. 
In a post-analysis process, raw data were converted to peak lists using Proteome Discoverer 
1.4 (Thermo). For peptide identification, MS/MS spectra were submitted to the mouse 
database using Mascot Version 2.2.04 (Matrix Science) with the following settings: 10 ppm 
and 20 mmu deviation for precursor and fragment masses, respectively; no enzyme was 
specified. All reported hits were assessed manually, and peptides with MASCOT scores <35 
were generally discarded.  
 
Statistical analysis 
All statistical testing was performed using Prism 7 (GraphPad Software).  Different groups 



















Carbamylated self-antigens facilitate a breach in T cell tolerance.  
Posttranslational modification of an antigen could potentially result in the generation of 
neo-epitopes and subsequently induce a breach of tolerance towards self-antigens at a T 
cell level. To study whether carbamylation of a self-antigen can have this effect, we 
immunised mice with either Ca-mouse albumin (Ca-mAlb) or non-modified-mouse albumin 
using a protein free adjuvant (aluminum hydroxide). Since aluminum hydroxide is known to 
be a Th-2 response skewing adjuvant in mice (9) IL-5 production was used as a outcome 
measure for T cell reactivity. Antigen specific INF-γ production by spleen cells from these 
mice could not be detected (data not shown). Spleen cells from Ca-mAlb immunized mice 
produced IL-5 after stimulation with Ca-mAlb in vitro, while mAlb stimulation did not induce 
IL-5 production (Figure 1A). To determine whether the IL-5 production was due to a Ca-
mAlb specific effect, spleen cells of Ca-mAlb or mAlb immunised mice were restimulated in 
vitro with Ca-mAlb pulsed D1 dendritic cells (DCs). Spleen cells of mice previously 
immunised with Ca-mAlb gave a significant higher IL-5 production which suggests the loss 
of T cell tolerance towards a carbamylated self-antigen; however the induced T cell 
proliferation was less pronounced (Figure 1B).  
When D1 DCs were pulsed with chymotrypsin or trypsin digested Ca-mAlb, IL-5 production 
was still induced by activation of spleen cells from Ca-mAlb immunised mice. Proteinase K 
digestion of Ca-mAlb results in very short peptides (less than 9 amino acids). After treatment 
with proteinase K, DCs pulsed with digested Ca-mAlb did not induce any IL-5 production 
(Figure 1C). Since, proteinase K digestion results in peptide fragments too short for MHCII 
presentation, this confirms that the observed IL-5 production is actually a T cell response to 
a protein antigen. To identify which epitope(s) of Ca-mAlb were recognized, chymotrypsin 
digested Ca-mAlb was fractioned based on hydrophobicity. Different fractions were then 
subsequently used to pulse DCs for T cell stimulation. DCs pulsed with fraction 2142941 
induced an IL-5 response by spleen cells of Ca-mAlb immunised mice (Figure 1D). Fraction 
2142941 was subsequently further analyzed by mass-spectometry and the most abundant 
Ca-peptides with a length of at least 9 amino acids were identified (Table 1). Only five 
identified peptides were actually derived from Ca-mAlb as other identified Ca-peptides had 
a different serological protein origin. We next aimed to test whether the identified Ca-mAlb 
peptides were capable of the induction of T cell stimulation and IL-5 production. To this end 
we immunised mice with Ca-mAlb and stimulated the spleen cells with either one of the 
five identified peptides pulsed DCs. After stimulation of the spleen cells we observed that 
all four immunised mice responded to peptide 7 EkLGEYGFQNAILVRY, the bold underlined 




Figure 1. T cell activation and cytokine production after stimulation with carbamylated mouse 
Albumin. (A) Mice were immunised with carbamylated mouse albumin (Ca-mAlb) or native mouse 
albumin (mAlb) in aluminium hydroxide and boosted with the same antigen mixture. Spleen cells were 
in vitro stimulated with D1 cells pulsed with Ca-mAlb or mAlb. Phytohemagglutinin (PHA) mitogen was 
added to spleen cells as a positive control. IL-5 ELISA was performed as readout for T cell activation. 
(B) Spleen cells from mice immunised with Ca-mAlb (black bars) or mAlb (white bars) were in vitro 
stimulated with D1 cells pulsed with Ca-mAlb, mAlb or non-pulsed DCs. IL-5 ELISA was performed as 
readout for T cell activation (right panel) and cells were pulsed with 3[H]-thymidine as a readout for T 
cell proliferation (left panel). The samples are pooled data from two independent experiments (n=10 
mice per group). Statistical differences were determined by the Mann-Whitney U test or the Kruskal-
Wallis test *p<0.05, **p<0.01, ***p<0.005.  (C) Ca-mAlb digested by chymotrypsin, trypsin or 
proteinase K was used to pluse D1 cells. Spleen cells from mice immunised with Ca-mAlb were 
stimulated in vitro and an IL-5 ELISA was performed as readout (n=4 mice per group). (D) Chymotrypsin 
digested Ca-mAlb was fractioned based on hydrophobicity. D1 cells were pulsed with different 
fractions of mAlb and used for stimulation of spleen cells of Ca-mAlb immunised mice 1L (white bars) 







Table 1. List of homocitrullin conainting peptides in fraction 2142941 derived from carbamylated 
mouse Albumin. Chymotrypsin digested fractions of Carbamylated mouse Albumin were  fractionated 
based on hydrophobicity. Fraction 2142941 was analysed by Mass Spectomery to identify 
homocitrulline containing peptides with a length of at least 9 amino acids.  
 
In spleen cells stimulated with the other Ca-mAlb peptides similar T cell responses were 
observed although not all mice responded consistently. To determine whether the observed 
IL-5 response towards peptide 7 was homocitrulline specific we next stimulated spleen cells 
with DCs pulsed with peptide 7 that contained either a homocitrulline residue or a lysine 
residue at this particular position. Interestingly, the observed IL-5 response was in all 5 mice 
significantly higher towards the carbamylated version of peptide 7 (Figure 2B).  
Finally, we aimed to determine whether immunization with carbamylated self-peptides 
could result in a breach homocitrulline specific T-cell tolerance. In a first experiment we 
immunised mice with peptide 7 containing a homocitrulline (Hcit) or a lysine (Lys) residue 
using aluminum hydroxide as an adjuvant. In this setting, low levels of IL-5 were detected 
in spleen cells cultures after stimulation with either the carbamylated or non-modified 
peptide 7 (Figure 3A and B). In a second experiment we therefore switched to Complete 
and Incomplete Freund’s Adjuvant (CFA/IFA) to induce a Th-1 skewed immune response. 
Mice received two immunisations with Hcit or Lys peptide 7 emulsified in CFA/IFA. Antigen 
specific INF-γ production by spleen cells from these mice was subsequently measured as an 
outcome for T-cell reactivity. Spleen cells of mice immunised with Hcit peptide 7 (Figure 2C, 
left panel) responded with a significant higher IFN-γ production to the carbamylated 
Peptide number identified peptides            protein 
1 DAGLTPNNLOPVAAEFYGSVEHPQTY Serotransferin 
2 MVOVLDAVRGSPAVDVAVOVF Transthyretin OS 
3 HWPQGPSTVDAAFSWDDOVY Hemopexin OS 
4 GVYVRATDLODWVQETMAON Haptoglobin 
5 RSVSELPIMHQDWLNGOEF IgG1 chain contant region 
6 ONPITSVDAAFRGPDSVF Hemopexin 
7 EOLGEYGFQNAILVRY Serum albumin 
8 DEHAOLVQEVTDFAOT Serum albumin 
9 VRQSPGOGLEWLGVIW Ig heavy chain V region 
10 DLGEQHFOGLVLIAF Serum albumin 
11 SQTFPNADFAEITOL Serum albumin 
12 VHLTDAEOAAVSGLW Beta-globin 
13 RGPDSVFLIOEDOVW Hemopexin OS 
14 YAEAODVFLGTF Serum albumin 
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peptide compared to the control peptide. In mice immunised with Lys peptide7 no anti-
carbamylated specific T cell responses were detected (Figure 2C, right panel). Together, 
these data show that posttranslational modification of a self-antigen can result in the 
generation of neo-epitopes and subsequently induce a breach of tolerance towards self-




Figure 2. Homocitrulline specific T cell responses after stimulation with carbamylated peptide 7 (A) 
Mice were immunised with carbamylated mouse albumin (Ca-mAlb) in aluminium hydroxide and 
boosted with the same antigen mixture. Spleen cells were in vitro stimulated with D1 cells pulsed with 
different carbamylated peptides derived from Ca-mAlb. IL-5 ELISA was performed as readout for T cell 
activation. (B) Mice were immunised twice with Ca-mAlb in aluminium hydroxide. D1 cells were pulsed 
with a carbamylated or non-modified version of peptide 7 EkLGEYGFQNAILVRY, the bold underlined 
non-capital k represents indicates the position of the homocitrulline residue or the lysine residue. 
Spleen cells from Ca-mAlb immunised mice were subsequently in vitro stimulated with pulsed D1 cells 
and cultures were analysed for IL-5 production (n=5 mice per group, left panel) and T-cell proliferation 
(n=3 mice per group, right panel). (C) Mice were immunised with a carbamylated (left panel) or non-
modified version of peptide 7 (right panel). Spleen cells were in vitro stimulated with D1 cells pulsed 
with carbamylated peptide 7, non-modified peptide 7 or with no antigen. IFN-γ ELISA was performed 
as readout for T cell activation. The samples are pooled data from two independent experiments (n=8 




Figure 3. Low levels of IL-5 production after stimulation with carbamylated peptide 7 Mice were 
immunised with a carbamylated  (A) or non-modified version of peptide 7 (B) using aluminum 
hydroxide. Spleen cells were in vitro stimulated with D1 cells pulsed with carbamylated peptide 7, 
non-modified peptide 7 or with no antigen. IL-5 ELISA was performed as readout for T cell activation. 
The samples are pooled data from two independent experiments (n=8 mice per group). Statistical 













A key characteristic of one of the most common autoimmune diseases, rheumatoid 
arthritis, is the occurrence of autoantibodies against posttranslational modified proteins 
(10). We previously showed that carbamylation of both self- and foreign proteins is 
sufficient for a breach of immunological tolerance and the formation of anti-CarP 
antibodies. These findings show that posttranslational modification of self-proteins, in 
particular carbamylation, represents one way in which immune tolerance is bypassed both 
at a B cell and T cell level.  
Carbamylated antigens have a different structure and charge, a feature which might have 
implications for antigen recognition and processing that can subsequently lead to a breach 
of tolerance towards self-antigens. Stimulation of spleen cells with Ca-antigen pulsed DCs 
led to the induction of a strong T cell response, cytokine production and proliferation, in 
contrast to stimulation with the non-modified version of the antigen. Protein digestion of 
Ca-mAlb with proteinase K resulted in short peptides that were too short for MHCII 
presentation and subsequent T cell activation. Stimulation of spleen cells with Ca-mAlb 
derived homocitrulline containing peptides identified by mass spectrometry resulted in a 
PTM specific T-cell response. Together these findings suggest that carbamylation of an 
autoantigen can result in the generation of neo-epitopes and subsequently induce a breach 
of tolerance towards self-antigens at a T cell level. Homocitrulline residues in a protein may 
function in a ‘hapten-like manner’ capable of eliciting a specific immune response once 
bound to a carrier-protein. Similar to posttranslational citrullination (11), carbamylation of 
antigens is, in itself, not specific for RA which demonstrated by the fact that anti-CarP 
antibodies have been described in different forms of autoimmune arthritis and other 
inflammatory diseases (12-14). 
We consider it likely that anti-CarP immune responses can occur resulting from 
inflammatory conditions induced for example during infection, as it is conceivable that such 
conditions lead to carbamylation of self-proteins. Interestingly, carbamylated-albumin, 
which is able to induce a break of tolerance in mice was previously shown to be present in 
rheumatic joints of RA patients and antibodies reactive to carbamylated albumin have been 
found in approximately 40% of RA patients (6).      
To summarize, we have shown that carbamylated proteins are able to trigger primary 
immune responses, including autoantibody production, T cell activation and cytokine 
production. Posttranslational modification of self-proteins by carbamylation is one way in 
which ‘new’ antigens are created for which immune tolerance does not exist. In the case of 
RA the formation of homocitrulline residues seems to promote tolerance loss and 
autoimmunity, it is unknown, however, whether immune responses to carbamylated 
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Autoantibodies against post-translationally modified proteins (Anti-Modified Protein 
Antibodies or AMPA) are a hallmark of Rheumatoid Arthritis (RA). A variety of classes of 
AMPAs against different modifications on proteins, such as citrullination, carbamylation and 
acetylation, have now been described in RA. At present, the origin or mutual relationship of 
AMPAs is poorly understood. Here, we aimed to study the origin of AMPA-responses by 
postulating that the AMPA-response shares a common “background” that evolves into 
different classes of AMPAs.  
  
Methods 
Mice were immunized with acetylated-, carbamylated- or non-modified ovalbumin and 
analyzed for AMPA-responses. In addition, serum reactivity towards modified antigens was 
determined for RA patients.  
 
Results  
Immunisation of mice with carbamylated proteins induced an antibody response not only  
recognizing carbamylated proteins, but also acetylated proteins. Similarly, immunization 
with acetylated proteins led to the formation of (autoreactive) AMPAs against other 
modifications as well. Analysis of antibodies purified from blood of RA patients using 
citrullinated antigens revealed that these antibodies, besides being citrulline-reactive, can 
also display reactivity to acetylated and carbamylated peptides. Similarly, affinity-purified 
anti-carbamylated protein antibodies showed cross-reactivity against all three post-
translational modifications tested. 
 
Conclusions 
Our data show that different AMPA-responses can emerge from exposure to only a single 
type of modified protein. These findings indicate that different AMPA-responses can 
originate from a common B cell response that diversifies into multiple distinct AMPA-
responses and explain the presence of multiple AMPAs in RA, one of the hallmarks of 












Rheumatoid arthritis (RA) is an autoimmune disease affecting the synovial joints. The 
disease is characterized by the presence of autoantibodies, recognizing self-proteins. The 
most extensively  studied antibodies are Rheumatoid Factor (RF), recognizing the Fc-part of 
IgG molecules, and Anti- Citrullinated-Protein Antibodies (ACPA), antibodies that recognize 
a particular Post-Translational Modification (PTM) on proteins. Due to the specificity of 
these autoantibodies for RA, sero-status of these autoantibodies has been included in the 
2010 ACR/EULAR classification criteria for RA (1).   
ACPAs have been shown to recognize citrullinated proteins, a PTM resulting from the 
deimidation of arginine within proteins. The process of deimination is mediated by 
PeptidylArginine Deiminases (PAD), enzymes present in all human cells and involved in 
several cellular processes (reviewed in (2)). Both polyclonal and monoclonal ACPA can 
display an extensive citrulline-dependent cross-reactivity towards multiple citrullinated 
peptides and proteins (3). Interestingly, the citrullinated epitope-recognition profile 
expands before clinical onset of disease, possibly as a consequence of the activation of new 
ACPA-expressing B cells and/or progressive somatic hypermutation of individual B cell 
clones (4-8). Besides autoantibodies targeting citrullinated antigens, other post-
translationally modified proteins have been found to be recognized by autoantibodies, in 
particular carbamylated and acetylated proteins (9). Both carbamylation and acetylation 
are conversions of lysine. Carbamylation is a chemical process mediated by cyanate, a 
compound increased during inflammation (10). The resulting homocitrulline resembles 
citrulline, but contains an additional methylene group. Acetylation can occur through 
intracellular acetyltransferases, a process that can be mimicked chemically in vitro. Anti-
Carbamylated protein (anti-CarP) antibodies are present in approximately 45% of early RA 
patients (11). These antibodies can be cross-reactive to citrullinated antigens, but can also 
display a more restricted recognition profile directed against carbamylated proteins only. 
Indeed, 10-20% of ACPA-negative RA patients are positive for anti-CarP antibodies, 
indicating that these antibodies represent a different class of Anti-Modified Protein 
Antibodies (AMPA) (11). Anti-Acetylated Protein Antibodies (AAPAs) have been reported to 
be present in approximately 40% of RA patients(12). The presence of these antibodies was 
mainly found in ACPA-positive RA, although also some ACPA-negative RA patients were 
positive for AAPA. Inhibition experiments showed limited cross-reactivity between anti-
acetylated, anti-carbamylated and anti-citrullinated peptide antibodies, indicating that also 
AAPA represent another class of AMPA (12). These previous observations are interesting as 
they indicate that AMPA-reactivity, due to their combined appearance in RA, has a 
commonality that is currently not understood. Here, we studied the possibility that the 
AMPA-response originates from a common event by analyzing whether exposure to one 
particular class of modified proteins can generate different AMPA-responses.  
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Chapter 5 
Materials and Methods 
 
Proteins and modifications 
Mouse albumin was purchased from Merck Millipore (Cat# 126674), human fibrinogen and 
chicken ovalbumin (OVA) were purchased from Sigma Aldrich (Cat# F4883 and Cat# A5503 
respectively). Carbamylation of proteins was achieved by incubating the proteins with 
potassium cyanate (Cat#215074, Sigma Aldrich) as has been described before (11). In short, 
OVA and mouse albumin were incubated overnight at 37°C in an end concentration of 1M 
potassium cyanate at a protein concentration ranging between 1 and 5mg/mL. Human 
fibrinogen was incubated in 0.5M potassium cyanate for 3 days at 4°C. All proteins were 
subsequently extensively dialyzed in PBS for 3 days.  
Acetylation was performed as previously described (13). In short, proteins were diluted to 
a  concentration of 1mg/mL in 0.1M Na2CO3. Per 20mL of protein solution, 100uL of acetic 
anhydride was added and subsequently 400uL of pyridine. Proteins were incubated at 30°C 
for 5 hours or overnight whilst shaking. After incubation, the acetylation reaction was 
stopped by adding 400uL (per 20mL solution) of 1M Tris. Acetylated proteins were purified 
by exchanging the buffer for PBS through Zeba Spin Desalting columns (Thermo Scientific). 
Citrullination of OVA and fibrinogen was  performed by incubation of the proteins with 
PeptidylArginine Deiminase (PAD) 4 enzyme (Cat# 1584, Sigma Aldrich) in the presence of 
0.1M Tris-HCl (pH 7.6) and 0.15M CaCl2. For OVA, 3 units of PAD were added per mg of 
protein for the citrullination process whereas for fibrinogen 5U PAD per mg protein was 
used. Both proteins are incubated overnight at 53°C. Modifications were validated  by ELISA. 
 
ELISA modified antigens 
Modification of fibrinogen and OVA were validated by ELISAs using commercial polyclonal 
rabbit anti-carbamyl-lysine antibodies (Cat# STA-078, Cell Biolabs) and commercial 
polyclonal rabbit antiacetylated-lysine antibodies (Cat# ADI-KAP-TF120-E, Enzo 
Lifesciences), or our human ACPA monoclonal antibody as described in (14). In short, 
proteins were coated at a concentration of 10µg/mL (in 0.1M carbonatebicarbonate buffer, 
pH 9.6) on Nunc Maxisorp plates (Cat# 430341, Thermofisher Scientific) and incubated 
overnight at 4°C. Wells were blocked with PBS + 2% BSA to inhibit unspecific antibody 
binding to the plastic for 4 hours at 4°C before incubating the plates with the anti-carbamyl-
lysine antibodies, anti-acetylated-lysine antibodies or the ACPA monoclonal (diluted in RIA 
buffer containing 10mM TRIS (pH 7.6), 350mM NaCl, 1% TritonX, 0.5% Nadeoxycholate and 
0.1% SDS) overnight at 4°C. Binding of the antibodies was detected by a goat-antirabbit 
Horse RadishPeroxidase (HRP)-conjugated antibody (for the rabbit polyclonal antibodies) 
(#P0448, DAKO) or a rabbit-anti-human-IgG HRP-conjugated antibody (for the human ACPA 
monoclonal) (Cat# P0214, DAKO) (4hrs at 4°C or 2hrs at RT). HRP content was visualized by 
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incubation with ABTS (2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) with 1:2000 
H2O2.   
 
Mass spectrometry 
Mass spectrometry for MS analysis, modified proteins and their non-modified counterparts 
were subjected to 4-12% PAGE (NuPAGE Bis-Tris Precast Gel, Life Technologies). Bands were 
cut from the gel, and the proteins subjected to reduction with dithiothreitol, alkylation with 
iodoacetamide and in-gel trypsin digestion using Proteineer DP digestion robot (Bruker). 
Tryptic peptides were extracted from the gel slices, lyophilized, dissolved in 95/3/0.1 v/v/v 
water/acetonitril/formic acid and subsequently analyzed by on-line C18 nanoHPLC MS/MS 
with a system consisting of an Easy nLC 1000 gradient HPLC system (Thermo, Bremen, 
Germany), and a LUMOS mass spectrometer (Thermo).  
Fractions were injected onto a homemade precolumn (100 μm × 15 mm; Reprosil-Pur C18-
AQ 3 μm, Dr. Maisch, Ammerbuch, Germany) and eluted via a homemade analytical nano-
HPLC column (15 cm × 50 μm; Reprosil-Pur C18-AQ 3 um). The gradient was run from 10% 
to 40% solvent B (20/80/0.1 water/acetonitrile/formic acid (FA) v/v/v) in 20 min. The nano-
HPLC column was drawn to a tip of ∼5 μm, and acted as the electrospray needle of the MS 
source. The LUMOS mass spectrometer was operated in data-dependent MS/MS (top-10 
mode) with collision energy at 32 V and recording of the MS2 spectrum in the orbitrap. In 
the master scan (MS1) the resolution was 120,000, the scan range 400-1500, at an AGC 
target of 400,000 at maximum fill time of 50 ms. Dynamic exclusion after n=1 with exclusion 
duration of 10 s. Charge states 2-5 were included. For MS2 precursors were isolated with 
the quadrupole with an isolation width of 1.2 Da. HCD collision energy was set to 32 V. First 
mass was set to 110 Da. The MS2 scan resolution was 30,000 with an AGC target of 50,000 
at maximum fill time of 60 ms.  In a post-analysis process, raw data were first converted to 
peak lists using Proteome Discoverer version 2.1 (Thermo Electron), and then submitted to 
the Uniprot database (452772 entries), using Mascot v. 2.2.04 (www.matrixscience.com) 
for protein identification. Mascot searches were with 10 ppm and 0.02 Da deviation for 
precursor and fragment mass, respectively, and trypsin as enzyme. Up to two missed 
cleavages were allowed, and carbamidomethyl on Cys was set as a fixed modification. 
Methionine oxidation, carbamylation (Lys) and acetylation (Lys) were set as variable 
modification.  
Protein modifications were finally compared using Scaffold software version 4.7.5 
(www.proteomesoftware.com). The interpretation of MS2 spectra of modified peptides 








8-10 week-old female C57BL6/J mice were purchased from Charles River. Mice received two 
injections i.p. with antigen (100ug) emulsified in Alhydrogel (Cat# vac-alu-250, Invivogen) in 
a 1:1 ratio. Animal experiments were approved by the local Ethical Committee for Animal 
Experimentation and performed conform national guidelines. All immunized mice were 
healthy and showed no signs of autoimmunity throughout the experiment.   
 
Detection of Anti-Modified-Protein Antibodies 
For the detection of AMPAs in mice, the following Enzyme-Linked ImmunoSorbent Assay 
(ELISA) was performed: Modified proteins and their unmodified counterparts were coated 
at a concentration of 10ug/mL in 0.1M carbonate-bicarbonate buffer (pH 9.6) overnight on 
Nunc Maxisorp plates (Thermo Scientific). The plates were blocked with PBS + 1% BSA. The 
mouse sera were diluted in RIA buffer (10mM TRIS (pH 7.6), 350mM NaCl, 1% TritonX, 0.5% 
Sodiumdeoxycholate, 0.1% SDS) and incubated overnight. Binding of mouse IgG was 
detected with HorseRadish Peroxidase (HRP)-conjugated goat-anti-mouse IgG1 (Cat# 1070-
05, Southern Biotech) and subsequently visualized with ABTS. Washing steps were 
performed between each incubation with PBS + Tween20. All incubations, aside from the 
incubations with goat-anti-mouse IgG1 and ABTS, were performed at 4°C, the final two 
steps were performed at room temperature. Arbitrary units were calculated using a 
standard serum serial dilution. For the inhibition experiments, the sera were pre-incubated 
with 0 – 0.2mg/mL protein for 1 hour before transferring them to the ELISA plate. For avidity 
studies, wells were incubated for 15 minutes at RT with sodium thiocyanate (0 – 5M) after 
sera incubation. After the 15 minutes of incubation, the standard protocol was proceeded. 
The Relative Avidity Index (RAI) was calculated as previously been described in been 
described in (15): 
 
𝑅𝑅𝑅𝑅𝑅𝑅 =  
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑟𝑟𝑎𝑎𝑟𝑟𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑟𝑟 𝑎𝑎𝑎𝑎 1𝑀𝑀 𝑆𝑆𝑆𝑆𝑆𝑆 (𝐴𝐴𝐴𝐴𝑚𝑚𝑚𝑚)
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑎𝑎𝑎𝑎𝑏𝑏𝑎𝑎𝑎𝑎 𝑎𝑎𝑎𝑎 0𝑀𝑀 𝑆𝑆𝑆𝑆𝑆𝑆 (𝐴𝐴𝐴𝐴𝑚𝑚𝑚𝑚)
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Reactivity of purified ACPA and Anti-CarP antibodies, obtained from sera and synovial fluid 
of RA patients, was measured using modified vimentin peptides (plates and reagents were 
kindly provided by Orgentec), according to the protocol previously described (12). In short, 
sera and purified antibodies were diluted 200ug/mL and 2,5ug/mL respectively for ACPA 
and 100ug/mL and 2.5ug/mL respectively for anti-CarP in diluent and incubated for 30’. 
Subsequently enzyme conjugate was added for 15’ and reactivity was detected by TMB 
substrate. All steps were performed at room temperature. In addition, purified ACPA and 
anti-CarP-antibodies were tested on CCP2 and Ca-FCS respectively according to protocols 





Specific AMPAs are isolated as has been previously described in (17). In short, plasma or 
serum samples and SF were acquired from patients. Synovial fluid was treated with 
hyaluronidase (derived from bovine testes type IV; Cat#: H3884, Sigma Aldrich) for 30 
minutes at room temperature, before centrifugation at 3000 RPM for 10 minutes. The 
plasma, serum and SF samples were subsequently filtered (0.2µM filters, Millipore) before 
purifying AMPA with protein affinity chromatography (ÄKTA, GE Healthcare). Purification 
was performed using HiTrap streptavidin HP 1ml columns (GE-Healthcare) coupled with 
biotinylated CCP2-peptides (obtained from J.W. Drijfhout, IHB LUMC) for the isolation of 
ACPA (17) or in-house prepared biotinylated (Ca-)FCS for the isolation of anti-CarP 
antibodies. PTM-specificity was controlled by attaching a control column coated with the 
native version (CCP2 arginine or FCS) before the column coated with the modified version 
(CCP2 citrulline or Ca-FCS). Antibodies were eluted using 0.1M glycine hydrogen chloride 
(HCl) pH 2.5 and neutralized with 2M Tris. ACPA-IgG1,2,4 was subsequently purified from 
ACPA with Prot A and Prot G 156 HiTrap-columns.  
FCS was biotinylated using EZ-link Sulfo-NHS-biotin (Pierce) incubated for ~24h on ice at 4°C 
at low pH to ensure N-terminal biotinylation (end concentration 20mg/ml FCS and 10mg/ml 
biotin  solution), with subsequent extensive dialyzing. Part of the biotinylated FCS was 
carbamylated using 1M KOCN and the other part (native control) not. Both were incubated 
for ~12h at 37°C and extensively dialyzed afterwards. 
 
Statistics 
Statistical tests were performed with Prism7 (Graphpad). Significance of AMPA reactivity on 
proteins was tested with paired t-test. Differences in titer and avidity were tested with 














Cross-reactive AMPA are induced upon vaccination with one defined modified antigen. 
To analyze whether AMPA can be induced upon immunization with an antigen with one 
defined modification and to determine whether these AMPA also recognize other classes 
of PTMs, we immunized mice with either non-modified, carbamylated, citrullinated or 
acetylated Ovalbumin (OVA). The presence of either homocitrulline as a result of 
carbamylation or acetylated lysine as a consequence of acetylation was confirmed by mass 
spectrometry (raw MS data are available online at the ProteomeXchange) and commercially 
available antibodies against either carbamylated or acetylated lysines in ELISA (Figure 1A). 
Non-modified OVA was found to be acetylated, but not carbamylated, at the N-terminus by 
mass-spectrometry and therefore the latter antigen was included in all immunization 
experiments as additional specificity control. To discriminate between reactivity against the 
PTM and protein-backbone used for immunization, we used modified fibrinogen instead of 
modified OVA as read-out. In doing so, antibodies recognizing OVA were not interfering with 
the detection of AMPA (18). Fibrinogen was not recognized by commercially antibodies 
against either carbamylated or acetylated lysine, indicating the absence of PTMs in non-
modified fibrinogen (figure 1B). To control for possible baseline-reactivity towards modified 
proteins, sera from non-immunized mice were taken along in the ELISA experiments. 
Indeed, no reactivity was observed to non-modified fibrinogen or its modified counterparts 
in naïve animals, indicating that without immunizations, AMPA-responses are not present 
(Figure 2A) (18, 19). Likewise, although a strong reaction against OVA was noted (data not 
shown), indicating proper immunization, mice immunized with unmodified OVA did not 
harbor a reaction against CaFib, AcFib or CitFib (Figure 2B) (18). These results indicate that 
neither non- modified OVA or the adjuvant used is driving AMPA production. Despite 
reported ACPA presence in  murine models after different immunization strategies (20-22), 
we were unable to detect reactivity  towards citrullinated fibrinogen using our standard 
vaccination strategy (Figure 2C). Antibody reactivity  was additionally tested towards 
modified Myelin Basic Protein (MBP), showing no reactivity towards  the citrullinated form 
(Figure 3). Furthermore, mice immunized with carbamylated OVA (Ca-OVA)  displayed a 
strong reactivity towards carbamylated fibrinogen (Ca-Fib), but not non-modified fibrinogen 
as determined in ELISA (Figure 2D). These data indicate that anti-CarP-antibodies are 
induced  by immunization with Ca-OVA, but not by non-modified or citrullinated OVA. 
Remarkably, the sera of  mice immunized with Ca-OVA also reacted to Ac-Fib and to some 
extend to citrullinated fibrinogen  (Figure 2D). This reactivity was further validated by ELISA 
using modified MBP (Figure 3). These data are  intriguing as they indicate that antibody 
responses induced by carbamylated antigens are able to  recognize multiple modifications, 
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pointing to the presence of cross-reactive antibodies against one  class of modified proteins 
that is induced by exposure to another class of modified proteins.   
 
 
Figure 1. Structural overview of the posttranslational protein modifications. Schematic view of the 
amino acid structures of arginine and lysine, and their conversions towards citrulline, homocitrulline 
and acetylated lysine (A). ELISA with commercial polyclonal anti-acetylated-lysine antibodies, 
polyclonal anti-carbamylated-lysine antibodies or monoclonal ACPA to test modified proteins for the 
presence of post-translational modifications (B). OVA, ovalbumin; Fib, fibrinogen; Ca, carbamylated; 
Cit, citrullinated; Ac, acetylated; OD, optical density; PAD, peptidylarginine deiminase; ACPA, anti-




Figure 2. Immunization with CaOVA or AcOVA induces antibody responses towards modified 
fibrinogen. Immunization with Ca-OVA or Ac-OVA induces antibody responses towards modified 
fibrinogen. Antibody reactivity towards modified fibrinogen in sera derived from non-immunized (A), 
OVA-immunized (B), Cit-OVA-immunized (C), Ca-OVA-immunized (D) or Ac-OVA-immunized (E) mice 
was measured by ELISA. Reactivity is depicted with OD values measured at 415nm. For all groups, n = 
6. Representative data from two experiments are shown. ** = p-value of <0.005 ;**** = p-value of 





Figure 3. Immunization with CaOVA or AcOVA induces antibody responses towards modified MBP. 
Antibody reactivity towards modified MBP in sera derived from non-immunized (A), OVA-immunized 
(B), CitOVA-immunized (C), CaOVA-immunized (D) or AcOVA-immunized (E) mice was measured by 
ELISA. Reactivity is depicted with OD values measured at 415nm. For all groups, n = 6. Representative 
data from two experiments is shown. OVA, ovalbumin; Cit, citrullinated; Ca, carbamylated; Ac, 





Next, we wished to determine whether cross-reactive anti-Ac-Fib antibodies could also be 
induced by immunization with acetylated OVA. We observed that reactivity against Ac-Fib 
was readily  generated by immunization with Ac-OVA as expected, but reactivity towards 
Ca-Fib was also clearly detectable (Figure 2E). On the other hand, reactivity towards 
citrullinated fibrinogen was only moderately apparent, which could not be validated using 
cit-MBP as antigen (Figure 3). These results suggest that immunization with acetylated OVA 
induces antibodies cross-reactive to homocitrulline. 
To further investigate the cross-reactive nature of the AMPA-responses generated, we next 
analyzed  the level and titer of anti-Ca-Fib and Ac-Fib antibodies in mice immunized with 
respectively Ca-OVA or Ac-OVA. A strong correlation was noted in reactivity towards Ac-Fib 
and Ca-Fib in mice immunized with Ca-OVA (Figure 4A). Although all, but one, mice mounted 
a high level of antibodies recognizing Ac-Fib, some mice displayed a high level of reactivity 
towards Ca-Fib, whereas others showed a lower  level of Ca-Fib-reactivity (Figure 4B). These 
findings were further substantiated by determining the titer  of anti-Ca-Fib- and anti-Ac-Fib-
antibodies through dilution of sera from immunized animals. Similar  antibody titers were 
observed towards Ac-Fib and Ca-Fib in mice immunized with Ca-OVA, whereas the titer of 
antibodies recognizing Ac-Fib was considerable higher than the antibody-titer against Ca- 
Fib in Ac-OVA-immunized mice (Figure 5A).  
These data indicate that the antibody response induced in  Ca-OVA-immunized mice 
displays similar reactivity towards both Ca-Fib and Ac-Fib, suggesting that the antibody 
response induced in this setting is possibly cross-reactive. Likewise, these data also suggest 
that this reactivity is different in Ac-OVA-immunized mice as the antibody titer against  
acetylated antigens is considerably higher compared to the antibody-titer directed against 
carbamylated proteins, and hence that not all AAPA cross-react to Ca-Fib. Thus, together 
these data  imply that cross-reactive antibodies to acetylated and carbamylated antigens 
are induced upon vaccination with only carbamylated- or acetylated antigens, though the 





Figure 4. Correlation between CaFib- and AcFib-reactivity for CaOVA- and AcOVA-immunized mice. 
Reactivity towards CaFib and AcFib in sera from CaOVA- (A) and AcOVA-immunized (B) mice was 
measured with ELISA and correlated to each other. Data shown for two separate immunization 
experiments (diamonds (n=5) and circles (n=6)). Correlations are analyzed with Spearman, p < 0,05 
depicts significance. OVA, ovalbumin; Ca, carbamylated; Ac, acetylated; Fib, fibrinogen; OD, optical 
density. 
 
Cross-reactive antibody responses harbor different PTM recognition profiles, including 
differences  in avidity. 
To examine the AMPA-response in more detail, the avidity of the anti-CarP- and AAPA-
response was  determined by means of elution ELISAs using chaotropic salt (23, 24). Our 
results indicate that in Ca- OVA-immunized mice, the avidity of the antibody response to 
Ca-Fib is higher than the response to  Ac-Fib showing a Relative Avidity Index (RAI) at 1M 
SCN of 58.5 vs 32.8 (Figure 5B). Furthermore, for the  Ac-OVA-immunized mice, the avidity 
of the response towards Ac-Fib was somewhat higher as compared to the response towards 
Ca-Fib (RAI at 1M of 47.1 vs 31.5 respectively) (Figure 5B). Thus, these data indicate that the 
avidity of the AMPA-response is highest towards the respective modification used for 
immunization. The data presented in figure 5A indicate that immunization of mice with 
acetylated proteins induces  an antibody response that is only partly cross-reactive to 
carbamylated antigens, whereas most  antibodies induced by immunization with 
carbamylated antigens recognized both acetylated- and  carbamylated antigens. These data 
imply that inhibition studies using acetylated proteins and sera  from Ca-OVA-immunized 
mice (highly cross-reactive) would show good inhibition of reactivity  towards carbamylated 
and acetylated antigens. In contrast, inhibition of reactivity towards  acetylated antigens by 
carbamylated proteins of sera from Ac-OVA-immunized mice is predicted to be modest as 
most antibodies will not be cross-reactive. To test and confirm these notions, the binding 
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capacity towards Ca-Fib or Ac-Fib was analyzed after pre-incubation with increasing 
concentrations of modified fibrinogen. Indeed, for the Ca-OVA-immunized mice, the 
antibody reactivity towards either Ca-Fib or Ac-Fib could be inhibited by incubating the sera 
with Ca-Fib or Ac-Fib (Figure 6A and 6B). In contrast, whereas Ca-Fib-reactivity by Ac-OVA-
immunized mice was blocked by incubation with Ca-Fib or Ac-Fib (Figure 6C), Ac-Fib 
reactivity could only be inhibited by competing with Ac-Fib (Figure 6D). These data further 
verify that antibodies generated by Ca-OVA-immunization are highly cross-reactive in 
nature, whereas for the AMPA induced by Ac-OVA-immunization, only a part of the 
antibodies are cross-reactive towards both modifications. 
 
Figure 5. Antibody titers and avidity in sera of CaOVA- and AcOVA-immunized mice. Antibody titers 
as measured by ELISA on CaFib and AcFib for CaOVA- and AcOVA-immunized mice (A). IC50 depicts 
the dilution at which half of the highest reactivity is still visible. Representative data from two 
experiments is shown. (B) Avidity shown as residual antibody binding in the presence of different 
concentrations of NaSCN. Representative data from two immunization experiments is shown. Ca, 
carbamylation; Ac, acetylation; OVA, ovalbumin; Fib, fibrinogen; IC50, inhibitory concentration at 




Figure 6. Inhibition of antibody binding by pre-incubation of mouse sera with modified fibrinogen. 
Cross-reactivity of antibodies is studied by assessment of the inhibitory capacity of pre-incubating sera 
with modified fibrinogen. Sera from CaOVA-immunized mice was pre-incubated with varying 
concentrations of modified fibrinogen before testing the antibody reactivity on CaFib (A) or AcFib (B). 
Sera from AcOVA-immunized mice was pre-incubated with varying concentrations of modified 
fibrinogen before testing the antibody reactivity on CaFib (C) or AcFib (D). Results show representative 
data of two experiments. OVA, ovalbumin; Fib, fibrinogen; Ca, carbamylated; Ac, acetylated; OD, 







Immunization with modified foreign-antigen is able to induce a breach of tolerance 
towards  different classes of modified self-antigens. 
The data presented above are important as they indicate that exposure to a particular class 
of modified proteins can induce an immune response against another class of modified 
proteins as well. However, these experiments did not address the question whether the 
antibodies induced are autoreactive, i.e. able to recognize modified self-proteins. 
Therefore, we next wished to investigate whether the AMPA-responses induced by 
exposure to foreign modified proteins bind to modified self-proteins as well. To this end, 
sera of immunized mice were tested for reactivity towards modified mouse albumin (mAlb) 
as model self-protein. Non-immunized mice or mice immunized with non-modified OVA did 
not react towards native or modified mAlb (Figure 7A). In contrast, sera from Ca-OVA-
immunized mice reacted to both Ac-mAlb and Ca-mAlb (Figure 7A). Likewise, sera from Ac-
OVA-immunized mice recognized both classes of modified mAlb as well, albeit that the 
reactivity towards Ca-mAlb was relatively low in concordance with the data depicted in 
Figure 2. Additionally, when the reactivity towards Ac-mAlb and Ca-mAlb was correlated for 
both immunized groups, a similar difference in correlation was apparent as is shown in 
figure 2 (Figure 7B). Together, these results indicate that exposure to modified foreign 
proteins is capable of inducing a breach of tolerance towards self-antigens carrying different 







Figure 7. Break of tolerance towards modified self-proteins in CaOVA- and AcOVA-immunized mice. 
Reactivity in towards carbamylated and acetylated mouse albumin was tested by ELISA (A) with sera 
derived from non-immunized, OVA-, CaOVA- and AcOVA-immunized mice and shown with OD values. 
Results show representative data from two immunization experiments. Correlation between Ca-
mouse albumin and Ac-mouse albumin was analyzed for both CaOVA- and AcOVA-immunized mice 
(B). Both immunization experiments are depicted (diamonds (n=5), circles (n=6 for CaOVA-immunized 
mice, n=5 for AcOVA-immunized mice)). Correlation coefficient is calculated with Spearman, p < 0,05 
depicts significance. OVA, ovalbumin; Ca, carbamylated; Ac, acetylated; AU, arbritrary units; r, 




Cross-reactive antibodies towards different modifications are present in RA patients. 
The data presented above were all obtained in mice and do not address whether also in 
humans, AMPA are cross-reactive towards different classes of modified antigens. Therefore, 
we next isolated ACPA-IgG from synovial fluid or plasma of 7 patients as previously 
described (17, 25). We focused on ACPA as the ACPA-response is the most prominent 
AMPA-response in RA. As depicted in figure 8 and B, ACPA-IgG were strongly enriched 
following isolation. Next, the purified ACPA-IgG were analyzed for their reactivity towards 
a citrullinated, carbamylated or acetylated peptide from vimentin. In all cases, purified 
ACPA also showed a highly enriched reactivity towards these differently modified peptides. 
These data indicate that ACPA-IgG from RA patients are not only cross-reactive towards 
carbamylated antigens as also observed previously (11), but that they can also recognize 
acetylated antigens. To analyze whether also anti-CarP antibodies display cross-reactivity 
towards different classes of PTMs, we next isolated anti-CarP antibodies from sera of 2 anti-
CarP-positive patients. As shown in figure 6C, the isolated antibodies were highly enriched 
for anti-CarP-reactivity. Likewise, as observed for isolated ACPA, also purified anti-CarP 
antibodies showed strongly enriched reactivity towards different classes of modified 
antigen. Together, these data indicate that different families of human AMPA are cross-










Figure 8. Cross-reactivity of purified human ACPA or anti-CarP antibodies towards modified 
vimentin peptides. ACPA and anti-CarP antibodies were isolated from RA patients. ACPA from 
synovial fluid (A, n=4) and serum (B, n=3) from patients were tested on CCP2 and modified vimentin 
peptides. Anti-CarP antibodies from serum of RA patients (C, n=2) were tested on CaFCS and modified 
vimentin peptides. Reactivity is depicted as arbitrary units per mg IgG and calculated based on 
standards. CCP2, cyclic citrullinated peptide; CArgP2, cyclic arginine control peptide; Vim, vimentin 
peptide; Cit, citrullinated; Arg, arginine control; AcLys, acetylated lysine; Lys, lysine control; hCit, 
homocitrulline (carbamylated); FCS, fecal calf serum; Ca, carbamylated; AU/mg IgG, arbitrary units 
























Rheumatoid Arthritis is an autoimmune disease characterized by the presence of 
autoantibodies directed against different post-translationally modified antigens, including 
citrullinated, carbamylated and acetylated proteins. The origin of these different reactivities 
present in RA is still poorly understood. Here we show, by immunizing mice with a foreign 
protein carrying one defined PTM, that exposure to a protein carrying one particular PTM 
can lead to the induction of antibody-responses towards different PTMs. Likewise, we also 
show that AMPA from RA patients purified against one PTM can recognize different classes 
of PTMs. These findings are important as they indicate that the different AMPA-responses 
observed in RA patients can be derived from the same inciting antigen(s) carrying only one 
particular modification. Similarly, they provide a rationale for the presence of multiple 
AMPAs in RA, one of the hallmarks of disease.   
Given the observations that different AMPAs target different antigens and are generally 
seen as distinct auto-antibody families, it has been intriguing to note that their presence 
often go together in RA. In contrast, AMPAs are less frequently present in other rheumatic 
diseases and their co-occurrence is rarely observed outside RA. The co-occurrence of 
different AMPAs represents an interesting conundrum as it is unclear why, after activation 
of a B-cell with a receptor for a particular modified protein, another B cell expressing a 
receptor recognizing a differently modified protein would also be activated in the same 
subject. In general, the activation of a particular B cell will not directly influence the 
activation of other B cells directed against other antigens, although it has been shown in a 
transgenic mouse model for SLE that epitope-spreading to other antigens can occur once 
tolerance is broken for one self-antigen (26).  
Our data indicate that exposure to a defined antigen displaying a particular class of PTM, 
can lead to a cross-reactive antibody-response recognizing several classes of modified 
antigens, conceivably explaining the co-occurrence of multiple AMPA-reactivities in RA. In 
concordance with the data obtained in mice, our data indicate that also AMPA obtained 
from RA-patients are cross-reactive. It has been shown previously that anti-CarP-antibodies 
and ACPA can be cross-reactive towards respectively citrullinated and carbamylated 
antigens (11). Citrullination and carbamylation are highly similar, as they differ only one 
methyl-group, even though they are conversions from different amino acids. We now show 
that also acetylated antigens can be recognized by these antibodies. The latter observation 
was unexpected as, in contrast to homo-citrulline, acetylated-lysine shares less structural 
homology to citrulline as acetylation results in the substitution of the amine-group of lysine 
with a methyl-moiety. The cross-reactivity towards acetylated antigens was even more 
prominent in mice as the antibodies induced by CaOVA immunisation are unable to 
recognise citrullinated proteins, despite the similarity, even though they are able to 
recognise acetylated lysines. At present it is unclear how AMPA recognize antigens 
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harbouring these different PTMs at the molecular level, but it would be relevant to 
determine how the binding to these PTMs by an AMPA is accommodated by e.g. 
crystallization studies to obtain further molecular understanding of this interaction.  
The finding that exposure to e.g. an acetylated protein leads to the formation of auto-
antibodies against proteins carrying other classes of PTM as well, is also relevant for 
considerations on the breach of tolerance and induction of AMPA-responses. From our 
findings, it can be postulated that the inciting antigen responsible for the induction of e.g. 
ACPA or anti-CarP-antibodies does not have to be citrullinated or carbamylated, but could 
be represented by, for example, an acetylated protein. An increasing number of studies 
suggest that mucosal surfaces, specifically the periodontium, the gut and the lungs, as sites 
of disease initiation of RA and indicate the microbiome as an important driver of the 
initiation of auto-immunity. In this respect, especially protein–acetylation by bacteria might 
now also be incriminated in the induction of auto-antibody responses against PTM proteins. 
Recent evidence shows that many bacterial species are able to acetylate proteins (27), 
including bacteria proposed as link between periodontal infection and RA (28). Given our 
observation that AMPAs recognizing citrullinated and carbamylated proteins can be cross-
reactive to acetylated proteins, these findings together provide a novel and stimulating 
angle to the notion that the microbiome contributes to the induction of auto-immunity in 
RA. Therefore, a logical next step is to test faecal extracts from RA patients for the presence 
of acetylated bacterial proteins to obtain more insight on the possible link between the 
microbiome, the presence of acetylated proteins, and RA. 
Through the formation of acetylated proteins, disturbances of the microbiome (e.g. through 
infection) could lead to the formation of acetylated proteins detected by the immune 
system and thereby to the induction of AMPA-responses. In doing so, the origin of the T cell 
help required for the B cell to undergo isotype-switching and somatic hypermutation could 
come from different sources as, in this scenario, it is highly conceivable that microbe-
specific T cells help the B cell initially recognizing the microbe-derived modified protein. 
Upon further somatic hypermutation, the B cell response could be selected/start 
recognizing other modified proteins explaining the cross-reactive  nature of AMPAs and the 
observation that different AMPAs often appear together in patients. Likewise, the 
diversification towards other PTMs could, potentially, also explain the observation that the 
HLA-Shared-Epitope (SE) is associated with ACPA-positive RA, whereas the initial 
appearance of ACPA is HLA-SE- independent. Possibly, by diversification of an, initially, HLA-
SE-independent AMPA-reaction, new HLA-SE-restricted T cells are recruited into this 
response, associated with ACPA-positive RA. Thus, in this scenario, the link to the 
microbiome, the cross-reactive nature of AMPAs, the breach of tolerance to self-modified 
proteins, including PTM modified histones as emerging autoantigens in RA, the HLA-Shared-
Epitope-association with the “second hit”, as well as the concordant appearance of AMPAs 
in disease can be explained.   
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Our study has several limitations as we did not show that also in humans the inciting antigen 
carrying a particular PTM will lead to the induction of a cross-reactive AMPA-response. 
Obviously, studies immunizing a host with a defined modified antigen, as was performed in 
mice, is not feasible in humans and therefore the concepts obtained from such animal-
studies will be difficult to demonstrate in the human system. Nonetheless, the observation 
that also human AMPAs are cross-reactive to several different PTM does support such 
views. Despite the advantages of using a controlled setting for the immunization of mice, a 
major pitfall of studying RA-associated antibodies in mice is the inability to induce the 
production of ACPAs with our standard immunization protocol, i.e. two subsequent 
immunisations in aluminium hydroxide. Consequently, the analysis of antibody cross-
reactivity towards citrullinated antigens is limited and restricted to the human setting. In 
addition, our antibody experiments are focused on polyclonal antibody responses. 
Therefore, we are unable to predict the cross-reactivity on monoclonal level. Nevertheless, 
our inhibition studies do suggest that individual antibodies are capable of cross-recognising 
multiple PTM, though isolation of monoclonal antibodies will be necessary to validate this 
notion.  
In conclusion, our data show that induction of antibodies in mice towards multiple PTM 
reactivities can be achieved by the encounter with a protein carrying one specific 
posttranslational modification. These studies indicate that the different AMPA present in 
RA could have a common “background” and provide novel insight into the origins of AMPAs, 
















1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 
Rheumatoid arthritis classification criteria: an American College of Rheumatology/European 
League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. 
2. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of 
citrullinating enzymes: genes, features and involvement in disease. Bioessays. 
2003;25(11):1106-18. 
3. van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, 
Verpoort KN, et al. Epitope spreading of the anti-citrullinated protein antibody response 
occurs before disease onset and is associated with the disease course of early arthritis. Ann 
Rheum Dis. 2010;69(8):1554-61. 
4. van de Stadt LA, de Koning MH, van de Stadt RJ, Wolbink G, Dijkmans BA, Hamann D, et al. 
Development of the anti-citrullinated protein antibody repertoire prior to the onset of 
rheumatoid arthritis. Arthritis Rheum. 2011;63(11):3226-33. 
5. Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody 
epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. 
PLoS One. 2012;7(5):e35296. 
6. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout 
JW, van Tol MJ, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in 
undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. 
Arthritis Rheum. 2006;54(12):3799-808. 
7. Titcombe PJ, Wigerblad G, Sippl N, Zhang N, Shmagel AK, Sahlstrom P, et al. Pathogenic 
Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis. Arthritis Rheumatol. 
2018;70(12):1933-45. 
8. Suwannalai P, van de Stadt LA, Radner H, Steiner G, El-Gabalawy HS, Zijde CM, et al. Avidity 
maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum. 
2012;64(5):1323-8. 
9. Trouw LA, Rispens T, Toes REM. Beyond citrullination: other post-translational protein 
modifications in rheumatoid arthritis. Nat Rev Rheumatol. 2017;13(6):331-9. 
10. Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, et al. Carbamylation 
and antibodies against carbamylated proteins in autoimmunity and other pathologies. 
Autoimmun Rev. 2014;13(3):225-30. 
11. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. 
Autoantibodies recognizing carbamylated proteins are present in sera of patients with 
rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 
2011;108(42):17372-7. 
12. Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, et al. Identification of novel 
antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum 
Dis. 2016;75(6):1099-107. 
13. Guan KL, Yu W, Lin Y, Xiong Y, Zhao S. Generation of acetyllysine antibodies and affinity 
enrichment of acetylated peptides. Nat Protoc. 2010;5(9):1583-95. 
14. Verheul MK, van Veelen PA, van Delft MAM, de Ru A, Janssen GMC, Rispens T, et al. Pitfalls 
in the detection of citrullination and carbamylation. Autoimmun Rev. 2018;17(2):136-41. 
116 
Chapter 5 
15. Suwannalai P, Scherer HU, van der Woude D, Ioan-Facsinay A, Jol-van der Zijde CM, van Tol 
MJ, et al. Anti-citrullinated protein antibodies have a low avidity compared with antibodies 
against recall antigens. Ann Rheum Dis. 2011;70(2):373-9. 
16. Kerkman PF, Rombouts Y, van der Voort EI, Trouw LA, Huizinga TW, Toes RE, et al. Circulating 
plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with 
rheumatoid arthritis. Ann Rheum Dis. 2013;72(7):1259-63. 
17. Rombouts Y, Willemze A, van Beers JJ, Shi J, Kerkman PF, van Toorn L, et al. Extensive 
glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in 
rheumatoid arthritis. Ann Rheum Dis. 2016;75(3):578-85. 
18. Dekkers JS, Verheul MK, Stoop JN, Liu B, Ioan-Facsinay A, van Veelen PA, et al. Breach of 
autoreactive B cell tolerance by post-translationally modified proteins. Ann Rheum Dis. 
2017;76(8):1449-57. 
19. Stoop JN, Fischer A, Hayer S, Hegen M, Huizinga TW, Steiner G, et al. Anticarbamylated 
protein antibodies can be detected in animal models of arthritis that require active 
involvement of the adaptive immune system. Ann Rheum Dis. 2015;74(5):949-50. 
20. Cantaert T, Teitsma C, Tak PP, Baeten D. Presence and role of anti-citrullinated protein 
antibodies in experimental arthritis models. Arthritis Rheum. 2013;65(4):939-48. 
21. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, et al. Arthritis induced by 
posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med. 
2008;205(4):967-79. 
22. Kidd BA, Ho PP, Sharpe O, Zhao X, Tomooka BH, Kanter JL, et al. Epitope spreading to 
citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis 
Res Ther. 2008;10(5):R119. 
23. Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using 
thiocyanate elution. J Immunol Methods. 1986;86(1):83-7. 
24. van Delft MAM, Verheul MK, Burgers LE, Rantapaa-Dahlqvist S, van der Helm-van Mil AHM, 
Huizinga TWJ, et al. The anti-carbamylated protein antibody response is of overall low 
avidity despite extensive isotype switching. Rheumatology (Oxford). 2018;57(9):1583-91. 
25. Hafkenscheid L, Bondt A, Scherer HU, Huizinga TW, Wuhrer M, Toes RE, et al. Structural 
Analysis of Variable Domain Glycosylation of Anti-Citrullinated Protein Antibodies in 
Rheumatoid Arthritis Reveals the Presence of Highly Sialylated Glycans. Mol Cell Proteomics. 
2017;16(2):278-87. 
26. Degn SE, van der Poel CE, Firl DJ, Ayoglu B, Al Qureshah FA, Bajic G, et al. Clonal Evolution 
of Autoreactive Germinal Centers. Cell. 2017;170(5):913-26 e19. 
27. Ouidir T, Kentache T, Hardouin J. Protein lysine acetylation in bacteria: Current state of the 
art. Proteomics. 2016;16(2):301-9. 
28. Butler CA, Veith PD, Nieto MF, Dashper SG, Reynolds EC. Lysine acetylation is a common 
post-translational modification of key metabolic pathway enzymes of the anaerobe 


















































Hans Holbein der Jügere (1497-1543) Erasmus writing (detail), 
















Autoantibody Status is not Associated with Early Treatment 
Response to first-line Methotrexate in Patients with Early 
Rheumatoid Arthritis 
 
Rheumatology (Oxford). 2019 Jan 1;58(1):149-153. 
 
 
Jacqueline S. Dekkers1, Sytske Anne Bergstra1,  Arvind Chopra2, Mohammed Tikly3 , João 
Eurico Fonseca4 , Karen Salomon-Escoto5, Tom W.J. Huizinga1, Diane van der Woude1  
 
1. Department Of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands 
2. Centre For Rheumatic Diseases, Pune, India 
3. Division Of Rheumatology, University of Witwatersrand, Johannesburg, South Africa. 
4. Rheumatology Research Unit, Lisbon Academic Medical Centre, Portugal 










In rheumatoid arthritis (RA), the relationship between autoantibody status and treatment 
response to methotrexate remains unclear. We investigated the association between 
autoantibody status and early remission in newly diagnosed RA-patients treated with 
methotrexate using real-world data.     
 
Methods 
RA-patients initially treated with methotrexate were selected from an international 
observational database (METEOR). Patients were stratified into autoantibody-positive 
(rheumatoid factor (RF)- and/or anti-citrullinated-protein antibodies (ACPA)-positive) or 
autoantibody negative (RF- and ACPA- negative). The effect of autoantibody status on the 




Data from 1826 RA-patients were available for analysis. DAS remission was achieved in 17% 
(318/1,826). This was similar in autoantibody-positive (17% (282/1629)) and -negative 
patients (18% (36/197)). Hence, autoantibody positivity was not associated with remission 
(HR0.89, 95%CI 0.57;1.38). Similar findings were found when stratified for methotrexate 
monotherapy (HR0.75, 95%CI 0.41;1.37) or combination treatment (HR0.76, 95%CI 
0.37;1.54). Good physical function (HAQ<0.5) was achieved in 33% (530/1590) of all 




Autoantibody status is not associated with early remission in newly diagnosed RA-patients 
receiving methotrexate. This indicates that methotrexate is  effective as initial treatment 










Rheumatoid arthritis (RA) is generally considered to consist of two separate entities: 
autoantibody-positive and -negative disease, each with distinct genetic and environmental 
risk factors and disease outcomes. Autoantibody-positive patients have worse long-term 
outcomes with less functional ability, worse disease activity and more radiographic joint 
damage(1-3). The presence of autoantibodies is associated with a better treatment 
response to rituximab(4) and abatacept(5), but whether an association exists with other 
(more commonly used) drugs, most notably methotrexate, remains unknown.  
The presence of rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA), 
especially at high levels, is mentioned as poor prognostic factor for treatment response to 
methotrexate in international treatment recommendations(6) even though the relationship 
between autoantibody status and treatment response to methotrexate is unclear. Some 
studies have suggested that autoantibody-positive patients might respond better to 
methotrexate, while other studies do not support this conclusion(7-10). In a previous cohort 
study disease-modifying antirheumatic drug (DMARD) treatment was equally effective in 
autoantibody-positive and -negative patients, but treatment differed and not all patients 
received methotrexate(11, 12). As methotrexate is the most widely used anti-rheumatic 
drug in clinical practice(6), it would be important to know whether the presence of 
autoantibodies is associated with better treatment response, since patients may benefit 
from treatment tailored to “autoantibody status”. We therefore investigated the 
relationship between autoantibody status and remission in newly diagnosed RA-patients 





















Data were obtained from the METEOR register(13). This is an international, observational 
database of patients with a diagnosis of RA according to the rheumatologist, attending daily 
clinical practice. Data of RA-patients with symptom duration <5 years, baseline Disease 
Activity Score (DAS) >1.6 and follow-up visits after 3-6 months were selected. At least one 
of the following measures had to be available: DAS, DAS28, Simplified Disease Activity Index 
(SDAI), Clinical Disease Activity Index (CDAI), erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP) or health assessment questionnaire (HAQ). Data regarding 
autoantibody status (ACPA and/or RF, which were measured locally at the participating 
centers) had to be available and methotrexate had to be part of initial treatment. Data were 
gathered between 1995-2017 and contained irregular time intervals and different numbers 
of follow-up visits per patient due to the observational design of the database. All follow-
up visits within 3 to 6 months after treatment initiation were selected.  
 
Statistical analysis 
Patients were stratified into autoantibody-positive (RF- and/or ACPA-positive) and -
negative patients (RF- and ACPA-negative) and summary statistics were generated for 
baseline characteristics. Missing data were imputed using multivariate normal multiple 
imputation (30 imputations)(14). The variables patient-reported pain, ACPA and DAS 
contained most missing values (17 to 28% of values missing). Variables included for 
imputation were: year of birth, sex, RF, ACPA, CRP, ESR, weight, height, Ritchie articular 
index, SDAI, CDAI, erosions, HAQ, swollen joint count, DAS, DAS28, doctor’s and patient’s 
global assessment, and patient-reported pain. The effect of autoantibody status on the 
chance of achieving remission (DAS<1.6) or good physical function (HAQ<0.5) was analysed 
using Cox-proportional hazards regression with DAS or HAQ as time-dependent 
covariates(15) and correcting for confounders. Sub-analyses of methotrexate treatment 
strategies were performed. Patients were stratified into four groups according to initial 
medication strategy and we tested whether there was effect modification of these 
medication groups. In addition, we evaluated the presence of effect modification by testing 
for statistical interaction between autoantibody status and country. If no interactions were 
found (p>0.10), data of all countries were combined. Moreover, patients were stratified 
based symptom duration and assessed whether symptom duration was an effect modifier. 







Complete case analysis was performed as a sensitivity analysis. Linear mixed model (LMM) 
analyses were performed as sensitivity analyses to assess the effect of autoantibody status 
on DAS, HAQ and ESR as continuous outcomes during treatment with methotrexate. To 
account for irregular time intervals, random intercept and slope were added to each model. 
Interaction between time in follow-up and autoantibody status was added and adjusted for 
potential confounders, to assess whether the effect of autoantibody status on treatment 
outcome differed over time. Sensitivity analysis based on patients of European centers was 


































Of the individuals registered in the METEOR database, 1,826 patients fulfilled the selection 
criteria. A flow-chart of patient selection is depicted in Figure 1. Patients originated from 20 
different countries, with 93% of data originating from India, South-Africa, Portugal, the 
Netherlands, the United States, Mexico and Great Britain. 1,629 (89%) patients were 
autoantibody-positive (RF positive n=1,554, ACPA positive n=849) and 197 patients (11%) 
were autoantibody-negative. Baseline characteristics are depicted in Table 1. At baseline, 
autoantibody-positive patients were younger, had longer disease duration, higher baseline 
DAS and increased levels of acute-phase reactants (p< 0.001). Autoantibody-negative 
patients more often received methotrexate monotherapy and less frequently combination 
therapy with other conventional synthetic DMARDs compared to autoantibody-positive 
patients (p< 0.001).  
 




Figure 1. Flow-chart of patient selection. No effect modification of country on autoantibody status 
was present (p=0.62), therefore data of all countries were combined. In a period of 6 months, DAS 
remission was achieved by a similar percentage of autoantibody-positive (17%, 282/1629) and -
negative (18%, 36/197) patients. The probability of achieving DAS remission over time is depicted for 
autoantibody-positive and negative RA-patients in Figure 2. Accounting for potential confounders, 
autoantibody positivity did not associate with remission (HR 0.89, 95%CI 0.57;1.38) (Table 2). Similar 
findings were found when stratified for methotrexate monotherapy (HR 0.75, 95%CI 0.41;1.37) or 
combination treatment (HR 0.76, 95%CI 0.37;1.54).  
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Table 1. Complete case analysis 
DAS Remission Hazard ratio 95% CI for HR 
Lower          Upper 
p Value 
A: Adjusted Model* 1.01 0.66 1.55 0.97 
B: Adjusted Model* 0.84 0.46 1.54 0.57 
C: Adjusted Model* 0.78 0.40 1.53 0.47 
HAQ <0.5 Hazard ratio 95% CI for HR 
Lower          Upper 
p Value 
E: Adjusted Model* 1.13 0.78 1.63 0.51 
F: Adjusted Model* 0.95 0.54 1.67 0.86 
G: Adjusted Model* 1.38 0.82 2.34 0.22 
 
Complete case analysis based on cox-proportional hazard regression analysis. Selection of 
covariates for adjustment was based on potential confouding variables with uneven distribution 
and change-in-estimation (e.g. significant change in OR). Potential counfouding variables tested: sex, 
age, symptom duration at diagnosis, follow-up duration, DAS at baseline, HAQ at baseline, country, 
smoking and medication. 
A/E: association between autoantibody positivity and DAS remission/HAQ<0.5 
B/F: methotrexate monotherapy stratum 
C/G: combinationtherapy stratum 
*Adjusted for sex, symptom duration at diagnosis, country, smoking, methotrexate treatment 





Figure 2. Probability of achieving remission over time. Newly diagnosed RA-patients were analysed 
for probability of achieving remission (DAS < 1.6). Month 0 corresponds to the time of starting initial 
treatment with methotrexate mono- or combination therapy. Autoantibody-positive patients (ACPA 
and/or RF) (red line, n=1,629) and autoantibody-negative patients (ACPA and RF negative) (blue line, 
n=197) are depicted. The depicted figure is based on non-imputed data. RA, rheumatoid arthritis; DAS, 
disease activity score; ACPA, anti-citrullinated protein antibodies; RF, rheumatoid factor.    
 
Regarding good physical function (HAQ < 0.5), 236 patients had good physical function at 
baseline and an additional 33% (530/1590) achieved this outcome within 6 months. 
Percentages were comparable for autoantibody-positive (35%, 491/1413) and -negative 
(33%, 39/117) patients. Thus, autoantibody positivity did not associate with HAQ<0.5 
(HR1.05, 95%CI 0.71;1.57). Complete case sensitivity analysis showed very similar results as 
the analysis based on imputed data (Table 3). Additional analyses based on LMM revealed 
no differences between autoantibody-positive and -negative patients regarding DAS 
(p=0.71), HAQ (p=0.59) or ESR (p=0.27). Sub-analyses of methotrexate treatment strategies 
revealed no presence of effect modification by medication strategy (p>0.10). In addition, 
we stratified based on symptom duration and assessed whether symptom duration was an 
effect modifier, but also did not find such an effect (p=0.22).   
Although ACPA and RF often co-occur, RF testing has been used longer and is in some 
countries still determined more often than ACPA. We therefore performed a sensitivity 
analysis to evaluate the association between RF-positivity and short-term remission. In line 
with our previous findings, RF-positivity alone did not associate with short-term DAS 
remission nor the ability to regain function (Table 4). Additional sensitivity analysis based 
on patients of European centers only, revealed similar results (Table 5). 
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Table 2. Patient characteristics at baseline  











Summary statistics Values 
available 





ACPA (positivity), n (%) 1,121 849 (75)  924 849 (92) 197 0 (0) <0.001 
RF (positivity), n (%) 1,810 1,554 (85) 1,613 1,554 (96) 197 0 (0) <0.001 
Gender (female), n (%) 1,814 1,429 (79) 1,620 1,288 (80) 194 141 (73) 0.03 
Age at diagnosis (years), mean ±SD 1,815 48±13 1,619 47±13 197 54±16 <0.001 
      Symptom duration (months), median (IQR) 1,826 15 (6;36) 1,629 18 (7;36) 197 7 (3;17) <0.001 
Visit count, mean ±SD  4,265 3.14±1.05 3,782 3.13±1.02 483 3.27±1.24 0.13 
           Follow-up duration (months), mean ±SD 1,826 4.2±1.2 1,629 4.2±1.2 197 4.2±1.1 0.98 
Cigarette smoking, n (%) 
  Never 
  Current 














ESR (mm/hr), median (IQR) 1,588 51 (29;85) 1,413 55 (31;85) 175 30 (15;48) <0.001 
CRP (mg/dl), median (IQR) 1,498 23 (9;49) 1,324 24 (11;52) 154 10 (3;24) <0.001 
VAS, median (IQR)  1,357 50 (50;75) 1,212 50 (50;75) 145 50 (35;75) 0.59 
SJC in 44 joints, median (IQR) 1,664 5 (2;10) 1,492 5 (2;10) 172 6 (3;11) 0.12 
RAI, median (IQR) 1,661 9 (5;16) 1,489 10 (5;16) 172 6 (4;9.5) 0.13 
DAS, mean ±SD 1,078 3.8±1.1 979 3.9±1.0 117 3.4±1.1 0.35 
HAQ, median (IQR) 1,505 1.0 (0.6;1.6) 1,384 1.0 (0.6;1.6) 121 1.1 (0.5;1.6) 0.32 
First-line treatment strategy: 














MTX & csDMARD & glucocorticoid , n (%) 1,826 806 (44) 1,629 728 (45) 197 78 (40)  
MTX & synthetic DMARD, n (%) 1,826 351 (19) 1,629 338 (21) 197 13 (7)  
MTX & biological DMARD, n (%) 1,826 16 (<1) 1,629 14 (<1) 197 2 (<1)  
All data are mean and SD or median and interquartile range (IRQ, 25th ; 75th percentile). ACPA, anti-citrullinated protein antibody; RF, rheumatoid factor, ESR, erythrocyte sedimentation rate; CRP, 
C-reactive protein; VAS, visual analogue scale general health patient; SJC, swollen joint count on a 44-joint count; RAI, Ritchie articular index on a 53 joint count; DAS, disease activity scores (ESR) 
on a 44-joint count; HAQ, Health Assessment Questionnaire; SDAI, Simplified Disease Activity Index; MTX, methotrexate; DMARD, disease modifying anti-rheumatic drugs. 
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95% CI for HR 
Lower          Upper 
 
p Value 
A: Adjusted Model* 0.89 0.57 1.38 0.61 
B: Crude Model 0.96 0.67 1.35 0.79 
C: Adjusted Model** 0.75 0.41 1.37 0.35 
D: Crude Model 0.88 0.56 1.38 0.57 
E: Adjusted Model** 0.76 0.37 1.54 0.45 








95% CI for HR 




A: Adjusted Model* 1.05 0.71 1.57 0.80 
B: Crude Model 1.65 1.19 2.28 <0.01 
C: Adjusted Model** 0.79 0.44 
 
1.42 0.43 
D: Crude Model 2.02 1.26 3.25 <0.01 
E: Adjusted Model** 1.28 0.74 2.22 0.38 
F: Crude Model 1.65 1.03 2.66 0.04 
Selection of covariates for adjustment was based on potential confouding variables with uneven 
distribution and change-in-estimation (e.g. significant change in OR). Potential confouding variables 
tested: sex, age, symptom duration at diagnosis, follow-up duration, DAS at baseline, HAQ at baseline, 
country, smoking and medication.  
A/B: association between autoantibody positivity and DAS remission/HAQ<0.5.  
C/D: methotrexate monotherapy stratum.  
E/F: combination therapy stratum 
*Adjusted for sex, symptom duration at diagnosis, country, smoking, methotrexate treatment 
strategies and DAS/HAQ at baseline 
**Adjusted for sex, symptom duration at diagnosis, country, smoking and DAS/HAQ at baseline 
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95% CI for HR 
Lower          Upper 
 
p Value 
A: Adjusted Model* 1.05 0.70 1.58 0.81 
B: Crude Model 0.96 0.70 1.32 0.82 
C: Adjusted Model** 1.05 0.55 2.00 0.89 
D: Crude Model 0.83 0.55 1.25 0.37 
E: Adjusted Model** 0.95 0.50 1.79 0.87 
F: Crude Model 
 








95% CI for HR 




C: Adjusted Model* 1.14 0.82 1.60 0.44 
D: Crude Model 1.39 1.06 1.83 0.02 
C: Adjusted Model** 0.86 0.50 1.48 0.59 
D: Crude Model 1.90 1.25 2.90 <0.01 
E: Adjusted Model** 1.31 0.85 2.02 0.22 
F: Crude Model 
 
1.26 0.87 1.82 0.23 
Selection of covariates for adjustment was based on potential confouding variables with uneven 
distribution and change-in-estimation (e.g. significant change in OR). Potential counfouding 
variables tested: sex, age, symptom duration at diagnosis, follow-up duration, DAS at baseline, HAQ 
at baseline, country, smoking and medication.  
A/B: association between rheumatoid factor positivity and DAS remission/HAQ<0.5.  
C/D: methotrexate monotherapy stratum.  
E/F: combinationt herapy stratum 
*Adjusted for sex, symptom duration at diagnosis, country, smoking, methotrexate treatment 
strategies and DAS/HAQ at baseline 











95% CI for HR 
Lower          Upper 
 
p Value 







95% CI for HR 
Lower          Upper 
 
p Value 
B: Adjusted Model* 1.44 0.63 3.26 0.38 
 
A/B: association between autoantibody positivity and DAS remission/HAQ<0.5 
*Adjusted for sex, symptom duration at diagnosis, country, smoking, methotrexate treatment 

























This study reveals that autoantibody status does not associate with short-term DAS 
remission and good physical function in newly diagnosed RA-patients receiving 
methotrexate in a real-world setting. Autoantibody-positive RA-patients present with more 
severe disease (higher baseline disease activity and increased levels of acute-phase 
reactants) compared to autoantibody-negative patients. We found that 17% of newly 
diagnosed RA-patients achieved DAS remission, independent of autoantibody status. In 
accordance, the percentage of patients achieving a good physical function was independent 
of the autoantibody status. Together, these findings indicate that methotrexate is effective 
as initial treatment strategy  regardless of autoantibody status.  
Previous intervention studies suggested that the presence of ACPA in early RA-patients may 
be associated with a better response to methotrexate, with higher levels indicating an 
improved response (10, 16, 17). Moreover, ACPA-positive undifferentiated arthritis patients 
receiving methotrexate were found to be less likely to progress to RA10. A possible 
explanation for the discrepancies between these previous findings and our data may be 
related to differences in study populations, with the previous randomized controlled trials 
including only a selection of RA patients with high baseline disease activity. A strength of 
our study is that it is based on a large international real-world cohort that best mimics 
routine clinical practice. Our findings are in line with the results of a previous cohort study 
reporting equal treatment responses independent of autoantibody status in patients 
receiving various different initial DMARDs (11).  
This study has several limitations. As the METEOR database is an observational database 
gathered during daily clinical practice most variables contain missing values. Data regarding 
ACPA status were more often missing compared to RF status, which may be explained by 
the time period of inclusion. To account for missing data we applied multiple imputations 
(14). Reciprocal analysis based on non-imputed data revealed no differences between 
autoantibody-positive and -negative patients. Another concern with real-world data is the 
variation in clinical scoring and a higher noise to signal ratio. It is to be expected that 
differences in DAS or other outcome measurements exist between different centres. 
However, it is less likely that measurements within one centre differ between autoantibody-
positive and -negative individuals. Due to the observational nature of the database, we had 
to take several precautions to limit the influence of potential bias - multiple imputation, 
testing for effect modification and adjusting for potential confounders – but it is always 
possible that residual confounding remains.  
A striking feature of our dataset was the high percentage of autoantibody-positive RA-
patients (up to 89%), which is higher than in European cohorts but consistent with other 
international cohorts (11, 18). Some countries, particularly those with limited financial 
resources, included only a very limited number of autoantibody-negative patients, perhaps 
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because these patients are less frequently referred to rheumatologists in those settings. 
Never smokers were more prevalent among autoantibody positive RA patients. This is 
remarkable, since smoking is associated with ACPA-positive RA(19).This can be explained by 
the large proportion of Indian patients included in the analyses. The majority of these 
patients were autoantibody positive. After exclusion of Indian patients, 54% (350/651) of 
autoantibody positive patients were never smokers compared to 86% (1,250/1,461) found 
in the whole dataset. It has been previously published that especially the number of women 
smoking in India is low (approximately 3%)(20). Furthermore, the use of smokeless tobacco 
products is relatively high in India, which was not captured in this database (21). 
In our dataset, information regarding autoantibody status was limited to ACPA and RF 
serology. We cannot exclude that some of the autoantibody-negative patients express 
other RA-associated serological markers such as anti-carbamylated protein antibodies or 
anti-acetylated protein antibodies (22). However, these novel autoantibodies are expected 
to be present in only a limited proportion of the ACPA- and RF-negative population. 
In conclusion, we found that autoantibody status was not associated with early remission 
in newly diagnosed RA-patients receiving methotrexate in real-world clinical practice. The 
results from our study therefore do not support the hypothesis that treatment should be 
tailored to “autoantibody status” when it comes to initiating methotrexate therapy as first-
line anti-rheumatic treatment. Rather, our results indicate that that methotrexate is 
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Current research in rheumatoid arthritis focusses on preclinical disease phases as it is 
hypothesized that early preclinical treatment might prevent progression to full-blown 
disease. Since performance of studies in pre-arthritis phases in humans is challenging, 
animal models offer an opportunity to evaluate preventive treatments. We performed a 
systematic literature review and summarized treatment effects during different stages of 
arthritis development in animal models. 
 
Methods 
Eight medical literature databases were systematically searched. Studies were selected if 
they reported effects of synthetic or biological disease-modifying anti-rheumatic drugs in 
animal models of arthritis (collagen-induced arthritis and adjuvant-induced arthritis) on 
arthritis severity, as measured with arthritis severity scores, paw swelling or paw volume. 
Quality was assessed using an eleven item checklist. Study characteristics were extracted 
and effect sizes obtained in high-quality studies were summarized in meta-analyses. Studies 
were categorized in three groups; prophylactic (prior to generation of autoantibody 
response), pre-arthritis (after induction of autoantibody response) and therapeutic 
intervention (after arthritis development). 
 
Results 
Out of 1415 screened articles, 22 studies (including n=712 animals) were eligible, of good 
quality and included in meta-analyses. Prophylactic (16 experiments, n=312 animals) and 
pre-arthritis treatment (9 experiments, n=156 animals) both were associated with a 
reduction of arthritis severity (p<0.001 and p=0.005 respectively). Stratified analyses for 
different anti-rheumatic drugs initiated in the pre-arthritis phase suggested higher efficacy 
of methotrexate than of anti-TNF. 
 
Conclusions 
Data of experimental studies in animal models of arthritis suggest that prophylactic and pre-
arthritis treatment strategies are effective and hint at differences in efficacy between anti-







During recent years, research in the field of rheumatoid arthritis (RA) has focused on the 
earliest stages of the disease. This has provided novel insights into the immunological 
processes that precede the transition from healthy to established disease. Currently, the 
field of RA is moving from disease suppressive treatments to prevention strategies, 
focussing on initiation of treatment in pre-arthritis phases. Within RA it has been shown 
that a prolonged symptom duration at treatment start is associated with a worse disease 
outcome, including a lower chance on achieving disease modifying anti-rheumatic drug 
(DMARD)-free sustained remission [1-4]. Therefore it is hypothesized that treatment 
initiation during pre-arthritis stages might result in an improved efficacy in preventing 
disease chronicity [5]. Within type I diabetes preventive trials have shown efficacy of very 
early intervention to prevent full blown disease [6-8]. 
To evaluate of very early treatment initiation can also prevent the development of RA, 
several placebo-controlled randomized controlled clinical trials have been initiated recently. 
These clinical trial studies will investigate the therapeutic potential of several 
immunomodulatory agents such as rituximab (PRAIRI study: NTR No. 1969), abatacept 
(APIPPRA study: ISRCTN No. 46017566 and ARIAA study: EudraCT No. 2014-000555-93), 
hydroxychloroquine (StopRA trial; NCT No. 02603146) and methotrexate (TREAT EARLIER; 
NTR No. 4853) in individuals at a risk of RA. A study evaluating the immunomodulatory 
effect of atorvastatin in seropositive arthralgia patients has also been initiated (STAPRA 
study: NTR No. 22389). Interestingly, design of these trials does not follow the normal 
development of phase 1,2 and subsequently phase 3 trials. Moreover, dosages used are 
from other indications targeting different biology and the length of treatment is relatively 
randomly defined. The performance of randomized clinical trials on preventative treatment 
strategies in individuals at risk for RA is therefore difficult to interpret. Early identification 
and recruitment of patients at risk for RA is difficult and execution of these studies is time 
consuming. Altogether, it will take several years before the majority of these currently 
ongoing clinical trials are completed and the results are known. Likewise, because of 
difference in study-design and patient selection it will be difficult to compare side-by-side 
which intervention will be most effective in reaching sustained symptom- and drug-free 
benefit.  
Animal models of arthritis can function as innovative tools to study the potential of 
preventive therapies. Animal studies provide an opportunity to study the developing 
(auto)immune response at a very early disease phase and the translation of different stages 
of experimental arthritis development to the evolution of human disease might provide 
valuable information regarding possibilities of disease prevention. Murine models of 
arthritis are scientifically well defined, highly reproducible, genetic identical, represent 
different disease pathways relevant for RA and are readily available. While current animal 
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research mainly focusses on testing anti-rheumatic drugs in established disease, it is 
unknown whether preventive treatment in mouse models is also effective. In addition, it is 
unknown if the efficacy of prophylactic or pre-arthritis intervention depends on the type of 
anti-rheumatic drug used. These questions prompted us to perform a systematic literature 
review and summarize the knowledge on the efficacy of treatment initiated before arthritis 
was clinically evident. Our first aim was to evaluate if prophylactic or pre-arthritis treatment 
is effective in animal models of arthritis. The second aim was to evaluate the efficacy of 
different synthetic and biological DMARDs treatments initiated in pre-arthritis phases. 
We focused on two widely accepted experimental models for RA; collagen-induced arthritis 
(CIA) and adjuvant-induced arthritis (AIA), both models are based on immunization-induced 
arthritis. In the CIA model, arthritis is induced by immunizations with cartilage proteins 
causing a break of tolerance and an immune-mediated inflammatory attack on the joints [9 
10]. Animals receive type II collagen emulsified in complete Freund’s adjuvant typically 
followed by a second injection three weeks later, leading to the development of chronic 
destructive arthritis. There are three developmental stages of arthritis in the CIA model; an 
induction phase, a pre-arthritis phase were auto-immunity is present in the absence of 
clinical symptoms, and established arthritis [11]. The AIA-model requires intradermal 
immunization with mycobacterial cell wall components suspended in mineral oil causing an 
acute and systemic inflammation. The development of arthritis in the AIA-model is thought 
to depend on a heat shock protein specific T-cell response. In contrast to CIA, AIA is self-
limiting and contains three developmental stages of arthritis; incubation phase, pre-arthritis 
phase and a peak phase followed by a gradual regression of inflammation [12]. Thus, these 
experimental models of arthritis have clearly defined developmental stages that can be 
identified by immunological disease markers.  According to these developmental stages of 
arthritis we discerned three types of treatment; prophylactic (prior to generation of 
autoantibodies), pre-arthritis (after induction of an autoantibody response) and therapeutic 
intervention (after arthritis development) (Figure 1). We performed a systematic literature 





Figure 1. Schematic representation of developmental stages of collagen-induced arthritis (CIA) and 
human RA.  Type of intervention during different developmental stages of experimental arthritis in 
the collagen-induced arthritis (CIA) model. Arthritis is generally induced by immunization with CII 
emulsified in complete Freund’s adjuvant followed a booster injection three weeks later of CII in 
incomplete Freund’s adjuvant. After immunization with type II collagen, during the initiation phase, 
auto-immunity towards collagen will develop (blue circles). Drug intervention during this time period 
is referred to as prophylactic treatment. This first stage is followed by a pre-arthritis phase which is 
characterized by the onset of autoimmunity and is marked by the development of autoantibodies 
against type II collagen which occurs around day 10. The time period in which auto-immunity is 
present and arthritis is still absent is referred to as the pre-arthritis period. Intervention during this 
pre-arthritis disease stage is described as pre-arthritis treatment. The time period of pre-arthritis 
arthritis is followed by the onset of arthritis (red triangles), which occurs around day 20 and leads to 
chronic destructive arthritis. Drug intervention at the established arthritis stage is described as 
therapeutic intervention (A). Schematic representation of human RA development. Genetic and 
environmental factors drive the onset of auto-immunity which subsequently leads to undifferentiated 






Eight bibliographic databases (PubMed, Medline, Embase, Web of Science, Cochrane 
Library, CINAHL, Academic Search Premier and Science Direct), were searched to identify 
studies investigating treatment strategies in animal models for experimental arthritis 
(search conducted April  14, 2016). A systematic search strategy was developed for PubMed 
(see online supplementary file 1) and was subsequently applied in all other databases. 
Search terms were: rheumatoid arthritis, experimental models for arthritis, therapeutic 
intervention DMARDs (Methotrexate, Leflunomide, Cyclosporine, Sulfasalazine, 
Azathioprine or Hydroxychloroquine, Prednisolone) or biologicals (anti-TNF, Anti-IL-1, 
CTLA4-Ig, anti-IL-6 or anti-CD20) combined with the Boolean operators AND/OR.  
 
Inclusion and exclusion criteria 
The inclusion criteria are described in table 1. In short, we included published peer-reviewed 
studies reporting the effect of therapeutic intervention (synthetic or biological DMARDs) in 
the most commonly used in vivo models of experimental arthritis (CIA and AIA). 
Furthermore experiments should be prospectively controlled and information on clinical 
outcome and joint structural changes should be provided. Abstracts were assessed based 
on type of research (animal studies), drugs tested, outcome measures (arthritis severity) 
and duplicates. Full papers were assessed to identify experimental arthritis models, study 
design, treatment and control groups, therapeutic interventions and outcomes 
measurements used in the studies.  
Table 1. Inclusion criteria for experimental studies reporting:  
1. prospective controlled experiments using small animals 
2. treatment group with experimentally induced arthritis CIA or AIA model 
3. matched control group of animals with induced arthritis which receive control treatment 
(placebo) or animals with arthritis without any intervention.  
4. testing of anti-rheumatic drugs; synthetic DMARDs (Methotrexate, Leflunomide, 
Cyclosporine, Sulfasalazine, Azathioprine, Hydroxychloroquine or 
Prednisolone/Dexamethasone) or biological DMARDs (anti-TNF, anti-IL-1, CTLA4-Ig, anti-IL-
6 or anti-CD20 monoclonal antibodies) 
5. effects on clinical outcome defined as arthritis severity score, paw swelling or paw volume 
6. effects on joint structural changes: histological- (synovial hyperplasia, cell infiltration, 
pannus formation, oedema, fibrosis, cartilage and bone destruction) or radiological scores 





Furthermore, studies were only selected if the following clinical outcomes were evaluated: 
arthritis severity scores (ordinal scale), paw swelling (mm) or paw volume (ml), or outcome 
measurements for joint structural changes by quantitative histological or radiographic 
scores measured with X-ray or microCT. An overview of the outcome measurements is 
presented in Table 2. 
 
 
Table 2. Summary of study characteristics of the 22 studies included in the meta-analyses. 
Study characteristic  Sub-groups Number of studies 
Model of experimental arthritis CIA   16 
    AIA   8 
Species    Rat   16 
    Mice   6 
Drugs tested    synthetic DMARDs  Dose mg/kg 
Methotrexate  10 0.1-50mg/kg 
    Leflunomide  2 3.75-10mg/kg 
    Cyclosporine  1 2.5mg/kg 
    Sulfasalazine  1 80mg/kg 
    Azathioprine  1 5mg/kg  
    Hydroxychloroquine 1 25mg/kg 
    Methylprednisolone 1 2mg/kg 
Dexamethasone  1 0.5mg/mg 
    Biological DMARDs   Dose mg/kg 
    anti-TNF   5 0.75-2mg/kg 
    Anti-IL-1   4 0.1-1mg/kg 
    CTLA4-Ig   2 1-5mg/kg 
Route of administration  Oral   15 
    Subcutaneous  6 
    Intraperitoneal  9 
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Treatment duration  1 week   6 
    2-4 weeks  8 
    >1 month  8 
Treatment strategy  Prophylactic  16 
    Pre-arthritis  9 
    Therapeutic  12 
Clinical outcome   Arthritis severity score  14 
    Paw swelling (mm)  8 
    Paw volume (ml)  5 
Joint structural changes  (Semi-)quantitative histological data scores: 
    synovial hyperplasia   5 
    cell infiltration    10 
    pannus formation    3 
    oedema     1 
    fibrosis     2 
    cartilage destruction   10 
    bone erosion    10 
    Quantitative radiographic scores based on: 
    X-ray     8 
    microCT     2 











We extracted individual study characteristics from each publication, and, where a 
publication reported more than 1 experiment, these data were also extracted and 
considered independent experiments. Extracted data included: experimental arthritis 
model, species, number of animals per group, drug and dose, route and time of drug 
administration, clinical-, histological- or radiological scores. Where arthritis severity 
measurements were performed serially, we only extracted the final time point. 
 
Quality assessment of methodology 
Study quality and  risk of selection- and detection bias was assessed by a modified 11-point-
item checklist, adapted from CAMARADES (Collaborative Approach to Meta-Analysis  and 
Review of Animal Data from Experimental studies) [13]. The checklist comprises items of 
study methodology: randomisation (1); allocation concealment (2); blinding (3); evidence of 
induced arthritis (macroscopic, histological or radiological) (4), sample size/power 
calculations (5), statement of conflict of interest (6), statement of compliance with animal 
welfare regulations (7), standardized method for data collection (8), (semi)quantitative 
scoring method for disease activity (9), (semi)quantitative scoring method for joint damage 
(10) and clear data presentation (11). Each item was scored as 1 if the data were reported 
satisfactorily and 0 if not (unclear risk of bias) and maximum score was 11. The median 
quality score of six was considered to be sufficiently high quality for further analysis. An 














Table 3. Methodological quality assessment form for study quality and potential risk of bias as judged 
by the quality of reporting. Each item was scored as 1 if performed and 0 if not reported or not 
performed. Maximum score was 11 points.  
Risk of 
Bias 
       Criteria  Explanation 
Selection 
bias 
1. Randomization  
 2. Allocation concealment Concealing the allocation sequence from those 
assigning animals to experimental and control groups 





3. Blinding Keeping the persons who perform the experiment, 







4. Evidence of proper 
arthritis induction  
 
Histological, macroscopic, microscopic or X-ray 
evidence 
 
 5. Sample size/power 
calculations before 
start of experiment 
 
 
 6. Statement regarding 
potential conflict of 
interest 
 
 7. Statement of 




 8. Standardized method 
data collection 
Data collection at predefined time points 
 
 9. Validated scoring 
method for arthritis 
severity   
 
Semi-quantitative clinical scoring system for each 
paw in a range from 0-4, caliper measurements of 
ankle joints, or use of a plethysmometer for 
measurements of small volume changes in paw 
volume. 
 
 10. Validated scoring 
method for joint 
damage 
 
X-ray: modified Larsen scoring method. Histology: 
semi-quantitative for synovial and extra articular 
inflammation (in a range from 0-3) and bone 
erosions (in a range from 0-5).  
 
 11. Clear data presentation  
 
Numbers of animals per group, data of both 
treatment and control group available.   
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Categorisation of studies according to type of intervention 
Studies were discerned into three groups according to the time point of treatment 
initiation:  (1) Prophylactic treatment (day 0-9): therapy is initiated prior to injection of 
arthritis-stimulators or after injection of arthritis-stimulator but prior to the development 
of a systemic autoimmune response which is characterized by production of 
autoantibodies. (2) Pre-arthritis treatment (day 10-20): start of therapy after the 
development of auto-immunity but before the onset of clinically evident arthritis. (3) 
Therapeutic treatment (>20 day): initiation of treatment after the onset of arthritis, which 
occurs generally around day 21-22.  
  
Meta-analysis 
Only studies with high methodological quality (score ≥ 6) were summarized in meta-
analyses. Furthermore; studies that did not provide standard deviations (SD) or standard 
errors of the mean (SEM) were excluded for the meta-analyses. To compare the severity of 
arthritis in the treatment group to an arthritic untreated control animal, we calculated the 
normalized mean difference (NMD) of arthritis clinical score, paw volume or paw swelling. 
The NMD effect size in the treated animals is calculated as a proportion of the mean in the 
control group [14]. Similarly, we calculated the NMD for each experimental comparison as 
the proportional improvement in the treated group compared with the control group, along 
with the standard error of the estimate. To account for anticipated heterogeneity we 
applied the DerSimonian and Laird random effects model [15] to calculate an overall 
treatment effect, this random-effects model for meta-analysis uses both within-the study 
variance and the between-study variance. We used Cochran’s Q to calculate heterogeneity 















Study selection and study quality 
Our systematic search identified a total of 3486 titles from eight databases (Figure 2), 35 
studies met the inclusion criteria based on full paper assessment. A summary overview of 
these 35 studies is presented in Table 1, for the complete overview see online 
supplementary Table S5.   For further selection of studies for meta-analysis, 28 studies were 
considered to be of sufficient high methodological quality (score ≥ 6). Six of these studies 
did not report SDs or SEMs and therefore and could not be included in the meta-analyses 
[17-22]. Finally, the results of 22 studies, using a total of 712 animals (control animals, n 
=263 and treated animals, n = 449), were summarized in meta-analyses.  
The most frequently used model of experimental arthritis was the CIA model (CIA 16 
studies, AIA 8 studies). 16 studies used rats and 6 studies used mice (table 2). Thirteen out 
of 22 publications (59%) reported the blinded assessment of outcome, 15 (68%) reported 
randomization, and none reported performing a sample size calculation (table 4). The 
outcome summarized in the meta-analysis was the proportion reduction of arthritis severity 
(expressed in NMD).  
Histological- and radiographic scores were not consistently scored in uniform scoring scales. 












Table 4. Number and percentage of publications reporting individual components of the study quality 
checklist for the 22 studies that were included in the meta-analyses.  
The quality checklist is depicted in table 3. 
Quality criteria         Total studies (n=22) % 
Randomisation       15  69 
Allocation concealment      9  40 
Blinding        13  59 
Evidence of proper arthritis induction     20  90 
Sample size/power calculations     0  0 
Statement regarding potential conflict of interest    7  32 
Statement of compliance with animal welfare     17  77 
Standardized method for data collection    18  81 
Validated scoring method for arthritis severity     21  100 
Validated scoring method for joint damage    19  86 















Table 5. List of all 35 studies that met the inclusion criteria based on full paper assessment. Twenty-
two studies [20-41] are included in the meta-analyses.  
 
Author Type of 
intervention 




























prophylactic AIA rats Cyclosporin A 7 weeks paw swelling 
(mm) 
6 
    Methotrexate 7 weeks   
Smith  
1996 [27] 
prophylactic CIA rats Methylpredni-
solone 
4 weeks clinical score 
(0-16), Δ paw 
volume  
7 
    Methotrexate 4 weeks   
    Azathioprine 4 weeks   
    Hydroxy- 
chloroquine 
















    Dexametha-
sone 
























































































therapeutic  CIA mice Etanercept 4 weeks paw swelling 
(mm), clinical  



































































rats Anti-IL-1 1 week paw volume 













therapeutic CIA rats Leflunomide,  3 weeks clinical  score 
(0-16) 
5 
    Metrotrexate 3 weeks   
Teramachi 
2011 [47] 









































Effect of intervention on clinical outcome  
The treatment efficacy on arthritis severity was studied per disease stage. 
 
Prophylactic treatment  
Sixteen experiments (including 312 animals) studied the effect of prophylactic intervention 
on the severity of arthritis (Figure 3A). Several DMARDs were tested in a prophylactic setting 
(methotrexate [6 experiments] [23-27], leflunomide [1 experiment] [28], cyclosporine A [2 
experiments] [26 27], azathioprine [1 experiment] [27], hydroxycholoroquine [1 
experiment] [27], and methylprednisolone/dexamethasone [2 experiments] [27 29], anti-
IL1 [1 experiments] [29] and CTLA4-Ig [2 experiments] [30 31]. The combined effect size of 
the different studies indicated that prophylactic intervention is associated with a reduction 
of arthritis severity in animal models of arthritis (p<0.001). Prophylactic treatment with 
both methotrexate (p< 0.001) and CTLA4-Ig (p<0.001) was significantly associated with a 
reduction in arthritis severity (Figure 3B). 
 
 
Figure 3. Prophylactic intervention in experimental models of arthritis. Effect of prophylactic 
intervention on arthritis severity reported in 16 individual experiments using synthetic or biological 
DMARDs. The pooled effect size of normalized mean difference (NMD) in arthritis severity is -40.1 
(95CI=-50.6 to -31.4, z-value=-8.2, p<0.001) (A). Stratified meta-analysis of the different experiments 
investigating the effects of different anti-rheumatic drugs further specified for methotrexate, pooled 
estimate -26.0 (95CI=-38.6 to -13.5, p<0.001)  and CTLA4-Ig, pooled estimate -80.2 (95CI=-100.0 to -










Pre-arthritis treatment  
Nine experiments (including 156 animals) studied the effect of early pre-arthritis treatment 
on arthritis severity (Figure 4A). DMARDs tested were leflunomide [1 experiments] [32], 
methotrexate [4 experiments] [33-35], anti-TNF [2 experiments] [36] , anti-IL1 [2 
experiments] [37]. A meta-analysis of these studies demonstrated that pre-arthritis 
intervention is associated with a reduction of arthritis severity in animal models of arthritis 
(p=0.005). Stratified analysis for most commonly used DMARDs revealed that treatment 
with methotrexate was significantly associated with less arthritis severity (p<0.01), while no 
statistically significant results were obtained for  anti-TNF (p=0.065) and anti-IL1 (p=0.098) 
(Figure 4B). None of the animal studies performed in a pre-arthritis stage evaluated a 









Figure 4. Pre-arthritis intervention in experimental models of arthritis. Effect of pre-arthritis 
intervention on arthritis severity reported in 9 individual experiments using synthetic or biological 
DMARDs in a pre-arthritis phase of arthritis. The pooled effect size of normalized mean difference 
(NMD) in arthritis severity is -21.2 (95CI=-35.9 to -6.5, z-value=-2.8, p=0.005) (A). Stratified meta-
analysis of the different experiments investigating the effects of different anti-rheumatic drugs further 
specified for methotrexate pooled estimate -29.5 (95CI=-50.6 to -8.4, p=0.006), anti-TNF pooled 
estimate -8.6 (95CI=-17.7 to 0.5, p=0.065), and anti-IL1 pooled estimate -9.0 (95CI=-19.6 to 1.6, 










Twelve experiments (including 244 animals) studied the effect of therapeutic treatment in 
established arthritis (Figure 5A). Anti-rheumatic drugs tested in established disease were 
sulfasalazine [1 experiment] [38], methotrexate [2 experiments] [39 40] , anti-TNF [4 
experiments] [39 41-43], anti-IL1 [3 experiments] [42 44] and CTLA4-Ig [2 experiments] [30]. 
Therapeutic treatment with methotrexate (p<0.001), anti-TNF (p<0.001) anti-IL1 (p<0.001) 
and CTLA4-Ig (p<0.001) in established disease were all significantly associated with a 






Figure 5. Therapeutic intervention in experimental models of arthritis. Effect of therapeutic 
intervention on arthritis severity reported in 12 individual experiments using synthetic or biological 
DMARDs in established arthritis. The pooled effect size of normalized mean difference (NMD) in 
arthritis severity is -44.2 (95CI=-54.4 to -34.0, z-value=-8.5, p<0.001) (A). Stratified meta-analysis of 
the different experiments investigating the effects of different anti-rheumatic drugs further specified 
for methotrexate -34.4 (95CI=-42.5 to -26.3, p<0.001), anti-TNF -32.2 (95CI=-49.2 to -15.1, p<0.001), 
anti-IL1 -70.6 (95CI=-79.9 to -61.3, p<0.001)and CTLA4-Ig -27.9 (95CI=-34.3 to -21.5, p<0.001). 
Treatment length was on average 4 weeks for methotrexate, 3.3 weeks for anti-TNF, 1 week for anti-









Since CIA and AIA somewhat differ in disease pathology we have performed separate sub-
analyses for these models which showed similar results as that of the total group (Fig. 6, 7). 
 
 
Figure 6. Sub-analysis of prophylactic intervention stratified for CIA and AIA. Effect of prophylactic 
intervention on arthritis severity stratified for the CIA model (9 studies). The pooled effect size of 
normalized mean difference (NMD) in arthritis severity is -44.1 (95CI=-61.6 to -26.6, z-value=-4.9, 
p<0.001) (A). Stratified meta-analysis of the different experiments investigating the effects of different 
anti-rheumatic drugs further specified for the AIA model (7 studies), pooled estimate -33.9 (95CI=-




Figure 7. Sub-analysis of pre-arthritis intervention stratified for CIA and AIA. Effect of prophylactic 
intervention on arthritis severity stratified for the CIA model (6 studies). The pooled effect size of 
normalized mean difference (NMD) in arthritis severity is -16.5 (95CI=-16.5 to -28.3, z-value=-4.6, 
p=0.006) (A). Stratified meta-analysis of the different experiments investigating the effects of different 
anti-rheumatic drugs further specified for the AIA model (3 studies), pooled estimate -21.3 (95CI=-






The present systematic literature review and the meta-analyses of data on treatment in 
animal models of experimental arthritis reveal that ‘prophylactic and pre-arthritis 
treatment strategies’ are effective and result in less severe disease. Currently research 
emphasises on early identification of individuals at risk for developing RA with as ultimate 
goal the reduction of disease severity or even to prevent clinically manifest disease. 
Although it will take years before the results of current clinical trials will be at the stage of 
publishing, results of the present study in animals support the concept that very early 
treatment may be effective. Observational studies in RA patients have provided evidence 
that support the concept of a therapeutic ‘window of opportunity’. The period in which the 
disease is most susceptible to treatment is presumed to consist of the first three months 
after symptom onset [52 53]. Although some studies have treated patients rapidly after 
arthritis has become clinically evident [54-57], studies that initiate treatment already in pre-
arthritis phases are more challenging to perform, because of the difficulty to identify 
patients with arthralgia and a high predicted risk for developing RA. Some of the preventive 
studies in human RA aim to target autoantibody positive subjects with arthralgia and we 
hypothesize that this phase corresponds to intervention in the pre-arthritis phase of the CIA 
model. But, although the CIA mouse model is widely used to mimic the antibody-dependent 
process of RA pathogenesis, anti-collagen antibodies are not the most prominent antibodies 
in human RA and conflicting results on ACPA induction in CIA exist [58]. Thus, while CIA and 
AIA are informative, these models only partially resemble the situation in human RA and 
reflect only some of the basic disease mechanisms and molecular pathways involved in RA 
development. Despite the disparities between animal models of arthritis and RA, animal 
models of arthritis are of interest, and the summarized data suggest that very early 
treatment is effective. 
The second aim was to evaluate the effect of different medications in animal models. The 
most frequently studied DMARDs were methotrexate and anti-TNF. In humans several 
other drugs (abatacept, hydroxychloroquine, atorvastatin) are now also being investigate in 
pre-arthritis phases. Studies investigating the effect of hydroxychloroquine on animal 
models are limited; in our meta-analysis we included only one study that evaluated 
hydroxychloroquine on CIA. Our literature search was limited to studies that tested 
DMARDs, statins were not included. Nevertheless, the effects of statins have been studied, 
with contrasting results; some studies reported anti-inflammatory effects [44, 45] while 
others pointed to an accelerated onset of CIA in mice [46]. In our meta-analysis we observed 
a higher effect for metrotrexate then for anti-TNF, this may suggest that methotrexate is 
more disease-modifying in this very early disease phase. Though, formal conclusions on the 
difference in efficacy or treatment dose cannot be made and translation to the human 
setting is limited. None of the pre-arthritis studies compared the different medications 
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head-to-head. We distinguished treatment started in the initiation phase (prophylactic 
intervention) and in the phase autoantibodies had developed (pre-arthritis intervention). 
Meta-analyses suggested that treatment started in both phases was effective. However, 
none of the studies performed side-by-side comparisons of prophylactic, pre-arthritis and 
therapeutic interventions. Therefore we cannot conclude if the first two strategies are more 
effective than treatment initiated in the established disease phase. Similarly, the results 
obtained on prophylactic strategies cannot be compared to those of pre-arthritis strategies.  
There are more limitations. Surprisingly, the majority of studies that aimed to test the 
efficacy of prophylactic treatment used an extended treatment period (average of 4.6 
weeks, thus continuing within the phase of established disease).  Principally, treatment is 
preventive if given in pre-clinical phases only. Studies that initiated treatment at a pre-
arthritis stage did treat animals with a short course of (at average) 1 week and still observed 
less severe arthritis in the clinical phase of the disease [33-37]. Furthermore none of the 
studies evaluated the occurrence of clinical arthritis. Hence there are no data from animal 
models to conclude if clinical disease can be prevented. For human translation, it would be 
most interesting to determine whether preventive treatment can actually reverse 
autoimmunity and prevent RA.  
The studies that were evaluated were heterogeneous in several aspects. The use of 
standard operating procedures for validation of results is crucial to reduce study 
heterogeneity. Using a 11-point-item quality checklist we aimed to select studies that had 
a reliable study design; despite the funnel used, still considerable differences were present 
in the experiments that were included in the meta-analysis. Mice as well as rats were 
studied. In addition, results of two different animal models (CIA, AIA) were evaluated.  Sub-
analyses stratified for CIA and AIA, however, showed similar results as that of the total 
group. Furthermore, arthritis severity was assessed in different ways. Although a validated 
method was use to compared these outcomes (normalized mean difference), this adds to 
the heterogeneity. For these different reasons, the NMDs –including those resulting from 
the meta-analyses performed for different disease phases and for the different treatments- 
should not be compared in their effect size. Thus although the efficacy of different 
treatment strategies cannot be compared, this study  provides an overview of all available 
data on animal models and provides  an evaluation if treatment initiated in very early 
disease phases is effective.    
Based on the present evaluation of the available literature we conclude that the ideal 
experiment on animals for this research question should still be performed. This study 
should test interventions side-by-side in different disease phases and with a similar 
treatment schedule to be able to compare efficacy. In addition, a head-to-head comparison 
of DMARDs like methotrexate, abatacept, rituximab and anti-TNF with a defined duration 
could answer the question whether pre-arthritis treatment can reverse autoimmunity and 
prevent arthritis in mouse models. Proper controls are sham-treated mice that develop a 
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natural course of experimental-induced arthritis. The presence and evolution of systemic 
autoimmunity in CIA, defined by autoantibody production against CII, should be determined 
and linked to clinical outcome. Ideally, the effect of (a short course of) pre-arthritis 
treatment should be evaluated over an extended period of time to determine whether 
there is long-term arthritis-free-‘benefit’ or a delayed onset of arthritis.  
In conclusion, this study systematically evaluated the results of animal studies and 
suggested that both prophylactic and pre-arthritis treatment strategies lead to a significant 
reduction of arthritis severity scores and hits at a possibility for preventive therapy in RA. 
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Periodontal disease is a chronic inflammatory condition affecting the tissues surrounding 
the teeth and is caused by dysbiosis of the oral microbiota. Periodontal disease and RA are 
closely linked as both diseases are characterized by localized chronic inflammatory 
reactions. Clinical studies have shown that periodontitis is more prevalent in patients witch 
active RA than in health individuals; conversely, the prevalence of RA is also higher in 
individuals with periodontitis than in those without periodontitis. (1)  
The periodontal pathogen Aggregatibacter actinomycetemcomitans (Aa) seems to 
represent a link between periodontal infection and autoimmunity. Recently, the group of 
Konig et al. describe a potential explanation for the link between periodontal infection and 
rheumatoid arthritis (RA) (2). They identify a specific periodontitis-associated bacterium: 
Aggregatibacter actinomycetemcomitans (Aa), which via its lytic toxin (leukotoxin A: LtxA) 
can dysregulate the activity of citrullinating enzymes in neutrophils. The thus-generated 
citrullinated autoantigens are the target of a key autoantibody system in RA: anti-
citrullinated protein antibodies (ACPA). Furthermore, the authors report that the effect of 
the most important genetic risk factor for RA: the human leukocyte antigen-DRB1 shared 
epitope (HLA SE) alleles, was limited to RA patients who had been exposed to Aa as 
determined by seropositivity to LtxA in a set of 194 RA patients. Based on these findings, 
the authors hypothesize that LtxA may be a key factor in the initiation of the RA-specific 
anti-citrullinated protein immune response in genetically predisposed individuals. In light of 
the crucial implications of this novel hypothesis for the current thinking regarding RA 
development, we aimed to replicate these findings. 
To this end, we focused on two main questions: 1) is the increased exposure to Aa as 
measured by the presence of anti-LtxA-antibodies specific for RA, or also present in other 
forms of inflammatory arthritis? 2) can we replicate the finding that the association 
between HLA SE alleles and ACPA-positive RA is limited to the anti-LtxA-positive subset?  
To answer these questions, we established an enzyme-linked immunosorbent assay (ELISA) 
against purified LtxA. The purification of LtxA was performed according to the method 
described by Reinholdt et al. (3), which is the same method carried out from the same clone 
of the strain of Aa (HK921; JP2 positive) in the same laboratory as in the manuscript by Konig 
et al.  The activity of LtxA was confirmed in a haemolytic assay, to correspond to the normal 
range of freshly purified LtxA. To confirm that the presence of antibodies against LtxA was 
indeed a reflection of exposure to the bacterium Aa, we first tested serum samples from 
periodontitis-patients (free from any chronic diseases such as RA) whose subgingival lesions 
had been tested for the presence of Aa by culturing techniques (4). As depicted in Figure 
1A, the levels of anti-LtxA-antibodies were clearly elevated in Aa-positive patients (median 
level (interquartile range (IQR): 8853 (5544; 14147)) versus Aa-negative patients (median 
level (IQR): 764 (523; 4636)) confirming the specificity of the ELISA (Mann-Whitney U-test 
p-value < 0.001). 
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Thus, we subsequently tested sera from 594 patients participating in the Leiden Early 
Arthritis Clinic with various different diagnoses, including RA according to the 1987 ACR 
criteria (5). Furthermore, we also measured anti-LtxA-levels and positivity in a group of 156 
healthy controls (without chronic illnesses) from the Leiden area. Figure 1B depicts the anti-
LtxA-levels in these various groups and illustrates that anti-LtxA antibodies could be found 
in a substantial proportion of RA patients, but also in patients with other forms of arthritis. 
Serial dilutions of a mix of 3 strongly positive RA patients were used as a standard, and the 
lowest point of the linear part of the standard curve (2000 AU/ml) was defined as the cut-
off. Next, we investigate whether within RA patients, anti-LtxA-antibodies were 
preferentially present within the ACPA-positive group, and whether there was an 
association with the HLA SE-alleles. As depicted in Figure 1C, neither of these associations 
could be found in our cohort. Furthermore, as can be seen in Table 1, the association 
between HLA DRB1 SE alleles and anti-CCP-positive RA was similar among RA patients 
positive and negative for anti-LtxA. Therefore, the effect of the HLA SE alleles appears not 
to be confined to the patient group positive for anti-LtxA-antibodies. 
 
 
Table 1 The association of SE alleles with anti-CCP based on exposure to LtxA in patients with 
RA. Anti-LtxA, anti-leukotoxin antibodies as determined by ELISA; Anti-CCP, anti-cyclic 
citrullinated peptide antibody, cut-off for positivity >20 U; SE, HLA-DRB1 shared epitope allele 
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In summary, in this large cohort of arthritis patients, anti-LtxA-antibodies were not 
specifically associated with RA, and within RA patients, there was no association with the 
presence of ACPA or HLA SE alleles, in contrast to the findings of Konig et al. A possible 
explanation for these divergent results could be that the anti-LtxA-assay as used here, may 
have differed from the assay in the previous publication. However, the essential constituent 
(LtxA) and set-up of the assay was derived from the same source. Furthermore, we 
performed various controls e.g. in periodontitis patients, the results of which confirmed the 
validity of our assay.  
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It is possible that differences in proportions of positive patients reported in the original 
study by Konig et al and in our study could be due to differences in patient population 
between the United States and the Netherlands. It seems likely that differences in living 
environment, genetic background and referral strategy exist between these two countries. 
However, given the fact that Aa is a prevalent micro-organism causing periodontitis in both 
countries, it appears unlikely that population differences can explain the contrasting 
findings regarding the possible role of Aa as found by Konig versus us.  
Although microbial influences may well be important in the development of RA, our results 
do not support a key role of exposure to LtxA originating from the periodontal pathogen Aa 
in linking the effect of the HLA SE alleles and periodontal disease to anti-citrullinated protein 
autoimmunity in RA.  
Whilst the hypothesis of a causal link between periodontitis/periodontitis-associated 
microorganisms and RA seems appealing, it is also possible that RA patients are more 
frequently anti-LtxA-positive simply because they have more periodontitis as is known from 
epidemiological studies. We hope our findings can contribute to the discussion about the 
origins of autoimmunity in RA, and look forward to other replication experiments regarding 



















Figure 1. Serum antibodies to leukotoxin A. (A) Serum antibodies to LtxA were measured in 
periodontitis patients with and without Aa infection (n=16 per group) confirmed by culturing. (B) 
Distribution of anti-LtxA antibodies in sera of 594 patients suffering from early arthritis and 156 
controls. Levels of anti-LtxA antibodies in the serum of each individual are shown. (C) Serum 
antibodies to LtxA were measured in RA patients stratified for the presence of anti-CCP2 antibodies, 
ACPA positive (n=214) and ACPA negative (n=155) RA patients (left panel). Presence of anti-LtxA 
antibodies in sera of RA patients carrying HLA-DRB1 shared epitope alleles, SE positive (n=243) and SE 
negative (n=117) RA patients (right panel). 
LtxA Leukotxin A, RA Rheumatoid arthritis, Aa Aggregatibacter actinomycetemcomitans, OA 
Inflammatory osteoarthritis, SpA Spondylarthritis with peripheral arthritis, PsA Psoriatic arthritis, Sarc 
Sarcoidosis, ACPA anti-citrullinated protein antibodies, SE shared epitope. Red lines indicate the 
median level per group. The dashed line indicates the cut-off. The number of patients per group and 
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Autoantibodies against post-translationally modified (PTM) proteins are a hallmark of RA. 
The reason why an immune response starts against PTM proteins is not known. However, 
it appears crucial to obtain understanding on the breach of tolerance towards PTM proteins 
as the immune response against these proteins has been intimately implicated in disease-
pathogenesis. In this thesis we report that exposure to modified self- and foreign proteins 
can lead to the generation of anti-modified protein antibodies (AMPA) which are directed 
against PTMs. Exposure of mice to carbamylated self- and foreign antigens can lead to the 
formation of self-reactive anti-CarP antibodies (chapter 3) (1). We also found that exposure 
to carbamylated self-proteins is sufficient to trigger primary immune responses, including 
autoantibody formation, T cell activation and cytokine production (chapter 4) (2). The 
studies in chapter 5 describe the observation that vaccinating mice with an acetylated 
protein leads to the formation of auto-antibodies against carbamylated proteins (anti-CarP 
antibodies) as well, indicating that different AMPA-responses can evolve from exposure to 
only one type of modified protein (3). In addition, we found that AMPA from RA-patients 
purified against one PTM can recognize different classes of PTMs. Chapter 6 describes the 
relationship between autoantibody status and treatment response. We found that in newly 
diagnosed RA patients who are receiving methotrexate, autoantibody status was not 
associated with the chance of achieving early remission. This indicates that methotrexate is 
effective as initial treatment strategy regardless of autoantibody status (4). The studies 
described in chapter 7 show that both prophylactic and pre-arthritis treatment strategies 
lead to a significant reduction of arthritis severity in animal models (5). Chapter 8 describes 
studies regarding the link between periodontal infection and autoimmunity. In a large 
cohort of arthritis patients we found that anti-LtxA antibodies were not specifically 
associated with RA. In addition, there was no association between ACPA or HLA SE alleles 
among RA patients.  Together, these studies highlight that the different anti-modified 
protein antibody responses present in RA could have a common origin which could be 
potentially implicated in disease pathogenesis. Regarding the described studies, several 
issues are worthwhile to be discussed in more detail.  
 
Detection of AMPA responses: specificity and reproducibility 
For the detection of AMPA we used anti-carbamylated protein, anti-citrulline and anti-
acetylated lysine ELISA antibody techniques (1-3). As these ELISA techniques are 
predominately used for the identification of these autoantibodies, its accuracy and 
reproducibility are crucial for the validity of our conclusions. The antigens used for 
identification are fetal calf serum, serum albumin and fibrinogen. These antigens were 
chosen as they are readily available, relatively cheap and easily to modify (i.e. carbamylate, 
citrullinate or acetylate) in a consistent manner. The non-modified counter parts served as 
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control. After protein modification by carbamylation, citrullination or acetylation, the 
presence of the modification on the antigens was confirmed by mass-spectrometry. This is 
a crucial step in order to confirm the solely presence of one particular modification in the 
absence of other, structurally similar, PTMs. Mass-spectrometry is a very specific method 
for compound identification as the citrulline and homocitrulline are distinguished based on 
their position within the protein (they are derived from either an arginine or a citrulline). 
Furthermore, homocitrulline differs from citrulline by 14 Da. Although mass-spectrometry 
is a specific technique, it is not a quantitative method. Therefore, we used commercial 
antibodies recognizing citrullinated, carbamylated or acetylated proteins to quantify the 
extent of modification present.  
We optimized in-house ELISAs to determine the presence of protein modifications and by 
titrating these antibodies the extent of modifications present can be estimated (although 
not in absolute terms). To confirm the reproducibility of our assays we performed several 
internal control experiments. Our previous studies with human sera showed an intra- and 
inter-assay variability of anti-carbamylated fetal calf serum (anti-Ca-FSC) and anti-
carbamylated fibrinogen (anti-Ca-FCS) of around 10-15% (6). Using sera of immunized mice, 
the intra- and inter-assay variability was more consistent (around 5-10%). In repeated 
measurements the chance of a false-positive sample in non-immunised mice was generally 
around 2-5%. It is important to acknowledge that there remains a certain degree of intra 
assay variation which can be considered as random variations due to the methodology of 
our assays (e.g. proteins rather than structurally defined peptides).  
 
 
AMPA responses and cross-reactivity 
Since homocitrulline structurally highly resembles citrulline, it is possible that anti-CarP 
antibodies are cross-reactive to citrullinated antigens. It has been reported that ACPA can 
bind peptides or proteins containing homocitrulline (7-9), however this does not directly 
implicate that antibodies in general cannot be specific for these PTMs. Previously, we have 
shown that human polyclonal antibodies can be specific for either carbamylation or 
citrullination (10). Additional studies indicate that the specificity towards citrullinated or 
homocitrulline does exist, but is dependent on the sera used (11). To test for cross-reactivity 
of polyclonal anti-CarP antibodies with carbamylated proteins, we performed inhibition 
assays with the same protein used both as antigen and inhibitor (1). This resembles a 
relevant positive control to show that at the chosen inhibitor concentration, inhibition is 
indeed present. The relevance of the inhibition assays lies in the comparison to the other 
modified proteins. Our data show that other, structurally unrelated, modified proteins are 
also able to inhibit the anti-CarP-response generated.  
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The studies in chapter 5 describe the exciting observation that vaccinating mice with e.g. an 
acetylated protein leads to the formation of anti-CarP antibodies as well (3), indicating that 
different AMPA-responses can evolve from exposure to only one type of modified protein. 
In our studies we found that the avidity of the antibody response to carbamylated 
fibrinogen and acetylated fibrinogen was similar after immunization with, respectively, 
carbamylated ovalbumin (RAI 64.3%) or acetylated ovalbumin (RAI 43.1%) (3). We 
subsequently found that avidity of the AMPA-response is highest towards the respective 
modified antigen used for immunization. Discrepancies in the degree of cross-reactivity may 
be a result of proteins that contain different numbers and locations of PTMs. So far a well-
defined chemical construct recognized by anti-CarP antibodies which could be used as a pan 
inhibitor for inhibition experiments has not been identified so far.    
In additional experiments we studied the polyclonal responses present in human serum. 
We used a biotinylated CCP2 peptide bound column to isolate anti-CCP2 antibodies and 
biotinylated Ca-FCS for the isolation anti-CarP antibodies in patients serum samples. After 
purification, ACPA were strongly enriched for reactivity towards both carbamylated and 
acetylated vimentin peptides (3). Following our studies on the cross-reactivity of purified 
ACPA from RA patients, our team has studied whether monoclonal ACPA (12) can cross-
react to acetylated antigens and other PTM proteins. Interestingly, we recently observed 
that this human monoclonal ACPA is able to react not only to citrullinated, but also to 
acetylated fibrinogen (data in preparation). Carbamylated fibrinogen was not recognized. 
Together these data are important as they show for the first time that ACPA can be cross-
reactive towards acetylated proteins as well. The relative cross-reactivity between ACPA, 
anti-CarP and anti-acetylated lysine antibodies suggests that these autoantibodies may 
originate from the same B-cell population. Acetylated lysine does not resemble citrulline 
but bears similarity to homocitrulline except at the side chain terminal amine, which is 
replaced by a methyl moiety.      
In our studies we observed that ACPA cannot only cross-react to some extent to 
carbamylated proteins, but also to acetylated proteins. In line with our data, others have 
shown that reactivity to citrullinated vimentin peptides was blocked by preincubation with 
the soluble citrullinated peptide as expected, with weak inhibition of binding by 
carbamylated (23%) and acetylated (17%) vimentin peptides. Similar specificity and low 
cross-reactivity was observed for the anti-acetylated vimentin antibodies as well as for anti-
carbamylated vimentin where 32% of the binding was inhibited by preincubation with 
citrullinated soluble peptide (8). These results might be explained by the notion that AMPA 
consist of different auto-antibody families that are largely distinct, but that can also display 
a certain degree of cross-reactivity.    
It is interesting to note that a defined antigen-receptor can recognize both citrullinated and 
acetylated antigens despite the structural dissimilarities of these two antigens. This 
indicates that different AMPA-responses can evolve from exposure to only one type of 
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modified protein. These data could represent a paradigm shift explaining the induction of 
AMPA-responses in RA since they show that the inciting antigen responsible for the 
induction of e.g. anti-CarP-antibodies does not have to be citrullinated or carbamylated, but 
could be represented by an acetylated protein. Increasing evidence suggests that mucosal 
surfaces, specifically the periodontium, the gut and the lungs, as sites of disease initiation 
of RA and indicate the microbiome as an important driver of the initiation of auto-immunity. 
In this respect, especially protein–acetylation by bacteria might now also be incriminated in 
the induction of auto-antibody responses against PTM proteins.  
In our future studies it would be interesting to generate and test more monoclonal ACPA 
for the antigen recognition profile. In addition, it would be of interest to establish a method 
to purify anti-acetylated protein antibodies to determine if- and to what extent human 
polyclonal AMPAs are cross-reactive towards different modified antigens. Together with 
current data, these future experiments will provide valuable insight into the magnitude and 
extent of the cross-reactive nature of human AMPAs towards three different modified 
antigens.  
 
AMPA responses in mice 
In chapter 4 we showed that stimulation of spleen cells with dendritic cells pulsed with 
carbamylated mouse albumin led to the induction of a strong T cell response, cytokine 
production and proliferation. Stimulation of spleen cells with homocitrulline containing 
peptides identified by mass spectrometry resulted in a PTM specific T-cell response. These 
findings suggest that posttranslational modification of self-proteins can result in ‘new’ 
antigens for which immune tolerance does not exist. It was recently shown by others that, 
sera of mice exposed to tobacco smoke contains anti-CarP antibodies and increased 
amounts of carbamylated vimentin (13). Although the formation of PTMs seems to promote 
tolerance loss and autoimmunity in RA, it is still unknown whether AMPA responses are 
directly pathogenic or a marker for inflammation.   
ACPA are considered to be a highly important serological marker in RA patients, however, 
their role and importance in mouse models of arthritis remains far less clear. In mouse 
models of RA the antibody dependent collagen-induced arthritis (CIA) and K/BxN model 
clearly require B cells, and the sera can be used to transfer disease, confirming a direct 
pathogenic role of humoral immunity in arthritis (14, 15). In the CIA model, inflammatory 
arthritis is induced in genetically susceptible mice by immunization with type II collagen (CII) 
(16) which subsequently leads to the induction of autoreactive anti-CII antibodies (17, 18). 
There is conflicting evidence whether ACPA are involved in CIA (19). It has been reported 
that ACPA can be found in sera of mice with arthritis that did not receive additional vaccines 
with citrullinated antigens (20-22). However, data whether ACPA can induce or exacerbate 
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symptoms are limited as the majority of animal studies show that passive transfer of ACPAs 
alone does not induce arthritis (21, 23-25).       
Our team has previously shown that anti-CarP antibodies, but not anti-CCP2 antibodies, are 
present in sera of DBA-1 mice and C57BL/6 with CIA. It was shown that the onset of arthritis 
was preceded by an increase of anti-CarP antibodies (26). These data are in line with the 
data that in asymptomatic blood bank donors there is a rise in anti-CarP levels prior to 
clinical onset of RA (27). For future studies it would be interesting to examine whether anti-
acetylated lysine antibodies are also present in sera of mice with arthritis. We recently 
studied the role of anti-CarP antibodies in arthritis using our monoclonal anti-CarP antibody 
(data in preparation). In a pilot experiment we tested whether exposure to anti-CarP 
antibodies could exacerbate arthritis. DBA-1 mice were injected with CFA and CII according 
to protocol and later received additional anti-CarP antibodies. In these first experiments, 
we observed no exacerbation of symptoms upon transfer of anti-CarP antibodies. It would 
be interesting in the future to study the role of AMPA in arthritis using additional 
monoclonal antibodies such as anti-acetylated lysine antibodies.   
In summary, the hypothesis that AMPA responses play a key role in the pathogenesis of RA 
needs solid and repeatable animal data. The identification of additional PTM responses 
besides ACPA, such as anti-carbamylate and acetylated protein antibodies, enables us to 
study the induction and role of these AMPA in animal models of arthritis.   
 
Autoantibodies in the pathogenesis of RA 
Despite many years of intensive research, the pathogenesis of RA remains elusive. It 
appears that breach of tolerance towards PTM proteins and the generation of AMPA is 
intimately implicated in disease-pathogenesis. Genetic predisposition and environmental 
factors such as smoking are thought to contribute to this break of tolerance. However, 
asymptomatic individuals can harbour autoantibodies without developing RA for many 
years, which suggests that the sole presence of an autoantibody is insufficient to trigger the 
onset of RA (27).     
Previous studies have shown that ACPA-producing B-cells are found to be enriched in 
synovial fluid (28, 29), suggesting that ACPA can be produced locally and directly contribute 
to synovial inflammation. So far, little information is currently available on the nature of 
carbamylate proteins that are present in the (inflamed) joint. Using mass-spectrometry we 
have been able to identify carbamylated serum albumin (1) and alfa-1-anti trypsin (30) in 
the synovial compartment of RA patients. Recently, other carbamylated proteins have been 
identified in patients with renal disease (31, 32), indicating that it is likely that also other 
carbamylated proteins can be carbamylated in RA patients. It will be interesting to see 
whether the nature and location of carbamylated proteins in the synovial compartment is 
similar or distinct from the citrullinated proteins found in the joint. Studies in chapter 6 
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describe the relationship between autoantibody status and remission in newly diagnosed 
RA-patients treated with first-line methotrexate. Methotrexate is the most widely used anti-
rheumatic drug in clinical practice (33). We found that in newly diagnosed RA patients who 
are receiving methotrexate, autoantibody status (ACPA and/or rheumatoid factor) was not 
associated with the chance of achieving early remission (4). In the future, patients may 
benefit from treatment tailored to “autoantibody status”.   
It has been hypothesised that very early treatment initiation can prevent the development 
of RA, a so called “window-of -opportunity". Animal models provide a model to study the 
developing (auto)immune response at a very early disease phase. The translation of 
different stages of experimental arthritis to the evolution of human disease might provide 
valuable information regarding possibilities of disease prevention. Based on different 
studies in animal models we found that both prophylactic and pre-arthritis treatment 
strategies lead to a significant reduction of arthritis severity, chapter 7 (5). Autoantibody 
formation against type II collagen can be used as a marker to characterize different stages 
of disease. The time period in which auto-immunity is present and arthritis is still absent 
was referred to as the pre-arthritis period. Current animal research mainly focusses on 
testing anti-rheumatic drugs in established disease and preventive treatment strategies are 
not studied frequently. In an ideal experiment, different interventions should be studied 
side-by-side in different disease phases and with a similar treatment schedule to be able to 
compare efficacy.         
Protein modification and periodontal disease appear to be relevant for the pathogenesis of 
RA, however, how these processes may be mechanistically related remains poorly defined. 
The periodontal pathogen Aggregatibacter actinomycetemcomitans (Aa) seems to 
represent a link between periodontal infection and autoimmunity. It was previously shown 
by others that Aa is capable to induce neutrophil hypercitrullinations through the secretion 
of leukotoxin A (LtxA), a bacterial pore-forming toxin that induces calcium influx and 
subsequent hyperactivation of PAD enzymes in the neutrophil. The studies in chapter 8 
describe that in a large cohort of arthritis patients, anti-LtxA antibodies (used as surrogate 
marker of Aa infection) were not specifically associated with RA but could also be identified 
in other forms of inflammatory arthritis (34). In addition, we found no association between 
ACPA or HLA SE alleles in contrast to the previous study (33). Differences in cohorts and 
methodology may account for the difference in effect size. In our cohort the anti-CCP 
positivity is 58% (Leiden) versus 77% (Baltimore). The Leiden Early Arthritis Clinic includes 
patients with recent onset arthritis in whom definitive diagnosis are established after1 year 
of follow up. In contrast, the Baltimore cohort includes a wide range of disease durations, 
form early disease to decades. Regarding methodology, the cut-off for positivity was based 
on the lowest point of the linear part of the standard curve (2000 arbitrary units/ml, 75% 
specificity). It remains important to emphasize that despite not affecting comparisons of 
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median antibody concentrations between groups, a degree of uncertainty in cut-off 
selection can alter any interaction analyses.      
Many bacterial species are able to acetylate proteins (35), including bacteria proposed as 
link between periodontal infection and RA (36). Disturbances of the microbiome, for 
example during infection, could lead to the increased formation of acetylated proteins 
which are detected by the immune system and thereby contribute to the induction of 
AMPA-responses. Microbe-specific T cells could initially help the B cells recognize the 
microbe-derived modified protein and thereby contributing to isotype-switching and 
somatic hypermutation.  
 
Final conclusions  
In conclusion, we showed that exposure to modified self- and foreign proteins can lead to 
the generation of AMPA. The observation that exposure to an acetylated protein leads to 
the formation of auto-antibodies against carbamylated proteins as well, indicates that 
different AMPA-responses can evolve from exposure to only one type of modified protein. 
Understanding the full AMPA response, the triggers that drive AMPA production, their 
mutual cross-talk and the pathways by which AMPA and/or AMPA expressing B cells 
possibly contribute to RA might – in the long run- allow interventions that prevent disease 
development, a highly desirable goal in the quest against rheumatic diseases. 
 
















1. Dekkers JS, Verheul MK, Stoop JN, Liu B, Ioan-Facsinay A, van Veelen PA, et al. Breach of 
autoreactive B cell tolerance by post-translationally modified proteins. Ann Rheum Dis. 
2017;76(8):1449-57. 
2. J.S. Dekkers JNS, L.A. Trouw, R.E.M. Toes. Carbamylation of self-antigens facilitates a breach 
in T-cell tolerance  
3. J.S. Dekkers¥ ASBK, , M. Volkov, A.M. Dorjee, L. Hafkenscheid, A. Kempers, M.A.M. van Delft, 
G.M.C. Janssen, P.A. van Veelen, T.M.W. Huizinga, D. van der Woude, R.E.M. Toes. Different 
classes of Anti-Modified Protein Antibodies are induced upon exposure to antigens 
expressing one type of modification. 
4. Dekkers JS, Bergstra SA, Chopra A, Tikly M, Fonseca JE, Salomon-Escoto K, et al. 
Autoantibody status is not associated with early treatment response to first-line 
methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2018. 
5. Dekkers JS, Schoones JW, Huizinga TW, Toes RE, van der Helm-van Mil AH. Possibilities for 
preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of 
arthritis: a systematic literature review and meta-analysis. Ann Rheum Dis. 2017;76(2):458-
67. 
6. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. 
Autoantibodies recognizing carbamylated proteins are present in sera of patients with 
rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 
2011;108(42):17372-7. 
7. Scinocca M, Bell DA, Racape M, Joseph R, Shaw G, McCormick JK, et al. 
Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and 
frequently bind citrullinated proteins/peptides. J Rheumatol. 2014;41(2):270-9. 
8. Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, et al. Identification of novel 
antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum 
Dis. 2016;75(6):1099-107. 
9. Reed E, Jiang X, Kharlamova N, Ytterberg AJ, Catrina AI, Israelsson L, et al. Antibodies to 
carbamylated alpha-enolase epitopes in rheumatoid arthritis also bind citrullinated 
epitopes and are largely indistinct from anti-citrullinated protein antibodies. Arthritis Res 
Ther. 2016;18(1):96. 
10. Shi J, Willemze A, Janssen GM, van Veelen PA, Drijfhout JW, Cerami A, et al. Recognition of 
citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity 
and the 'AMC-Senshu' method. Ann Rheum Dis. 2013;72(1):148-50. 
11. Verheul MK, van Veelen PA, van Delft MAM, de Ru A, Janssen GMC, Rispens T, et al. Pitfalls 
in the detection of citrullination and carbamylation. Autoimmun Rev. 2018;17(2):136-41. 
12. van de Stadt LA, van Schouwenburg PA, Bryde S, Kruithof S, van Schaardenburg D, Hamann 
D, et al. Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen 




13. Ospelt C, Bang H, Feist E, Camici G, Keller S, Detert J, et al. Carbamylation of vimentin is 
inducible by smoking and represents an independent autoantigen in rheumatoid arthritis. 
Ann Rheum Dis. 2017;76(7):1176-83. 
14. Christensen AD, Haase C, Cook AD, Hamilton JA. K/BxN Serum-Transfer Arthritis as a Model 
for Human Inflammatory Arthritis. Front Immunol. 2016;7:213. 
15. Nandakumar KS, Holmdahl R. Collagen antibody induced arthritis. Methods Mol Med. 
2007;136:215-23. 
16. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin 
Immunopathol. 2003;25(1):3-18. 
17. Holmdahl R, Andersson M, Goldschmidt TJ, Gustafsson K, Jansson L, Mo JA. Type II collagen 
autoimmunity in animals and provocations leading to arthritis. Immunol Rev. 1990;118:193-
232. 
18. Pearson CM. Development of arthritis, periarthritis and periostitis in rats given adjuvants. 
Proc Soc Exp Biol Med. 1956;91(1):95-101. 
19. Vossenaar ER, Nijenhuis S, Helsen MM, van der Heijden A, Senshu T, van den Berg WB, et 
al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis 
Rheum. 2003;48(9):2489-500. 
20. Kidd BA, Ho PP, Sharpe O, Zhao X, Tomooka BH, Kanter JL, et al. Epitope spreading to 
citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis 
Res Ther. 2008;10(5):R119. 
21. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against 
citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin 
Invest. 2006;116(4):961-73. 
22. Forster M, Raposo B, Ekman D, Klaczkowska D, Popovic M, Nandakumar KS, et al. Genetic 
control of antibody production during collagen-induced arthritis development in 
heterogeneous stock mice. Arthritis Rheum. 2012;64(11):3594-603. 
23. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of 
osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J 
Clin Invest. 2012;122(5):1791-802. 
24. Krishnamurthy A, Joshua V, Haj Hensvold A, Jin T, Sun M, Vivar N, et al. Identification of a 
novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-
associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016;75(4):721-9. 
25. Wigerblad G, Bas DB, Fernades-Cerqueira C, Krishnamurthy A, Nandakumar KS, Rogoz K, et 
al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation 
via a chemokine-dependent mechanism. Ann Rheum Dis. 2016;75(4):730-8. 
26. Stoop JN, Liu BS, Shi J, Jansen DT, Hegen M, Huizinga TW, et al. Antibodies specific for 
carbamylated proteins precede the onset of clinical symptoms in mice with collagen induced 
arthritis. PLoS One. 2014;9(7):e102163. 
27. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. 
Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. 
Ann Rheum Dis. 2014;73(4):780-3. 
191 
 
28. Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, et al. Antibodies to 
several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. 
Arthritis Rheum. 2010;62(1):44-52. 
29. Amara K, Steen J, Murray F, Morbach H, Fernandez-Rodriguez BM, Joshua V, et al. 
Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong 
bias toward citrullinated autoantigen recognition. J Exp Med. 2013;210(3):445-55. 
30. Verheul MK, Yee A, Seaman A, Janssen GM, van Veelen PA, Drijfhout JW, et al. Identification 
of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in 
patients with rheumatoid arthritis. J Autoimmun. 2017;80:77-84. 
31. Berg AH, Drechsler C, Wenger J, Buccafusca R, Hod T, Kalim S, et al. Carbamylation of serum 
albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med. 
2013;5(175):175ra29. 
32. Desmons A, Jaisson S, Pietrement C, Rieu P, Wynckel A, Gillery P. Homocitrulline: a new 
marker for differentiating acute from chronic renal failure. Clin Chem Lab Med. 
2016;54(1):73-9. 
33. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR 
recommendations for the management of rheumatoid arthritis with synthetic and biological 
disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964-75. 
34. Volkov M, Dekkers J, Loos BG, Bizzarro S, Huizinga TWJ, Praetorius HA, et al. Comment on 
"Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal 
infection to autoimmunity in rheumatoid arthritis". Sci Transl Med. 2018;10(433). 
35. Ouidir T, Kentache T, Hardouin J. Protein lysine acetylation in bacteria: Current state of the 
art. Proteomics. 2016;16(2):301-9. 
36. Butler CA, Veith PD, Nieto MF, Dashper SG, Reynolds EC. Lysine acetylation is a common 
post-translational modification of key metabolic pathway enzymes of the anaerobe 

































































Reumatoïde artritis (RA) is een chronische, systemische, auto-immuunziekte die wordt 
gekenmerkt door een chronische ontsteking van de synoviale gewrichten en de 
aanwezigheid van auto-antistoffen in het bloed. Belangrijk voor de klinische praktijk zijn 
anti-gecitrullineerde eiwit antilichamen (ACPA) en reuma factor (RF). Deze twee 
antilichamen zijn een onderdeel van de 2010 American College of Rheumatology / European 
League Against Rheumatism classificatiecriteria voor RA. ACPA binden aan eiwitten die een 
post-translationele modificatie hebben ondergaan. Citrullinatie is een chemische 
verandering waardoor het aminozuur arginine wordt omgezet in citrulline. Deze chemische 
verandering wordt gekatalyseerd door de zogenaamde peptidylarginine-de-iminase (PAD) 
enzymen. RF herkent het Fc gedeelte van IgG, een onderdeel betrokken bij complement 
activatie.  Zowel ACPA als RF zijn diagnostische markers voor RA en de aanwezigheid van 
deze markers is voorspellend voor het ontwikkelen van RA. ACPA en RF kunnen lange tijd 
aanwezig zijn in het bloed van patiënten, zelfs jaren voordat symptomen ontstaan en RA 
zich klinisch manifesteert. De aanwezigheid van ACPA verhoogt bij patiënten met 
gewrichtsklachten de kans op de ontwikkeling van RA aanzienlijk, terwijl bij 
gediagnosticeerde RA patiënten de aanwezigheid van deze auto-antistoffen een meer 
agressief karakter van de ziekte voorspelt.  
Naast ACPA zijn er recent ook andere RA-specifieke auto-antistoffen ontdekt die gericht zijn 
tegen post-translationeel gemodificeerde eiwitten. Deze antistoffen worden collectief 
beschreven als anti-gemodificeerde eiwit antistoffen (AMPA). AMPA kunnen naast citrulline 
ook gericht zijn tegen andere eiwit modificaties als homocitrulline en acetyllysine.  De 
aanwezigheid van verschillende AMPA in RA suggereert een gezamenlijke biologische 
oorsprong. Net als citrullinatie zijn carbamylatie en acetyllatie post-translationele 
modificaties die onder normale omstandigheden voorkomen. Desondanks vormt slechts in 
een deel van de mensen, en met name RA patiënten, auto-antistoffen tegen eiwitten met 
deze modificaties. Het is dus van essentieel belang om te begrijpen waarom mensen 
antistoffen ontwikkelen die gericht zijn tegen dergelijke eiwitmodificaties die onder 
normale condities ook plaatsvinden.  
Carbamylatie is een posttranslationele modificatie waarbij lysines worden gemodificeerd in 
homocitrullines onder invloed van cyanaat. De moleculaire structuur van homocitrulline 
lijkt veel op die van citrulline en is slechts één methyleen groep langer dan citrulline. 
Antistoffen gericht tegen gecarbamyleerde eiwitten worden beschreven als anti-
gecarbamyleerde eiwit antilichamen (anti-CarP). Anti-CarP antistoffen komen voor bij circa 
45% van de patiënten met een vroege vorm van RA. Daarnaast kunnen deze antistoffen ook 
gevonden worden bij proefdiermodellen met artritis. Kort geleden zijn antistoffen tegen 
acetyllysine geïdentificeerd als RA-specifieke AMPA. Deze antistoffen zijn aantoonbaar in 




Het doel van dit proefschrift was om de onderliggende immuunregulatie en doorbreking 
van tolerantie tegen gemodificeerde eiwitten in RA te ontrafelen. AMPA zijn kenmerkend 
voor RA en worden verondersteld een rol te spelen in de onderliggende pathogenese.  
In hoofdstuk 2 beschrijven we gebaseerd op verschillende studies dat auto-immuniteit 
tegen gecitrullineerde eiwitten al reeds in een preklinische fase van RA aanwezig is. 
Daarnaast laten de studies zien dat de ACPA respons zich verder ontwikkelt over tijd en dat 
adequate behandeling van artritis kan leiden tot een andere samenstelling van ACPA of 
lagere titers. Auto-immuniteit kan ontstaan als gevolg van falen of doorbreken van 
mechanismen die aan de basis liggen van zelf tolerantie van B-cellen, T-cellen of beide.  
Hoofdstuk 3 beschrijft het onderzoek naar het doorbreken van B-cel tolerantie. 
Blootstelling van proefdieren aan gecarbamyleerde eiwitten leidde tot de productie van 
anti-CarP antistoffen in het bloed. Daarnaast vonden we dat deze geïnduceerde anti-CarP 
antistoffen kruisreactief waren tegen andere gecarbamyleerde eiwitten, waarmee we auto-
immuniteit aantoonden. Deze observatie laat zien dat het doorbreken van zelf tolerantie 
van  B cellen door gemodificeerde lichaamsvreemde antigenen kan leiden tot kruisreactieve 
antilichamen tegen gemodificeerde lichaamseigen eiwitten. Voor de volledige activatie en 
differentiatie van rijpe B cellen zijn twee signalen nodig (1) interactie van oppervlakte-
immuunglobuline op de B cel met het antigen en (2) co-stimulatie door middel van CD40L-
CD40-interactie en cytokine productie door antigeen specifieke CD4+ T helper cellen. In 
hoofdstuk 4 hebben we verder onderzoek gedaan naar het doorbreken van T cel tolerantie 
voor gecarbamyleerde auto-antigenen. Muizen werden gevaccineerd met gecarbamyleerd 
muizen albumine en niet-gemodificeerd albumine. Na vaccinatie met gecarbamyleerd 
albumine konden wij antigeen specifieke T cellen aantonen gericht tegen carbamyleerd 
albumine. Deze observatie ondersteunt de hypothese dat post-translationele modificaties 
kunnen fungeren als een “hapteen” (een klein molecuul wat kan dienen als epitoop en niet 
zelf in staat is om een antistofrespons op te wekken) en op deze manier een bijdrage leveren 
aan het ontstaan van AMPA.  
Hoofdstuk 5 beschrijft het onderzoek naar de basis van AMPA reacties en AMPA 
producerende B cellen. Om antistoffen te kunnen detecteren gericht tegen geacetyleerde 
eiwitten hebben we een ELISA opzet gebaseerd op geacetyleerd ovalbumine en fibrinogeen. 
In deze studies onderzochten wij of blootstelling aan één soort post-translationele 
modificatie kan leiden tot de ontwikkeling van antistoffen gericht tegen andere 
modificaties. Na vaccinatie met gecarbamyleerde eiwitten konden wij in het bloed niet 
alleen anti-CarP antistoffen aantonen maar ook antistoffen gericht tegen geacetyleerde 
eiwitten. Vervolgens immuniseerden wij muizen met geacetyleerde eiwitten. Naast AAPA 
konden wij ook antilichamen aantonen gericht tegen andere PTM. Vervolgens vroegen wij 
ons af of gezuiverd ACPA naast citrulline reactiviteit ook reactief is tegen geacetyleerde en 
gecarbamyleerde eiwitten. Door antistoffen in het bloed van RA patiënten gezuiverd voor 
citrulline reactiviteit te isoleren en testen vonden wij dat deze antistoffen kruisreactief 
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kunnen zijn voor zowel acetyllysine als homocitrulline. Deze data geven aan dat in het serum 
van RA patiënten naast antilichamen die uniek reageren met ofwel gecitrullineerde eiwitten 
ofwel gecarbamyleerde eiwitten ook kruisreagerende populaties antistoffen aanwezig 
kunnen zijn. Vroege en agressieve interventie bij RA patiënten kan botschade voorkomen 
en vroege remissie induceren. De aanwezigheid van autoantistoffen kan een bruikbare bio-
marker zijn om patiënten te identificeren die van bepaalde behandelstrategieën wellicht 
meer baat hebben.  
In de studies beschreven in hoofdstuk 6 onderzochten we de associatie tussen auto-antistof 
status en het bereiken van vroege remissie bij recent gediagnosticeerde RA patiënten 
behandeld met methotrexaat. Voor ons onderzoek maakten wij gebruik van de 
internationale METEOR database wat bestaat uit data van verschillende reumatologische 
centra wereldwijd. Op basis van data van 1,826 RA patiënten concludeerden wij dat 
ongeacht de antistof status methotrexaat effectief is als inductie therapie.   
Hoofdstuk 7 beschrijft het onderzoek gericht op de preklinische fase van de ziekte en de 
mogelijkheid voor preventieve behandelstrategieën voor RA. Recent onderzoek heeft 
aangetoond dat indien de behandeling van reumatoïde artritis binnen 12 weken na het 
ontstaan van klachten wordt gestart patiënten minder gewrichtsschade ontwikkelen en een 
grotere kans hebben op het bereiken van remissie. Hierop vormden wij de hypothese dat 
vroege interventie het ontstaan van chronische inflammatie en gewrichtsschade kan 
voorkomen en het ontstaan van ziekte kan voorkomen. Omdat de ziektefasen van artritis in 
proefdiermodellen duidelijk te karakteriseren zijn, besloten we om dit als model te 
gebruiken voor onze onderzoeksvraag. Door middel van een meta-analyse concludeerden 
wij dat zowel profylactische als preklinische behandelstrategieën kunnen leiden tot 
significante reductie van ziekte ernst.  
De pathogenese van parodontitis en RA vertonen veel overeenkomsten, parodontitis wordt 
gekarakteriseerd door gingivitis en chronische inflammatie van het bot. Parodontitis kent 
een hogere prevalentie bij patiënten met RA en omgekeerd heeft RA een hogere prevalentie 
bij patiënten met parodontitis. Recent onderzoek toonde een verband aan tussen ACPA en 
de Aggregatibacter actinomycetemcomitans (Aa), een bacterie geassocieerd met 
parodontitis, en zijn lytische toxine (leutoxine A, Ltx-A) bij individuen met een genetische 
predispositie.  
In hoofdstuk 8 staan de studies beschreven naar de associatie tussen HLA-SE allelen en 
ACPA positieve RA wat eerder werd beschreven voor een anti-LxtA antistof positieve subset. 
Wij hebben hiervoor analyses uitgevoerd op 594 sera van patiënten uit het Leiden Early 
Arthritis Clinic (EAC) cohort, bestaande uit patiënten met alle vormen van vroege artritis 
zoals die in de polikliniek voorkomen. Op basis van deze sera konden wij concluderen dat 
de aanwezigheid van anti-LtxA antistoffen (als maat voor blootstelling aan Aa) niet specifiek 
is voor RA maar dat deze antistoffen ook voorkomen bij andere vormen van vroege artritis. 
Daarnaast vonden wij geen associatie tussen de aanwezigheid van ACPA of HLA SE allelen.  
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Ten slotte staat in hoofdstuk 9 een samenvatting en discussie van alle onderzoeksresultaten 
beschreven en de mogelijkheden voor onderzoek in de toekomst.    
 
Conclusies en toekomstperspectieven 
De laatste jaren is er binnen het veld van RA een verschuiving opgetreden richting de vroege 
identificatie en vroege behandeling met als doel om de chroniciteit en zelfs de ontwikkeling 
van RA te voorkomen. Biologische markers als AMPA zijn niet alleen waardevol voor vroege 
identificatie maar kunnen inzicht leveren in de onderliggende immuun-regulatie en 
pathogenese. De beschreven onderzoeken in dit proefschrift geven inzicht in de rol van 
gemodificeerde eiwitten en doorbreking van tolerantie tegen gemodificeerde eiwitten, 
aspecten die kenmerkend zijn voor RA. In dit proefschrift staat beschreven dat auto-
immuniteit tegen gecarbamyleerde eiwitten kan ontstaan als gevolg van het doorbreken 
van mechanismen die aan de basis liggen van zelf tolerantie zowel van B-cellen als T-cellen. 
Onze resultaten laten ook zien dat blootstelling aan andere gemodificeerde eiwitten kan 
leiden tot de productie van kruisreactieve antistoffen gericht tegen structureel andere 
modificaties. De methodologische aspecten in dit proefschrift hebben een fundament 
gelegd voor uitgebreidere studies naar de rol van post-translationele modificaties en het 
voorkomen van AMPA in patiëntengroepen. Toekomstige studies met monoklonale AMPA 
zouden meer inzicht kunnen geven in de mate van kruisreactiviteit en de mechanismen die 
aan basis van auto-immuniteit en tolerantiedoorbreking liggen. Het testen van monoklonale 
AMPA in proefdiermodellen van artritis kan inzicht geven in de rol van AMPA in het ontstaan 
van inflammatie en de ontwikkeling van artritis.  
Samengevat, post-translationele modificaties en auto-antistoffen is een fascinerend en 
complex systeem. Toekomstige studies zullen gericht zijn om de “pathologische capaciteit” 
van de AMPA in kaart te brengen en de consequenties van de aanwezigheid van deze auto-







































Edouard Manet (1832-1883), In the Conservatory (detail), 





























List of publications 
Different classes of Anti-Modified Protein Antibodies are induced upon exposure to 
antigens expressing one type of modification.  
J.S. Dekkers, A.S.B. Kampstra, M. Volkov, A.L. Dorjee, L. Hafkenscheid, A.C. Kempers, M. van 
Delft, T.Kissel, S. Reijm, G.M.C. Janssen, P.A. van Veelen, H. Bang, T.M.W. Huizinga, L.A. 
Trouw, D. van der Woude, R.E.M. Toes.  
Annals of the Rheumatic Diseases. 2019 Jul;78(7):908-916 
 
Autoantibody status is not associated with early treatment response to first-line 
methotrexate in patients with early rheumatoid arthritis.  
J.S. Dekkers, S.A. Bergstra, A. Chopra, M. Tikly, J.E. Fonseca, K. Salomon-Escoto, T.W. 
Huizinga, D. van der Woude.  
Rheumatology (Oxford). 2019 Jan 1;58(1):149-153. 
 
Aggregatibacter  actinomycetemcomitans–induced  hypercitrullination links periodontal 
infection  to autoimmunity in rheumatoid arthritis 
M. Volkov, J.S. Dekkers, B.G. Loos, S. Bizzarro, T.W.J. Huizinga, H.A. Praetorius, R.E.M. Toes, 
D. van der Woude.  
Science Translational Medicine. 2018 Mar 21;10(433). 
 
Breach of autoreactive B-cell tolerance by post-translationally modified foreign proteins. 
J.S. Dekkers, M.K. Verheul, J.N. Stoop, B. Liu, A. Ioan-Facsinay, P.A. van Veelen, A.H. de Ru, 
G.M.C. Janssen, M.Hegen, S.Rapecki, T.W. J. Huizinga, L.A. Trouw, R.E.M. Toes.  
Annals of the Rheumatic Diseases. 2017 Aug;76(8):1449-1457. 
 
Possibilities for preventive treatment in rheumatoid arthritis?  Lessons from experimental 
animal models of arthritis: a systematic literature review and meta-analysis.  
Dekkers J.S., Schoones J.W., Huizinga T.W., Toes R.E.M., van der Helm-van Mil A.H.  
Annals of the Rheumatic Diseases. 2017 Feb;76(2):458-467.  
 
The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis. 
Dekkers J, Toes RE, Huizinga TW, van der Woude D. 
Current Opinion in Rheumatology. 2016 May;(3):275-81. 
 
Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based 
immunotherapy for malignant mesothelioma.  
Mahaweni N.M., Kaijen-Lambers M.E., Dekkers J., Aerts J.G., Hegmans J.P. 






























Jacqueline Stephanie Dekkers werd op 3 mei 1989 geboren in Rotterdam. In 2007 behaalde 
zij haar vwo diploma op het Emmaus College te Rotterdam en startte zij met haar studie 
geneeskunde aan het Erasmus Medisch Centrum. In 2008 begon zij met haar tweejarige 
research master Molecular Medicine naast haar studie geneeskunde in Rotterdam. Voor 
haar research master heeft zij twee stages gedaan bij de afdeling Longziekten in het 
Erasmus MC en bij de afdeling Oncologie van het Gustave Roussy Instituut in Parijs. Voor 
haar onderzoeksproject ontving zij de prestigieuze KNAW young scientist grant en de 
Descartes Bourse d’excellence. Na het behalen van haar arts-examen in 2014 startte zij met 
haar promotieonderzoek op de afdeling Reumatologie van het LUMC onder begeleiding van 
prof.dr. R.E.M. Toes en prof.dr. T.W.J. Huizinga. Dit onderzoek richtte zich op de rol van 
auto-immuniteit en het ontstaan van auto-antistoffen in reumatoïde artritis. In september 
2017 begon zij aan haar medische specialisatie tot reumatoloog. Momenteel is zij werkzaam 











































Voor het voltooien van mijn proefschrift heb ik van velen steun en hulp gekregen. In mijn 
dankwoord wil ik graag gebruik maken om jullie hiervoor persoonlijk te bedanken.  
Allereerst wil ik iedereen op de afdeling Reumatologie bedanken voor de directe en 
indirecte bijdrage en met name het werkplezier en de goede sfeer op de afdeling. De 
afdeling reumatologie in het LUMC bestaat uit een prachtige groep collegae en ik heb het 
ontzettend naar mijn zin gehad tijdens mijn promotieonderzoek.  
Mijn promotor, professor Toes, beste René dank voor alle adviezen, begeleiding en de 
leerzame besprekingen. Jouw kritische blik voor de juiste studie opzet van experimenten en 
het schrijven van wetenschappelijke artikelen is ontzettend waardevol. Promotor professor 
Huizinga, beste Tom, jouw enthousiasme en passie om basaal onderzoek en de kliniek 
samen te brengen is een enorme inspiratie.  
Daarnaast wil ook graag Diane en Leendert bedanken voor hun steun en input in onze 
wetenschappelijke projecten. Diane, jij en Sytske-Anne hebben mij veel geleerd van de 
statistiek en onderzoeksmethoden, bedankt voor jullie hulp. Leendert, ik wil je graag 
bedanken voor al je enthousiasme voor het anti-CarP project. Je staat altijd open voor een 
nieuwe hypothese maar je blijft ook kritisch kijken naar de data.  
Verder wil ik heel graag al mijn collega promovendi van het lab en het klinisch onderzoek 
bedanken. Mijn collega’s van het anti-CarP team; Marije, Myrthe, Rosalie, Jeroen en Nivine, 
bedankt voor alle inbreng en de wetenschappelijke discussies. Sanne, Hester, Daniël, 
Mikhail, Jeroen en Ellen bedankt voor de hulp met de experimenten en de tijd samen met 
mij in het PDC.  
Lise, Hilde, Joost, Rochelle, Corrie, Hendy, Linda, Uli en Andrea bedankt voor de 
wetenschappelijke discussies en de gezelligheid! Sanne, Marije en Mikhail, bedankt voor de 
samenwerking met de experimenten en het schrijven van de artikelen. We kunnen samen 
trots zijn op het resultaat.  
Verder wil ik graag alle andere mede-promovendi bedanken; Sytske Anne, Joy, Debbie, 
Emma, Robin, Pauline, Anoek, Queeny, Sjoerd, Wendy, Leonie, Xanthe, Aleid, Wouter en 
Leonie. Bedankt voor de goede samenwerking en gezelligheid. Het is ontzettend leuk dat 
sommigen van jullie nog steeds mijn directe collega’s zijn in Gouda!  
Mijn lieve paranimfen Ilona en Femke, bedankt voor jullie hulp bij het voltooien van mijn 
boekje en tijdens mijn verdediging. Bedankt voor jullie enthousiasme. 
206 
Appendices 
Lieve Patricia, Roland en Ilona, ik wil jullie bedanken voor jullie onvoorwaardelijke steun. 
Bedankt voor jullie adviezen en alle aandacht die jullie mij geven. Dankzij jullie heb ik het 
doorzettingsvermogen en de inspiratie gekregen om deze uitdaging aan te gaan.  
Tot slot, lieve Raoul, wil ik jou bedanken voor al je liefde, steun en interesse in alles wat ik 
doe. We kunnen samen trots zijn op het mooie resultaat. Ik wil je bedanken voor al onze 
mooie momenten samen en ik kan niet wachten op onze nieuwe avonturen samen in de 
toekomst! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
207 
 
 
